Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Conditions: Venous Thromboembolism, Pulmonary Embolism, DVT
Sponsor: Brigham and Women's Hospital

 
 
 
 
 
 
 
 
 
 
 
Prediction of Findings from the Ongoing COBRRA Trial Using Healthcare Database 
Analyses  
 
DUPLICATE – COBRRA VTE 
 
March 11th, 2022  

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
1 
1. RCT Details 
This section provides a high-level overview of an ongoing RCT that the described real-world evidence study is trying to replicate 
as closely as possible given the remaining limitations inherent in the healthcare databases. 
 
1.1 Title 
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism 
(COBRRA) 
 
1.2 Intended aim(s) 
To compare the incidence of major and clinically relevant non-major bleeding events among subjects recently hospitalized 
with VTE initiating apixaban or rivaroxaban. 
 
1.3 Primary endpoint for replication  
Time from randomization to the first confirmed, adjudicated occurrence of a major bleeding or clinically relevant non-major 
bleeding event through 90 days of anticoagulation treatment. 
 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
The hazard ratio for the clinical trial is unknown because the trial is still ongoing. Based upon a recent meta-analysis 
comparing the safety of apixaban and rivaroxaban in a real-world evidence context, power was calculated using an array of 
effect sizes (Aryal et al. 2019). 
 
1.5 Secondary endpoint for replication (assay sensitivity) and RCT finding 
o Adjudicated major bleeding events 
o Adjudicated clinically relevant non-major bleeding events 
o Recurrent VTE  
o All-cause mortality 
 
1.6 Trial estimate 
The trial is ongoing and scheduled to complete in June of 2023. 
 
2. Person responsible for implementation of replication in Aetion 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
2 
Luke Zabotka, BA and Mufaddal Mahesri, MD, MPH, implemented the study design in the Aetion Evidence Platform. They are not 
responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation 
history is archived in the platform. 
 
3. Data Source(s) 
Optum CDM, IBM® MarketScan®, CMS NOAC 
 
4. Study Design Diagram 
 
The study design diagram visualizes key aspects of the longitudinal study design for expedited review. 
 
Figure 1.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
3 
5. Cohort Identification  
 
5.1 Cohort Summary 
An active-comparator, new-user design, propensity score matched, retrospective cohort study will be applied to compare patients 
that received apixaban or rivaroxaban. Subjects will be selected on the basis of having one or more diagnoses codes indicating 
hospitalization for PE or DVT and being of age 18 or older. Subjects will be excluded if they were not treatment-naïve with respect to 
the use of another DOAC or warfarin in the prior 180 days or have had any indication of stage IV or V CKD, ESRD, an active bleeding 
episode, cancer, obesity, liver disease, or another indication for long-term anticoagulation, such as atrial fibrillation (AF), in the prior 
180 days. Patients were also excluded if they have used any contraindicated medications in the prior 180 days. All patients were 
required to have continuous enrollment for 180 days prior to cohort entry to ensure incident use of the study drugs. 
 
5.2 Important steps for cohort formation 
New use of the exposure (apixaban or rivaroxaban) is defined as no use of either drug in 180 days prior to meeting all eligibility 
criteria and initiation of exposure.  
 
5.2.1 Eligible cohort entry dates 
The apixaban indication for treatment of DVT and PE was approved by the FDA on Aug 21, 2014. Rivaroxaban was initially 
approved for the same indication on Nov. 2, 2012. 
§ IBM® MarketScan®: Aug 21, 2014 – December 31, 2019 (end of available data)  
§ Optum CDM: Aug 21, 2014  – June 30, 2020 (end of available data)  
§ CMS NOAC: Aug 21, 2014 – Dec 31, 2017 (end of available data) 
 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date 
Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are 
provided in the Appendix and are summarized in the flowcharts below.  
 
5.3 Flowchart of the study cohort assembly 
For Apixaban vs. Rivaroxaban 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
4 
 
 
Optum CDM 
 IBM® MarketScan® 
CMS - NOAC 
 
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
All patients in our database 
 
81,796,156 
 
205,537,714 
 
6,886,908 
Patients with Apixaban/Rivaroxaban 
[measured between Aug 21, 2014 and June 
30, 2020.] 
 
815,310 
 
592,812 
 
1,877,831 
Excluded due to insufficient enrollment [-
180, 0] 
-114,272 
(14%) 
701,038 
-44,015 (7%) 
548,797 
-211,569 
(11%) 
1,666,262 
After wash-out for prior use of reference 
(Rivaroxaban) [-180, -1] 
-216,874 
(31%) 
484,164 
-203,091 
(37%) 
345,706 
-622,705 
(37%) 
1,043,557 
After wash-out for prior use of exposure 
(Apixaban) [-180, -1] 
-333,847 
(69%) 
150,317 
-205,703 
(60%) 
140,003 
-682,837 
(65%) 
360,720 
Excluded because patient qualified in >1 
exposure category 
-14 (<1%) 
150,303 
-23 (<1%) 
139,980 
-48 (<1%) 
360,672 
Exclusion of Missing Age [-180, 0] 
-5 (<1%) 
150,298 
-0 (<1%) 
139,980 
-120 (<1%) 
360,552 
Exclusion of Gender (Exclude Missing 
Values) [start of all available data, 0] 
-15 (<1%) 
150,283 
-0 (<1%) 
139,980 
- 
 
- 
 
Inclusion of Age >= 18 [0,0] 
-141 (<1%) 
150,142 
-332 (<1%) 
139,648 
- 
 
- 
 
Inclusion of Proximal DVT or PE 
Hospitalization [Day -14, Day 0] 
-135,497 
(90%) 
14,645 
-124,142 
(89%) 
15,506 
-323,753 
(90%) 
36,798 
Exclusion of Anticoagulant Use [-180, 0] 
-311 (2%) 
14,334 
-308 (2%) 
15,198 
-1,602 (4%) 
35,196 
Exclusion of CKD Stage 4/5 or ESRD [-180, 
Day 0] 
-345 (2%) 
13,989 
-171 (1%) 
15,027 
-1,265 (4%) 
33,931 
Exclusion of Dialysis or Renal Transplant) [ -
180, 0] 
-30 (<1%) 
13,959 
-43 (<1%) 
14,984 
-141 (<1%) 
33,790 
Exclusion of Bleeding [-180, 0] 
-805 (6%) 
13,154 
-1,750 (12%) 
13,234 
-5,812 (17%) 
27,978 
Exclusion of Cancer [-180, 0] 
-1,592 (12%) 
11,562 
-796 (6%) 
12,438 
-2,795 (10%) 
25,183 
Exclusion of Weight > 120 kg [-180, 0] 
-868 (8%) 
10,694 
-549 (4%) 
11,889 
- 
- 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
5 
Exclusion of Significant Liver Disease [-180, 
0] 
-356 (3%) 
10,338 
-199 (2%) 
11,690 
- 
- 
Exclusion of Use of Contraindicated 
Medications [-180, 0] 
-80 (<1%) 
10,258 
-85 (<1%) 
11,605 
-281 (1%) 
22,790 
Exclusion of Prosthetic Heart Valve [-180, 0] 
-24 (<1%) 
10,234 
-8 (<1%) 
11,597 
- 
- 
Exclusion of Pregnancy [-180, 0] 
-8 (<1%) 
10,226 
-17 (<1%) 
11,580 
- 
- 
Exclusion of Dual Antiplatelet Therapy [-
180, Day 0 
-176 (2%) 
10,050 
-164 (1%) 
11,416 
-624 (3%) 
22,115 
Exclusion of Coagulopathy [-180, Day 0] 
-196 (2%) 
9,854 
-132 (1%) 
11,284 
-338 (2%) 
21,777 
Exclusion of Atrial Fibrillation [-180, Day 0] 
-261 (3%) 
9,593 
-142 (1%) 
11,142 
-637 (3%) 
21,140 
Final cohort 
 
9,593 
 
11,142 
 
21,140 
 
*Data may be omitted to comply with the CMS cell suppression policy 
 
6. Variables  
 
6.1 Exposure-related variables:  
 
Study drug:  
The study exposure of interest is defined by a prescription drug claim indicating apixaban dispensation. New initiation will be 
defined by no such records of apixaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study 
eligibility criteria.  
 
Comparator agent: 
The comparator is defined by a prescription drug claim indicating rivaroxaban dispensation. New initiation will be defined by no such 
records of rivaroxaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria. 
 
6.2 Preliminary Covariates: 
• Age 
• Gender 
• CCI score 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
6 
The covariate listed above represents only a small subset of the covariate vector that will ultimately be controlled for in the 
design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be 
sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study 
has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (Appendix B).  
 
6.3 Outcome variables and study follow-up:  
 
6.3.1 Outcome variables 
 
Effectiveness outcome variables of interest (definitions provided in Appendix): 
§ Primary outcome: Major bleeding and clinically relevant non-major bleeding through 3 months of treatment with 
apixaban or rivaroxaban. 
§ Secondary outcomes:  
o To assess the frequency of major bleeding events and clinically relevant non-major bleeding individually 
o To assess extracranial and intracranial major bleeding events separately 
o To assess recurrent VTE 
o All-cause mortality 
 
6.3.2 Study follow-up 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on day of 
cohort entry. The as-treated will be the primary analysis. An allowable gap of 10 days between records indicating each treatment will 
qualify as “continuous therapy” with respect to follow-up in the as-treated analysis.  
The follow-up will start the day after drug initiation (i.e., cohort entry date), and will continue until the earliest date of the following 
events: 
• The first occurrence of the outcome of interest 
• The date of end of continuous registration in the database 
• End of the study period at 90 days 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
7 
• Measured death event occurs 
• Switch  
• Discontinuation (10-day allowable grace period and risk window) 
• Nursing home admission 
• Initiation of another DOAC (dabigatran or edoxaban) or warfarin 
 
In the secondary ITT analysis, we will not censor for discontinuation or switching among study drugs 
 
  
 
7. Initial Feasibility Analysis  
Aetion report name: 
For apixaban vs. rivaroxaban 
Optum CDM -  https://bwh-dope.aetion.com/projects/details/1775/rwrs/78117  
IBM® MarketScan® - https://bwh-dope.aetion.com/projects/details/1776/rwrs/78118  
CMS NOAC -  https://bwh-dope.aetion.com/projects/details/1777/rwrs/78119  
 
Date conducted: Updated 01/13/2022 
 
Complete Aetion feasibility analysis using age, gender, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed, nor will incidence rates be stratified by treatment group. 
 
• Report patient characteristics by treatment group 
§ 
Apixaban vs Rivaroxaban 
 
  
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Variable 
Rivaroxaban - 
Comparator 
Apixaban 
- Exposure 
Difference 
Rivaroxaban - 
Comparator 
Apixaban 
- Exposure 
Difference 
Rivaroxaban - 
Comparator 
Apixaban 
- Exposure 
Difference 
Number of 
patients 
4,502 
5,091 
 
6,339 
4,781 
 
12,786 
8,329 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
8 
Age 
 
 
 
 
 
 
 
 
 
...mean 
(sd) 
61.82 (16.97) 
69.00 
(15.57) 
-7.18 (-
7.83, -6.52) 
53.93 (15.65) 
57.11 
(15.97) 
-3.18 (-
3.78, -2.59) 
70.91 (13.02) 
74.18 
(12.37) 
-3.28 (-
3.63, -2.93) 
...median 
[IQR] 
64.00 [51.00, 
75.00] 
72.00 
[60.00, 
81.00] 
 
55.00 [44.00, 
63.00] 
57.00 
[47.00, 
66.00] 
 
72.00 [66.00, 
80.00] 
75.00 
[68.00, 
83.00] 
 
Gender 
 
 
 
 
 
 
 
 
 
M 
2,248 (49.9%) 
2,172 
(42.7%) 
7.3% (5.3%, 
9.3%) 
3,418 (53.9%) 
2,483 
(51.9%) 
2.0% (0.1%, 
3.9%) 
5,549 (43.4%) 
3,206 
(38.5%) 
4.9% (3.5%, 
6.3%) 
F 
2,254 (50.1%) 
2,919 
(57.3%) 
-7.3% (-
9.3%, -
5.3%) 
2,921 (46.1%) 
2,298 
(48.1%) 
-2.0% (-
3.9%, -
0.1%) 
7,237 (56.6%) 
5,123 
(61.5%) 
-4.9% (-
6.3%, -
3.5%) 
U 
 
 
 
 
 
 
 
 
 
CCI (180 
Days 
 
 
 
 
 
 
 
 
 
... mean 
(sd) 
2.62 (2.35) 
3.65 (2.64) 
-1.04 (-
1.14, -0.94) 
1.61 (1.72) 
2.19 (1.89) 
-0.58 (-
0.65, -0.51) 
2.17 (2.08) 
2.74 (2.27) 
-0.58 (-
0.64, -0.52) 
...median 
[IQR] 
2.00 [1.00, 
4.00] 
3.00 [2.00, 
5.00] 
 
1.00 [0.00, 
3.00] 
2.00 [1.00, 
3.00] 
 
2.00 [1.00, 
3.00] 
2.00 [1.00, 
4.00] 
 
 
• Report summary parameters of study population FEASIBILITY- FOR STUDY OUTCOME 
§ 
For Apixaban vs Rivaroxaban 
 
FEASIBILITY FOR STUDY OUTCOME 
 
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Number of patients in full cohort 
9,593 
11,142 
21,140 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
9 
Number of patients dropped as incomplete cases 
0 
0 
0 
Number of patients that did not begin follow-up 
7 
22 
25 
Number of patients in analytic cohort 
9,586 
11,120 
21,115 
Number of events 
172 
213 
1,049 
Number of person-years 
1,433.02 
1,933.00 
3,484.88 
Number of patients in group: Rivaroxaban - Comparator 
4,499 
6,339 
12,786 
Number of patients in group: Apixaban - Exposure 
5,087 
4,781 
8,329 
Risk per 1,000 patients 
17.94 
19.15 
49.68 
Rate per 1,000 person-years 
120.03 
110.19 
301.01 
 
• Report median follow-up time by treatment group 
§ 
For Apixaban vs Rivaroxaban 
 
FOLLOW-UP TIME FOR STUDY OUTCOME 
Median Follow-Up Time (Days) [IQR] – At 10 days gap 
Patient Group 
Optum CDM IBM® MarketScan® CMS - NOAC 
Overall Patient Population 
57 [27, 90] 
79 [38, 90] 
67 [38, 90] 
Referent - Rivaroxaban 
54 [29, 90] 
68 [38, 90] 
62 [38, 90] 
Exposure - Apixaban 
61 [18, 90] 
90 [38, 90] 
75 [38, 90] 
 
• Report reasons for censoring in the overall study population 
§ 
For Apixaban vs Rivaroxaban 
 
CENSORING REASONS FOR STUDY OUTCOME 
Reasons  
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Outcome 
123 (0.8%) 
187 (0.8%) 
601 (1.4%) 
Death 
79 (0.5%) 
1 (0.0%) 
459 (1.1%) 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
10 
Start of an additional exposure 
219 (1.5%) 
369 (1.5%) 
682 (1.6%) 
End of index exposure 
5,485 (36.6%) 
10,122 (40.6%) 
16,677 (38.5%) 
Maximum follow-up time reached 
6,595 (44.0%) 
10,590 (42.5%) 
18,372 (42.4%) 
End of patient data 
0 (0.0%) 
1,218 (4.9%) 
2,779 (6.4%) 
End of patient enrollment 
427 (2.8%) 
1,455 (5.8%) 
402 (0.9%) 
DOAC or Warfarin Initiation + Nursing Home Admission 2,073 (13.8%) 
961 (3.9%) 
3,393 (7.8%) 
 
• Report overall risk of the primary outcome. 
 
  
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Pooled 
Risk per 1,000 patients 
17.92974044 
19.11685514 
49.62157048 
34.24477612 
 
 
8. Initial Power Assessment 
 
Aetion report name: 
§ 
For Apixaban vs Rivaroxaban 
• 
Optum CDM - https://bwh-dope.aetion.com/projects/details/1775/rwrs/78120  
• 
IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1776/rwrs/78121  
• 
CMS NOAC -  https://bwh-dope.aetion.com/projects/details/1777/rwrs/78122  
 
Date conducted: Updated 01/13/2022 
 
In order to complete the initial power analysis, a dummy outcome indicating a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. A 1:1 
PS-matched comparative analysis was performed, including age, gender, and CCI score as the only covariates. Power calculations are 
based on the formulas from Chow et al. (2008). 
 
This emulation is of a trial that is not yet completed. The trial investigators have not published their power calculations. Therefore, 
we present a range of power calculations for different effect sizes given the feasibility counts and alpha of 0.05. The range in 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
11 
potential hazard rations come from prior studies in Aryal et al. (2019) comparing bleeding outcomes for apixaban versus rivaroxaban. 
The target enrollment for the trial is 2,760 patients. We anticipate having around 41,875 patients in our cohort. 
 
 
1. Pooled 
 
Superiority Analysis - Pooled 
  
  
  
  
  
Number of patients matched  
32,390 
32,390 
32,390 
32,390 
32,390 
Reference  
16,195 
16,195 
16,195 
16,195 
16,195 
Exposure  
16,195 
16,195 
16,195 
16,195 
16,195 
Risk per 1,000 patients  
34.24477612 
34.24477612 
34.24477612 
34.24477612 34.24477612 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
1109.188299 
1109.188299 
1109.188299 
1109.188299 1109.188299 
Power  
0.960445201 
0.999965466 
1 
1 
1 
 
2. Optum CDM 
 
Superiority Analysis - Optum 
  
  
  
  
  
Number of patients matched  
12,138 
12,138 
12,138 
12,138 
12,138 
Reference  
6,069 
6,069 
6,069 
6,069 
6,069 
Exposure  
6,069 
6,069 
6,069 
6,069 
6,069 
Risk per 1,000 patients  
8.19945337 
8.19945337 
8.19945337 
8.19945337 
8.19945337 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
  
  
  
  
  
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
99.524965 
99.524965 
99.524965 
99.524965 
99.524965 
Power  
0.19958509 
0.4283428 
0.72176747 
0.93287238 
0.99548076 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
12 
3. IBM® MarketScan® 
 
 
 
Superiority Analysis - MarketScan 
  
  
  
  
  
Number of patients matched  
9,016 
9,016 
9,016 
9,016 
9,016 
Reference  
4,508 
4,508 
4,508 
4,508 
4,508 
Exposure  
4,508 
4,508 
4,508 
4,508 
4,508 
Risk per 1,000 patients  
19.11685514 19.11685514 19.11685514 19.11685514 19.11685514 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
172.357566 
172.357566 
172.357566 
172.357566 
172.357566 
Power  
0.310539399 0.648532959 0.918223967 0.995201595 0.999974911 
 
4. CMS – NOAC 
 
Superiority Analysis – CMS NOAC 
  
  
  
  
  
Number of patients matched  
16,030 
16,030 
16,030 
16,030 
16,030 
Reference  
8,015 
8,015 
8,015 
8,015 
8,015 
Exposure  
8,015 
8,015 
8,015 
8,015 
8,015 
Risk per 1,000 patients  
49.62157048 49.62157048 49.62157048 49.62157048 49.62157048 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
795.4337748 795.4337748 795.4337748 795.4337748 795.4337748 
Power  
0.882335738 0.998928865 0.999999921 
1 
1 
 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
13 
• Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the 
analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons 
for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and 
reported in the subsequent sections, after incorporating feedback and refining the protocol. 
 
Reviewed by PI: 
Shirley Wang 
Initial Date reviewed: 
08/03/2021 
Reviewed by FDA: 
Ken Quinto 
Initial Date reviewed: 
08/18/2021 
Reasons for stopping 
analysis (if required): 
 
 
 
9. Balance Assessment 
 
Aetion report name: 
§ 
For Apixaban vs Rivaroxaban 
• 
Optum CDM - https://bwh-dope.aetion.com/projects/details/1775/rwrs/79764  
• 
IBM® MarketScan®-  https://bwh-dope.aetion.com/projects/details/1776/rwrs/79768 
• 
CMS NOAC - https://bwh-dope.aetion.com/projects/details/1777/rwrs/80116 
 
Date conducted: 02/25/2022 and 03/08/2022 
 
After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the 
dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete 
list of covariates. 
 
1. Provide plot of PS distributions stratified by treatment group. 
a. See Appendix B 
 
2. Report covariate balance after matching. 
a. See Appendix B 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
14 
*Data may be omitted to comply with the CMS cell suppression policy 
 
3. Report reasons for censoring by treatment group. 
Censoring Reasons for Study Outcome 
Reasons 
Overall 
Referent 
Exposure 
Death 
439 (1.0%) 
197 (0.8%) 
242 (1.3%) 
Start of an additional exposure 
609 (1.5%) 
354 (1.5%) 
255 (1.4%) 
End of index exposure 
15,737 (37.6%) 
9,948 (42.1%) 
5,789 (31.8%) 
Maximum follow-up time 
18,479 (44.2%) 
9,898 (41.9%) 
8,581 (47.2%) 
End of patient data 
1,676 (4.0%) 
761 (3.2%) 
915 (5.0%) 
End of patient enrollment 
1,169 (2.8%) 
660 (2.8%) 
509 (2.8%) 
DOAC or warfarin initiation + nursing home admission 
3,712 (8.9%) 
1,806 (7.6%) 
1,906 (10.5%) 
 
4. Report follow-up time by treatment group. 
FOLLOW-UP TIME FOR STUDY OUTCOME 
Median Follow-Up Time (Days) [IQR] – At 10 days gap 
Patient Group 
Optum CDM IBM® MarketScan® CMS - NOAC 
Overall Patient Population 
65 [31, 90] 
74 [38, 90] 
67 [38, 90] 
Referent - Rivaroxaban 
61 [35, 90] 
67 [38, 90] 
62 [34, 90] 
Exposure - Apixaban 
68 [28, 90] 
88 [38, 90] 
76 [38, 90] 
 
 
10. Final Power Assessment 
 
Date conducted: 03/08/2022 
 
Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All 
other parameters in the table should be the same as in Section 8. 
 
1. Pooled 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
15 
Superiority Analysis - Pooled 
  
  
  
  
  
Number of patients matched  
28,404 
28,404 
28,404 
28,404 
28,404 
Reference  
14,202 
14,202 
14,202 
14,202 
14,202 
Exposure  
14,202 
14,202 
14,202 
14,202 
14,202 
Risk per 1,000 patients  
17.898823 
17.898823 
17.898823 
17.898823 
17.898823 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
  
  
  
  
  
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
508.398168 
508.398168 
508.398168 
508.398168 
508.398168 
Power  
0.71080316 
0.98035484 
0.99992736 
1 
1 
 
2. Optum CDM 
 
Superiority Analysis - Optum 
  
  
  
  
  
Number of patients matched  
6,064 
6,064 
6,064 
6,064 
6,064 
Reference  
3,032 
3,032 
3,032 
3,032 
3,032 
Exposure  
3,032 
3,032 
3,032 
3,032 
3,032 
Risk per 1,000 patients  
11.5111765 
11.5111765 
11.5111765 
11.5111765 
11.5111765 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
  
  
  
  
  
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
69.8037746 
69.8037746 
69.8037746 
69.8037746 
69.8037746 
Power  
0.1539359 
0.31946556 
0.56907891 
0.82526402 
0.96910355 
 
3. IBM® MarketScan® 
 
Superiority Analysis - MarketScan 
  
  
  
  
  
Number of patients matched  
7,388 
7,388 
7,388 
7,388 
7,388 
Reference  
3,694 
3,694 
3,694 
3,694 
3,694 
Exposure  
3,694 
3,694 
3,694 
3,694 
3,694 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
16 
Risk per 1,000 patients  
8.02773904 
8.02773904 
8.02773904 
8.02773904 
8.02773904 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
  
  
  
  
  
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
59.308936 
59.308936 
59.308936 
59.308936 
59.308936 
Power  
0.13791552 
0.27918325 
0.50284704 
0.76086404 
0.94159663 
 
4. CMS – NOAC 
 
Superiority Analysis – CMS NOAC 
  
  
  
  
  
Number of patients matched  
14,952 
14,952 
14,952 
14,952 
14,952 
Reference  
7,476 
7,476 
7,476 
7,476 
7,476 
Exposure  
7,476 
7,476 
7,476 
7,476 
7,476 
Risk per 1,000 patients  
27.146628 
27.146628 
27.146628 
27.146628 
27.146628 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
  
  
  
  
  
  
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected  
405.896382 
405.896382 
405.896382 
405.896382 
405.896382 
Power  
0.61328522 
0.94876319 
0.99927824 
0.99999974 
1 
 
 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. 
Reviewed by PI: 
 
Date reviewed: 
 
Reviewed by FDA: 
 
Date reviewed: 
 
Reasons for stopping 
analysis (if required): 
 
 
11. Study Confidence and Concerns 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
17 
Deadline for voting on study confidence and listing concerns: 
Date votes and concerns are summarized:    
 
• If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
• All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
• After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here. 
 
12. Register study protocol on clinicalTrials.gov 
 
Date conducted:    
 
• Register the study on clinicalTrials.gov and upload this document. 
 
13. Comparative Analyses 
 
Aetion report name: 
Date conducted:    
 
13.1 
For primary analysis:  
 
13.2 
For sensitivity analyses: 
 
 
14.  Requested Results  
 
14.1 
Table 1: Baseline characteristics before and after adjustment 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
18 
Variable 
 
Before adjustment 
After adjustment 
Referent 
Exposure 
Std. diff. 
Referent 
Exposure 
Std. diff. 
Number of patients 
 
 
- 
 
 
- 
Age categories 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
14.2 
Table 2: Follow-up time 
 
Patient Group 
Median Follow-Up Time (Days) [IQR] 
Overall Patient Population 
 
Referent 
 
Exposure 
 
 
14.3 
Table 3: Censoring events 
 
 
Overall 
Referent 
Exposure 
Outcome 
 
 
 
Death 
 
 
 
Start of an additional exposure 
 
 
 
End of index exposure 
 
 
 
Specified date reached 
 
 
 
End of patient data 
 
 
 
End of patient enrollment 
 
 
 
… 
 
 
 
 
14.4 
Table 4: Results from primary analyses; 
 
Analysis 
No. exposed events 
No. referent events 
Exposed rate 
Referent rate 
HR (95% CI) 
Crude 
 
 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
19 
Analysis 1 
 
 
 
 
 
Analysis 2 
 
 
 
 
 
... 
 
 
 
 
 
HR, Hazard Ratio; CI, Confidence Interval. 
 
14.5 
Table 5: Results from secondary analyses; 
 
 
15. References 
 
Chow S, Shao J, Wang H. 2008.  Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 
177 
 
Madan Raj Aryal, Rohit Gosain, Anthony Donato, Han Yu, Anjan Katel, Yashoda Bhandari, Rashmi Dhital, Peter A. Kouides; Systematic 
review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 
2019; 3 (15) 2381 – 2387, doi: https://doi.org/10.1182/bloodadvances.2019000572.  

#
COBRRA - VTE  trial definitions 
Implementation in routine care
References/Rationale
Color coding
Please see the following Google Drive for further details or any missing information: https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV?usp=sharing
ICD-10 codes are not listed in this document because of excel cell size limitations and excessive number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google Drive Folder (link above). 
ICD-9 to ICD-10 code conversions were completed using a SAS macro that implements forward/ backward mapping based on the CMS ICD-9 to ICD-10 mapping
Criteria
Can be replicated in claims
Apixaban 10 mg PO BID for 1 week, then 5 mg PO BID for 3 months of treatment
vs.
Rivaroxaban 15 mg PO BID for 3 weeks, then 20 mg PO OD for 3 months of treatment
Apixaban: All generic
vs.
Rivaroxaban: All generic
Using dummy definitions for 
measuring in claims
Can't be measured in claims
The rate of adjudicated clinically relevant bleeding (CRB) events [Time Frame: For the duration of the study: 3 months] - CRB events are 
defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events
Measured  [0,90] in an inpatient setting in any diagnosis position (with transfusion codes for non-critical sites)
Major Bleeding:
See "Major Bleeding" Sheet
Measured [0,90] in an inpatient setting in any  diagnoses position (transfusion codes NOT included for non-critical sites)
Clinically Relevant Non-Major Bleeding Events:
See sheet "CRNM Bleeds"
Graham DJ, Reichman ME, Wernecke M, et al. Stroke, 
Bleeding, and Mortality Risks in Elderly Medicare 
Beneficiaries Treated With Dabigatran or 
Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA 
Intern Med. 2016;176(11):1662–1671. 
doi:10.1001/jamainternmed.2016.5954
Can't be measured in claims 
but not important for the 
analysis
1
Confirmed newly diagnosed symptomatic acute VTE (proximal power extremity DVT or segmental or greater PE)
Measured [-14, 0 ] in any diagnosis position in an inpatient setting:
Pulmonary Embolism:
ICD-9 Diagnosis: 415.1, 415.10, 415.11, 415.12, 415.13, 415.5, 415.16, 415.17, 415.19, 415.199
ICD-10 Diagnosis: I26.0, I26.01, I26.02, I26.09, I26.9, I26.92, I26.99, I26.90
Proximal DVT
ICD-9 diagnosis: 451.1x, 451.2x, 451.81, 451.9x, 453.1x, 453.2x, 453.8x, 453.9x, 453.40, 453.41, 453.42, 453.0
ICD-10 diagnosis: I80.1*, I80.2, I80.3, I80.9, I82.0, I82.1, I82.2* (EXCEPT I82.21), I82.4*, I82.6*, I82.890, I82.90,  I82.A1*, I82.B1*, I82.C1*) 
2
Age >= 18 years 
Age >= 18
Informed consent obtained 
N/A
1
Have received >72 hours of thereapeutic anticoagulation
Measured [- 180, 0] in prescription claims
Prior use of a DOAC or Warfarin: 
Apixaban, Rivaroxaban, Dabigatran, Edoxaban, or Warfarin
2
Creatine clearance < 30 ml/min calculated with the Cockcroft-Gault formula 
Measured [-180, 0 ] in any diagnosis position and inpatient or outpatient care setting 
CKD stage 4/5/ESRD
ICD-9 Diagnosis: 584.4x, 585.5x, 585.6x
ICD-10 Diagnosis: N18.4x, N18.5x, N18.6x 
Dialysis/Renal Transplant
See Sheet "Dialysis and Renal Transplant" 
3
Any contradiction for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to 
one of the following: 
4
 1) Active Bleeding 
Mesaured [-180, 0 ] in an inpatient, any diagnosis position (transfusion codes required for non-critical sites)
Major Bleeding:
See "Major Bleeding" Sheet
 
Measured [-180, 0] in an inpatient, any diagnosis position (transfusion codes NOT required for non-critical sites)
Clinically Relevant Non-Major Bleeding Events:
See "CRNM Bleeds Sheet"
Graham DJ, Reichman ME, Wernecke M, et al. Stroke, 
Bleeding, and Mortality Risks in Elderly Medicare 
Beneficiaries Treated With Dabigatran or 
Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA 
Intern Med. 2016;176(11):1662–1671. 
doi:10.1001/jamainternmed.2016.5954
5
2) Active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic 
disease; or c) currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or d) 
a hematologic malignancy not in complete remission
Measured [-180, 0] in any diagnosis position in an inpatient or outpatient setting
Cancer:
ICD-9 Diagnosis: 140.x-209.x (except 209.4x, 209.5x, 209.6x)
ICD-10 Diagnosis: C00.x-C96, D45 
For full list, see "Cancer Sheet"
6
3) Weight > 120 kg 
Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting:
Bypass Surgery:
HCPCS: 43659, 43999, 43842, S2082, 43644, 43645, 43770, 43843, 43845, 43846, 43847
ICD-9 Procedure: 43.89, 44.69, 44.31, 44.39, 44.95, 45.51, 45.91, 43.82, 44.38, 44.68
ICD-10 Procedure: 0D160JB, 0D160KL, 0D160Z9, 0D164JL, 0D1687L, 0D168JB, 0D168Z9, 0D168ZL, 0D190ZA, 0D194J9, 0D194K9, 0D194ZA, 0D198K9, 0D198ZA, 0D1A0JB, 0D1A0ZB, 0D1A87A, 0D1A8JB, 0D1A8KA, 
0D1A8KB, 0D1B4JB, 0D1B4KB, 0D1B8JB, 0D760DZ, 0DB63Z3, 0DB67ZZ, 0DB90ZZ, 0DM64ZZ, 0DN67ZZ, 0DQ64ZZ, 0DV60CZ, 0DV63CZ, 0D16079, 0D1607A, 0D1607L, 0D160ZL, 0D164J9, 0D164KA, 0D164KL, 0D1687A, 
0D168J9, 0D168ZA, 0D190K9, 0D190KB, 0D19479, 0D1947B, 0D194JA, 0D194KB, 0D1987A, 0D198ZB, 0D1A07A, 0D1A0KB, 0D1A47A, 0D1A4KA, 0D1A4ZB, 0D1A8ZA, 0D1A8ZB, 0D1B0JB, 0D763DZ, 0D764ZZ, 0DB60Z3, 
0DB67Z3, 0DB68Z3, 0DQ68ZZ, 0DU64KZ, 0DU677Z, 0DU67KZ, 0DU687Z, 0DU68JZ, 0DU68KZ, 0DV63ZZ, 0DV64CZ, 0DV64DZ, 0D164Z9, 0D168JL, 0D168KA, 0D168KB, 0D168ZB, 0D190Z9, 0D1947A, 0D194KA, 0D194ZB, 
0D1987B, 0D1A07B, 0D1A0JA, 0D1A4JA, 0D1A4KB, 0D763ZZ, 0D764DZ, 0DB63ZZ, 0DBB0ZZ, 0DF67ZZ, 0DF68ZZ, 0DN60ZZ, 0DQ60ZZ, 0DU60KZ, 0DU647Z, 0DU64JZ, 0DV60ZZ, 0DV64ZZ, 0D1607B, 0D160JL, 0D160K9, 
0D160KA, 0D164JB, 0D1687B, 0D1907B, 0D190J9, 0D190JB, 0D190ZB, 0D194Z9, 0D198J9, 0D198KA, 0D1A0ZA, 0D1A47B, 0D1A4JB, 0D1A4ZA, 0D1A8JA, 0D1B47B, 0D1B4ZB, 0D1B8KB, 0D1B8ZB, 0D760ZZ, 0DB64Z3, 
0DM60ZZ, 0DN63ZZ, 0DN64ZZ, 0DN68ZZ, 0DU607Z, 0DU60JZ, 0DV60DZ, 0DV63DZ, 0D160J9, 0D160JA, 0D160KB, 0D160ZA, 0D160ZB, 0D16479, 0D1647A, 0D1647B, 0D1647L, 0D164JA, 0D164K9, 0D164KB, 0D164ZA, 
0D164ZB, 0D164ZL, 0D16879, 0D168JA, 0D168K9, 0D168KL, 0D19079, 0D1907A, 0D190JA, 0D190KA, 0D194JB, 0D19879, 0D198JA, 0D198JB, 0D198KB, 0D198Z9, 0D1A0KA, 0D1A87B, 0D1A8ZH, 0D1B07B, 0D1B0KB, 
0D1B0ZB, 0D1B87B, 0D1B8ZH, 0DB60ZZ, 0DB80ZZ, 0DF60ZZ, 0DF63ZZ, 0DF64ZZ, 0DQ63ZZ, 0DQ67ZZ, 0DU67JZ, 0DV67ZZ, 0DV68ZZ
Obesity:
ICD-9 Diagnosis: 539.89, 649.1, V85.36, V85.41, V85.42, 649.10, 649.11, 649.20, 649.23, V85.37, V85.44, 278.01, 278.03, 539, 649.13, 649.14, 649.2, 649.22, 649.24, V85.31, V85.34, V85.35, V85.43, 278.0, 278.00, 
539.09, 539.8, 539.81, 649.12, 649.21, V85.38, V85.39, 539.0, 539.01, V85.30, V85.32, V85.33, V85.45 
ICD-10 Diagnosis: O99.215, Z68.41, O99.210, O99.214, O99.844, Z68.35, Z68.38, Z68.43, Z68.45, O99.845, Z68.32, Z68.33, Z68.36, O99.212, O99.841, O99.842, Z68.34, Z68.37, Z68.42, O99.211, O99.213, O99.840, 
O99.843, Z68.30, Z68.31, Z68.39, Z68.44
Weight Loss and Appetite Supressors:
DEXFENFLURAMINE HCL, NALTREXONE HCL/BUPROPION HCL, PHENTERMINE HCL/TOPIRAMATE, LORCASERIN HCL, ORLISTAT”, SIBUTRAMINE HCL M-HYDRATE, BENZPHETAMINE HCL, FENFLURAMINE HCL, DIETHYLPROPION HCL, 
PHENDIMETRAZINE TARTRATE, PHENTERMINE HCL
7
4) Liver Disease (Child=Pugh Class B or C)
Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting
Significant Liver Disease:
ICD-9 Procedure: 070.xx, 570.xx- 573.xx, 456.0x-456.2x, 576.8x, 782.4x, 789.5x 
ICD -10 Diagnosis: B16.1 ,B17.11 ,B17.2 ,B17.9 ,B18.2 ,B18.8 ,K71.0 ,K71.10 ,K71.2 ,K71.3 ,K71.51 ,K72.01 ,K72.10 ,K73.9 ,K74.3 ,K74.69 ,K75.2 ,K75.81 ,K75.89 ,K76.0 ,K76.1 ,K76.3 ,K76.6 ,K76.89 ,B19.0 ,B19.9 ,I85.11 
,K71.11 ,K71.7 ,K71.9 ,K72.11 ,K74.1 ,K74.4 ,K74.5 ,K75.3 ,K76.7 ,K87 ,R18.8 ,B15.9 ,B16.0 ,B16.2 ,B16.9 ,B18.0 ,B18.9 ,B19.10 ,B19.11 ,K70.10 ,K70.41 ,K71.4 ,K71.50 ,K72.91 ,K74.0 ,K74.2 ,K74.60 ,K75.1 ,K76.2 
,K76.81 ,K83.8 ,R17 ,B15.0 ,B19.21 ,B25.1 ,I85.00 ,K70.0 ,K70.11 ,K70.2 ,K70.9 ,K72.00 ,K72.90 ,K73.1 ,K73.8 ,K75.0 ,K76.9 ,R18.0 ,B17.0 ,B17.10 ,B17.8 ,B18.1 ,B19.20 ,I85.01 ,I85.10 ,K70.30 ,K70.31 ,K70.40 ,K71.6 
,K71.8 ,K73.0 ,K73.2 ,K75.4 ,K75.9 ,K76.4 ,K76.5 ,K77 ,K83.5 
ICD-9 Procedure: 39.1x, 42.91 
ICD-10 Procedure: See "Liver Bypass" Sheet
8
5) Use of contraindicated medications 
Measured [-180,0] in prescription claims
Strong CYP3A4 Inhibitors/Inducers:
Inhibitors: Ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir
Inducers: Rifampin, rifampicin/rifampin, phenytoin, carbamazepine
P-gp Inhibitors/Inducers: 
cobicistat, conivaptan, tipranavir
https://depts.washington.edu/anticoag/home/cont
ent/apixaban
CYP3A's Copied from PLATO: https://bwh-
dope.aetion.com/measures/details/211908/948/0/t
emplates/simpleEventSet?&tab=0
9
6) Another indication for long-term anticoagulation (eg. atrial fibrillation)
Measuered [-180, 0] in any diagnosis position in an inpatient or oupatient setting
Atrial Fibrilation:
ICD-9 Diagnosis: 427.3, 427.31, 427.32
ICD-10 Diagnosis: I48.0, I48.2, I48.91, I48.92, I48.1, I48.3, I48.4
Prosthetic Heart Valve:
ICD-9 Diagnosis: V43.3
ICD-10 Diagnosis: Z95.2
10
7) Pregnancy 
Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting 
Pregnancy
See "Pregnancy" Sheet
11
8)  Dual Antiplatelet Use
Measured [-180, 0] in prescription claims
Use of Antiplaelets:
Any of the following: cilostazol, dipyridamole, ticlopidine HCl, aspirin, clopidogrel bisulfate, prasugrel HCl, ticagerlor, aspirin/dipyridamole, ezetimibe
12
9)  Coagulopathy
Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting
Coagulopathy:
ICD-9 Diagnosis: 286, 286.1, 286.4, 286.5, 286.52, 286.53, 286.59, 287.5, 286.0, 286.2, 286.3, 286.6, 286.7, 286.9, 287.1, 287.3, 287.4
ICD-10 Dignosis: D67, D68, D68.1, D68.2, D68.3, D68.31, D68.311, D68.318, D68.4, D68.52, D68.61, D68.69, D68.8, D69.41, D69.49, D69.51, D69.59, D65, D66, D68.0, D68.312, D68.32, D68.5, D68.51, D68.59, D68.6, 
D68.62, D68.9, D69.1, D69.3, D69.4, D69.42, D69.5, D69.6
PRIMARY OUTCOME
TRIAL DETAILS 
EXPOSURE vs. COMPARISON
INCLUSION CRITERIA
EXCLUSION CRITERIA
Appendix A

Information from Trial
Trial Name: COBBRA clinicaltrials.gov/ct2/show/NCT0462430
NCT: NCT04642430
Therapeutic Area: Cardiology
RCT Category: Equivalence/Superiority
Brand Name: Eliquis and Xarelto
Generic Name: Apixaban and Rivaroxaban
Sponsor: Ottwa Hospital Research Institute
Year:  2020 - Present
Measurable Endpoint: Major Bleeding
Exposure: Apixaban
Comparator: Rivaroxaban
Populuation: Men and women ages 18 and older presenting with acute VTE
No. of Patients: 3,018 
Power: TBD
Appendix A

ICD-9 Dx
336.1  VASCULAR MYELOPATHIES
363.61  CHOROIDAL HEMORRHAGE UNSPECIFIED
363.62  EXPULSIVE CHOROIDAL HEMORRHAGE
376.32  ORBITAL HEMORRHAGE
377.42  HEMORRHAGE IN OPTIC NERVE SHEATHS
379.23  VITREOUS HEMORRHAGE
431  INTRACEREBRAL HEMORRHAGE
432  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE
432  NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1  SUBDURAL HEMORRHAGE
432.9  UNSPECIFIED INTRACRANIAL HEMORRHAGE
719.1  HEMARTHROSIS
719.11  HERARTHROSIS INVOLVING SHOULDER REGION
719.12  HEMARTHORSIS INVOLVING UPPER ARM
719.14  HEMARTHROSIS INVOLVING HAND
719.15  HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.17  HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.19  HEMARTHROSIS INVOLVING MULTIPLE SITES
729.92  NONTRAUMATIC HEMATOMA OF SOFT TISSUE
852  SUBARACHNOID SUBDURAL AND EXTRADURAL HEMORRHAGE FOLLOWING INJURY
852  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.01  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.03  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1 - 24 HOURS) LOSS OF CONSCIOUSNESS)
852.05  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.06  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.09  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.1  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.11  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.12  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.15  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.19  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.2  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.22  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.25  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.3  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.3  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.31  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.32  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.33  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.34  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.35  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.42  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN 1 HOUR) LOSS OF CONSCIOUSNESS
852.43  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE
852.45  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-24 HOURS) LOSS OF CONSCIOUSNESS-EXISTING CONSCIOUS LEVEL
852.49  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.54  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY
853  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
853.01  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
853.03  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
853.04  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.05  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.1  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
853.11  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
853.12  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
853.13  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
853.14  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED( MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
853.15  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
866.02  LACERATION OF KIDNEY WITHOUT OPEN WOUND INTO CAVITY
Appendix A

363.72  HEMORRHAGIC CHOROIDAL DETACH
423  HEMOPERICARDIUM
430  SUBARACHNOID HEMORRHAGE
568.81  HEMOPERITONEUM (NONTRAUMATIC)
719.1  HEMARTHROSIS SITE UNSPECIFIED
719.13  HEMARTHROSIS INVOLVING FOREARM
719.16  HEMARTHROSIS INVOLVING LOWER LEG
719.18  HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
852  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.02  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.04  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.1  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.13  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.14  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.16  SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.2  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.21  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.23  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.24  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.26  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.29  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.36  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.39  SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
852.4  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
852.4  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.41  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.44  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.46  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.5  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.5  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.51  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.52  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.53  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
852.55  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
852.56  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
852.59  EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
853  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND
853.02  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
853.06  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED
853.09  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
853.1  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
853.16  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
853.19  OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
866.01  HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITHOUT OPEN WOUND INTO CAVITY
866.11  HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITH OPEN WOUND INTO CAVITY
866.12  LACERATION OF KIDNEY WITH OPEN WOUND INTO CAVIT
The occurrence of Inpatient Confinement with the following attributes:
Procedure 
Code (Any 
Confinement 
Position)
ŝƐĂŶǇŽĨ͗΂͞ϵϵ͘Ϭϱ͕͟͞ϵϵ͘Ϭϯ͕͟͞ϵϵ͘Ϭϰ͕͟͞ϵϵ͘Ϭϲ͟΃
99.05  TRANSFUSION OF PLATELETS
99.03  OTHER TRANSFUSION OF WHOLE BLOOD
99.04  TRANSFUSION OF PACKED CELLS
99.06  TRANSFUSION OF COAGULATION FACTORS
AND 
ICD-9 Dx
Appendix A

455.1  INTERNAL THROMBOSED HEMORRHOIDS
455.7  UNSPECIFIED THROMBOSED HEMORRHOIDS
455.8  UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION
455.9  RESIDUAL HEMORRHOIDAL SKIN TAGS
459  HEMORRHAGE UNSPECIFIED
530.1  ESOPHAGITIS
530.1  ESOPHAGITIS UNSPECIFIED
530.13  EOSINOPHILIC ESOPHAGITIS
530.19  OTHER ESOPHAGITIS
530.7  GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME
530.82  ESOPHAGEAL HEMORRHAGE
531  ACUTE GASTRIC ULCER WITH HEMORRHAGE
531.01  ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2  ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21  ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.3  ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
531.4  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.5  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION
531.6  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.61  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.7  CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
531.9  GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
532  ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01  ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.1  ACUTE DUODENAL ULCER WITH PERFORATION
532.3  ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
532.4  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.41  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.5  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION
532.9  DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
533.1  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
533.2  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.21  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.5  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
533.6  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.9  PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.2  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.21  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.6  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.9  GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
535.11  ATROPHIC GASTRITIS WITH HEMORRHAGE
535.31  ALCOHOLIC GASTRITIS WITH HEMORRHAGE
535.4  OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE)
535.51  UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE
535.61  DUODENITIS WITH HEMORRHAGE
562.01  DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
562.03  DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.11  DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE)
562.12  DIVERTICULOSIS OF COLON WITH HEMORRHAGE
569.85  ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
578.1  BLOOD IN STOOL
599.71  GROSS HEMATURIA
623.8  OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA
626.8  OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT
Appendix A

784.7  EPISTAXIS
784.8  HEMORRHAGE FROM THROAT
786.3  HEMOPTYSIS
786.39  OTHER HEMOPTYSIS
280  IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC)
285.1  ACUTE POSTHEMORRHAGIC ANEMIA
455.2  INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.4  EXTERNAL THROMBOSED HEMORRHOIDS
455.5  EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.6  UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION
456  ESOPHAGEAL VARICES WITH BLEEDING
456.2  ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING
530.11  REFLUX ESOPHAGITIS
530.12  ACUTE ESOPHAGITIS
531  ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.1  ACUTE GASTRIC ULCER WITH PERFORATION
531.2  ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.4  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.41  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6  CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
532  ACUTE DUODENAL ULCER WITH HEMORRHAGE
532.2  ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2  ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21  ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.6  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61  CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.7  CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
533  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.3  ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION
533.4  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.6  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61  CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.7  CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.1  ACUTE GASTROJEJUNAL ULCER WITH PERFORATION
534.2  ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.3  ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
534.41  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.5  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION
534.61  CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.7  CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
535  ACUTE GASTRITIS (WITHOUT HEMORRHAGE)
535.01  ACUTE GASTRITIS WITH HEMORRHAGE
535.1  ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE)
535.2  GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE)
535.21  GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE
535.3  ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE)
535.41  OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE
535.5  UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE)
535.6  DUODENITIS (WITHOUT HEMORRHAGE)
537.83  ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE
562  DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
562.02  DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.1  DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE)
Appendix A

562.13  DIVERTICULITIS OF COLON WITH HEMORRHAGE
569.3  HEMORRHAGE OF RECTUM AND ANUS
578  HEMATEMESIS
578.9  HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
593.81  VASCULAR DISORDERS OF KIDNEY
599.7  HEMATURIA UNSPECIFIED
623.6  VAGINAL HEMATOMA
626.6  METRORRHAGIA
786.3  HEMOPTYSIS UNSPECIFIED
786.31  ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
ICD-10 Dx
G95.19 
 Other vascular myelopathies
H05.232 
 Hemorrhage of left orbit
H05.239 
 Hemorrhage of unspecified orbit
H31.30 
 Unspecified choroidal hemorrhage
H31.301 
 Unspecified choroidal hemorrhage, right eye
H31.303 
 Unspecified choroidal hemorrhage, bilateral
H31.312 
 Expulsive choroidal hemorrhage, left eye
H31.313 
 Expulsive choroidal hemorrhage, bilateral
H31.411 
 Hemorrhagic choroidal detachment, right eye
H31.419 
 Hemorrhagic choroidal detachment, unspecified eye
H43.1 
 Vitreous hemorrhage
H43.10 
 Vitreous hemorrhage, unspecified eye
H43.11 
 Vitreous hemorrhage, right eye
H43.13 
 Vitreous hemorrhage, bilateral
H47.022 
 Hemorrhage in optic nerve sheath, left eye
H47.023 
 Hemorrhage in optic nerve sheath, bilateral
H47.029 
 Hemorrhage in optic nerve sheath, unspecified eye
I60.0 
 Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation
I60.00 
 Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01 
 Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.1 
 Nontraumatic subarachnoid hemorrhage from middle cerebral artery
I60.11 
 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.31 
 Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.4 
 Nontraumatic subarachnoid hemorrhage from basilar artery
I60.51 
 Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.7 
 Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8 
 Other nontraumatic subarachnoid hemorrhage
I61.0 
 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.2 
 Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3 
 Nontraumatic intracerebral hemorrhage in brain stem
I61.5 
 Nontraumatic intracerebral hemorrhage, intraventricular
I61.6 
 Nontraumatic intracerebral hemorrhage, multiple localized
I61.8 
 Other nontraumatic intracerebral hemorrhage
I62 
 Other and unspecified nontraumatic intracranial hemorrhage
I62.0 
 Nontraumatic subdural hemorrhage
I62.00 
 Nontraumatic subdural hemorrhage, unspecified
I62.01 
 Nontraumatic acute subdural hemorrhage
I62.02 
 Nontraumatic subacute subdural hemorrhage
I62.9 
 Nontraumatic intracranial hemorrhage, unspecified
K66.1 
 Hemoperitoneum
M25.0 
 Hemarthrosis
M25.01 
 Hemarthrosis, shoulder
M25.012 
 Hemarthrosis, left shoulder
M25.019 
 Hemarthrosis, unspecified shoulder
M25.021 
 Hemarthrosis, right elbow
M25.029 
 Hemarthrosis, unspecified elbow
M25.03 
 Hemarthrosis, wrist
M25.039 
 Hemarthrosis, unspecified wrist
M25.05 
 Hemarthrosis, hip
Appendix A

M25.051 
 Hemarthrosis, right hip
M25.052 
 Hemarthrosis, left hip
M25.06 
 Hemarthrosis, knee
M25.061 
 Hemarthrosis, right knee
M25.07 
 Hemarthrosis, ankle and foot
M25.071 
 Hemarthrosis, right ankle
M25.073 
 Hemarthrosis, unspecified ankle
M25.074 
 Hemarthrosis, right foot
M25.075 
 Hemarthrosis, left foot
M25.08 
 Hemarthrosis, other specified site
M79.81 
 Nontraumatic hematoma of soft tissue
S06.4 
 Epidural hemorrhage
S06.4X 
 Epidural hemorrhage
S06.4X0 
 Epidural hemorrhage without loss of consciousness
S06.4X0D 
 Epidural hemorrhage without loss of consciousness, subsequent encounter
S06.4X1A 
 Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.4X2S 
 Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.4X3 
 Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.4X3A 
 Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.4X4 
 Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.4X4A 
 Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.4X5D 
 Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.4X5S 
 Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.4X6D 
 Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.4X7 
 Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
S06.4X7A 
 Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter
S06.4X9 
 Epidural hemorrhage with loss of consciousness of unspecified duration
S06.4X9A 
 Epidural hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.5 
 Traumatic subdural hemorrhage
S06.5X 
 Traumatic subdural hemorrhage
S06.5X0 
 Traumatic subdural hemorrhage without loss of consciousness
S06.5X2 
 Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.5X2A 
 Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.5X3A 
 Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.5X3D 
 Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.5X3S 
 Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.5X4S 
 Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
S06.5X5 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
S06.5X5A 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.5X5S 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.5X6A 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.5X6D 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.5X6S 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.5X8 
 Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness
S06.5X9A 
 Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.5X9D 
 Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S06.5X9S 
 Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela
S06.6X 
 Traumatic subarachnoid hemorrhage
S06.6X0 
 Traumatic subarachnoid hemorrhage without loss of consciousness
S06.6X0A 
 Traumatic subarachnoid hemorrhage without loss of consciousness, initial encounter
S06.6X0D 
 Traumatic subarachnoid hemorrhage without loss of consciousness, subsequent encounter
S06.6X1 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less
S06.6X1A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.6X1S 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.6X2D 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.6X3D 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.6X4 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.6X4A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.6X4S 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
S06.6X5 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
Appendix A

S06.6X5S 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
S06.6X6 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.6X6A 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.6X6S 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.6X7 
 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
S06.6X8A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, initial encounter
S06.6X9S 
 Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela
S26.0 
 Injury of heart with hemopericardium
S26.01 
 Contusion of heart with hemopericardium
S26.01XA 
 Contusion of heart with hemopericardium, initial encounter
S26.020 
 Mild laceration of heart with hemopericardium
S26.020A 
 Mild laceration of heart with hemopericardium, initial encounter
S26.021D 
 Moderate laceration of heart with hemopericardium, subsequent encounter
S26.021S 
 Moderate laceration of heart with hemopericardium, sequela
S26.022 
 Major laceration of heart with hemopericardium
S26.022D 
 Major laceration of heart with hemopericardium, subsequent encounter
S26.09 
 Other injury of heart with hemopericardium
S26.09XD 
 Other injury of heart with hemopericardium, subsequent encounter
S26.09XS 
 Other injury of heart with hemopericardium, sequela
S37.01 
 Minor contusion of kidney
S37.011D 
 Minor contusion of right kidney, subsequent encounter
S37.011S 
 Minor contusion of right kidney, sequela
S37.012A 
 Minor contusion of left kidney, initial encounter
S37.012D 
 Minor contusion of left kidney, subsequent encounter
S37.012S 
 Minor contusion of left kidney, sequela
S37.02 
 Major contusion of kidney
S37.021 
 Major contusion of right kidney
S37.021D 
 Major contusion of right kidney, subsequent encounter
S37.021S 
 Major contusion of right kidney, sequela
S37.022D 
 Major contusion of left kidney, subsequent encounter
S37.022S 
 Major contusion of left kidney, sequela
S37.029 
 Major contusion of unspecified kidney
S37.031A 
 Laceration of right kidney, unspecified degree, initial encounter
S37.031D 
 Laceration of right kidney, unspecified degree, subsequent encounter
S37.032 
 Laceration of left kidney, unspecified degree
S37.032D 
 Laceration of left kidney, unspecified degree, subsequent encounter
S37.032S 
 Laceration of left kidney, unspecified degree, sequela
S37.039 
 Laceration of unspecified kidney, unspecified degree
S37.039D 
 Laceration of unspecified kidney, unspecified degree, subsequent encounter
S37.04 
 Minor laceration of kidney
S37.041 
 Minor laceration of right kidney
S37.041A 
 Minor laceration of right kidney, initial encounter
S37.041D 
 Minor laceration of right kidney, subsequent encounter
S37.041S 
 Minor laceration of right kidney, sequela
S37.042A 
 Minor laceration of left kidney, initial encounter
S37.042D 
 Minor laceration of left kidney, subsequent encounter
S37.042S 
 Minor laceration of left kidney, sequela
S37.051 
 Moderate laceration of right kidney
S37.051A 
 Moderate laceration of right kidney, initial encounter
S37.051S 
 Moderate laceration of right kidney, sequela
S37.052S 
 Moderate laceration of left kidney, sequela
S37.059D 
 Moderate laceration of unspecified kidney, subsequent encounter
S37.059S 
 Moderate laceration of unspecified kidney, sequela
S37.061S 
 Major laceration of right kidney, sequela
S37.062 
 Major laceration of left kidney
S37.062S 
 Major laceration of left kidney, sequela
S37.069A 
 Major laceration of unspecified kidney, initial encounter
S37.069S 
 Major laceration of unspecified kidney, sequela
H05.23 
 Hemorrhage of orbit
H05.231 
 Hemorrhage of right orbit
Appendix A

H05.233 
 Hemorrhage of bilateral orbit
H31.302 
 Unspecified choroidal hemorrhage, left eye
H31.309 
 Unspecified choroidal hemorrhage, unspecified eye
H31.31 
 Expulsive choroidal hemorrhage
H31.311 
 Expulsive choroidal hemorrhage, right eye
H31.319 
 Expulsive choroidal hemorrhage, unspecified eye
H31.41 
 Hemorrhagic choroidal detachment
H31.412 
 Hemorrhagic choroidal detachment, left eye
H31.413 
 Hemorrhagic choroidal detachment, bilateral
H43.12 
 Vitreous hemorrhage, left eye
H47.02 
 Hemorrhage in optic nerve sheath
H47.021 
 Hemorrhage in optic nerve sheath, right eye
I23.0 
 Hemopericardium as current complication following acute myocardial infarction
I31.2 
 Hemopericardium, not elsewhere classified
I60 
 Nontraumatic subarachnoid hemorrhage
I60.02 
 Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10 
 Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.12 
 Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2 
 Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.3 
 Nontraumatic subarachnoid hemorrhage from posterior communicating artery
I60.30 
 Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.32 
 Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.5 
 Nontraumatic subarachnoid hemorrhage from vertebral artery
I60.50 
 Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.52 
 Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6 
 Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.9 
 Nontraumatic subarachnoid hemorrhage, unspecified
I61 
 Nontraumatic intracerebral hemorrhage
I61.1 
 Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.4 
 Nontraumatic intracerebral hemorrhage in cerebellum
I61.9 
 Nontraumatic intracerebral hemorrhage, unspecified
I62.03 
 Nontraumatic chronic subdural hemorrhage
I62.1 
 Nontraumatic extradural hemorrhage
M25.00 
 Hemarthrosis, unspecified joint
M25.011 
 Hemarthrosis, right shoulder
M25.02 
 Hemarthrosis, elbow
M25.022 
 Hemarthrosis, left elbow
M25.031 
 Hemarthrosis, right wrist
M25.032 
 Hemarthrosis, left wrist
M25.04 
 Hemarthrosis, hand
M25.041 
 Hemarthrosis, right hand
M25.042 
 Hemarthrosis, left hand
M25.049 
 Hemarthrosis, unspecified hand
M25.059 
 Hemarthrosis, unspecified hip
M25.062 
 Hemarthrosis, left knee
M25.069 
 Hemarthrosis, unspecified knee
M25.072 
 Hemarthrosis, left ankle
M25.076 
 Hemarthrosis, unspecified foot
S06.4X0A 
 Epidural hemorrhage without loss of consciousness, initial encounter
S06.4X0S 
 Epidural hemorrhage without loss of consciousness, sequela
S06.4X1 
 Epidural hemorrhage with loss of consciousness of 30 minutes or less
S06.4X1D 
 Epidural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.4X1S 
 Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.4X2 
 Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.4X2A 
 Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.4X2D 
 Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.4X3D 
 Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.4X3S 
 Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.4X4D 
 Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.4X4S 
 Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
Appendix A

S06.4X5 
 Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
S06.4X5A 
 Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.4X6 
 Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.4X6A 
 Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
S06.4X6S 
 Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
S06.4X8 
 Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness
S06.4X8A 
 Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness, initial encounter
S06.4X9D 
 Epidural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S06.4X9S 
 Epidural hemorrhage with loss of consciousness of unspecified duration, sequela
S06.5X0A 
 Traumatic subdural hemorrhage without loss of consciousness, initial encounter
S06.5X0D 
 Traumatic subdural hemorrhage without loss of consciousness, subsequent encounter
S06.5X0S 
 Traumatic subdural hemorrhage without loss of consciousness, sequela
S06.5X1 
 Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less
S06.5X1A 
 Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
S06.5X1D 
 Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.5X1S 
 Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.5X2D 
 Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.5X2S 
 Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.5X3 
 Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.5X4 
 Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours
S06.5X4A 
 Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.5X4D 
 Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.5X5D 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.5X6 
 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
S06.5X7 
 Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness
S06.5X7A 
 Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness, initial encounter
S06.5X8A 
 Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness, initial encounter
S06.5X9 
 Traumatic subdural hemorrhage with loss of consciousness of unspecified duration
S06.6 
 Traumatic subarachnoid hemorrhage
S06.6X0S 
 Traumatic subarachnoid hemorrhage without loss of consciousness, sequela
S06.6X1D 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.6X2 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.6X2A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.6X2S 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela
S06.6X3 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
S06.6X3A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
S06.6X3S 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.6X4D 
 Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06.6X5A 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
S06.6X5D 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
S06.6X6D 
 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
S06.6X7A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter
S06.6X8 
 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness
S06.6X9 
 Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration
S06.6X9A 
 Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, initial encounter
S06.6X9D 
 Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
S26.00 
 Unspecified injury of heart with hemopericardium
S26.00XA 
 Unspecified injury of heart with hemopericardium, initial encounter
S26.00XD 
 Unspecified injury of heart with hemopericardium, subsequent encounter
S26.00XS 
 Unspecified injury of heart with hemopericardium, sequela
S26.01XD 
 Contusion of heart with hemopericardium, subsequent encounter
S26.01XS 
 Contusion of heart with hemopericardium, sequela
S26.02 
 Laceration of heart with hemopericardium
S26.020D 
 Mild laceration of heart with hemopericardium, subsequent encounter
S26.020S 
 Mild laceration of heart with hemopericardium, sequela
S26.021 
 Moderate laceration of heart with hemopericardium
S26.021A 
 Moderate laceration of heart with hemopericardium, initial encounter
S26.022A 
 Major laceration of heart with hemopericardium, initial encounter
S26.022S 
 Major laceration of heart with hemopericardium, sequela
S26.09XA 
 Other injury of heart with hemopericardium, initial encounter
Appendix A

S37.011 
 Minor contusion of right kidney
S37.011A 
 Minor contusion of right kidney, initial encounter
S37.012 
 Minor contusion of left kidney
S37.019 
 Minor contusion of unspecified kidney
S37.019A 
 Minor contusion of unspecified kidney, initial encounter
S37.019D 
 Minor contusion of unspecified kidney, subsequent encounter
S37.019S 
 Minor contusion of unspecified kidney, sequela
S37.021A 
 Major contusion of right kidney, initial encounter
S37.022 
 Major contusion of left kidney
S37.022A 
 Major contusion of left kidney, initial encounter
S37.029A 
 Major contusion of unspecified kidney, initial encounter
S37.029D 
 Major contusion of unspecified kidney, subsequent encounter
S37.029S 
 Major contusion of unspecified kidney, sequela
S37.03 
 Laceration of kidney, unspecified degree
S37.031 
 Laceration of right kidney, unspecified degree
S37.031S 
 Laceration of right kidney, unspecified degree, sequela
S37.032A 
 Laceration of left kidney, unspecified degree, initial encounter
S37.039A 
 Laceration of unspecified kidney, unspecified degree, initial encounter
S37.039S 
 Laceration of unspecified kidney, unspecified degree, sequela
S37.042 
 Minor laceration of left kidney
S37.049 
 Minor laceration of unspecified kidney
S37.049A 
 Minor laceration of unspecified kidney, initial encounter
S37.049D 
 Minor laceration of unspecified kidney, subsequent encounter
S37.049S 
 Minor laceration of unspecified kidney, sequela
S37.05 
 Moderate laceration of kidney
S37.051D 
 Moderate laceration of right kidney, subsequent encounter
S37.052 
 Moderate laceration of left kidney
S37.052A 
 Moderate laceration of left kidney, initial encounter
S37.052D 
 Moderate laceration of left kidney, subsequent encounter
S37.059 
 Moderate laceration of unspecified kidney
S37.059A 
 Moderate laceration of unspecified kidney, initial encounter
S37.06 
 Major laceration of kidney
S37.061 
 Major laceration of right kidney
S37.061A 
 Major laceration of right kidney, initial encounter
S37.061D 
 Major laceration of right kidney, subsequent encounter
S37.062A 
 Major laceration of left kidney, initial encounter
S37.062D 
 Major laceration of left kidney, subsequent encounter
S37.069 
 Major laceration of unspecified kidney
S37.069D 
 Major laceration of unspecified kidney, subsequent encounter
The occurrence of Inpatient Confinement with the following attributes:
Procedure 
Code (Any 
Confinement 
Position)
ŝƐĂŶǇŽĨ͗΂͞ϯϬϮϯϬ,ϭ͕͟͞ϯϬϮϯϬDϭ͕͟͞ϯϬϮϯϬEϭ͕͟͞ϯϬϮϯϬWϭ͕͟͞ϯϬϮϯϬdϭ͕͟͞ϯϬϮϯϬsϭ͕͟͞ϯϬϮϯϬtϭ͕͟͞ϯϬϮϯϯ,ϭ͕͟͞ϯϬϮϯϯDϭ͕͟͞ϯϬϮϯϯZϭ͕͟͞ϯϬϮϯϯdϭ͕͟͞ϯϬϮϰϬ,ϭ͕͟͞ϯϬϮϰϬ<ϭ͕͟͞ϯϬϮϰϬWϭ͕͟͞ϯϬϮϰϬZϭ͕͟͞ϯϬϮϰϯ>ϭ͕͟͞ϯϬϮϰϯDϭ͕͟͞ϯϬϮϰϯEϭ͕͟͞ϯϬϮϰϯZϭ͕͟͞ϯϬϮϰϯtϭ͕͟͞ϯϬϮϯϬ<ϭ͕͟
͞ϯϬϮϯϬ>ϭ͕͟͞ϯϬϮϯϬZϭ͕͟͞ϯϬϮϯϯ<ϭ͕͟͞ϯϬϮϯϯ>ϭ͕͟͞ϯϬϮϯϯEϭ͕͟͞ϯϬϮϯϯWϭ͕͟͞ϯϬϮϯϯsϭ͕͟͞ϯϬϮϯϯtϭ͕͟͞ϯϬϮϰϬ>ϭ͕͟͞ϯϬϮϰϬDϭ͕͟͞ϯϬϮϰϬEϭ͕͟͞ϯϬϮϰϬdϭ͕͟͞ϯϬϮϰϬsϭ͕͟͞ϯϬϮϰϬtϭ͕͟͞ϯϬϮϰϯ,ϭ͕͟͞ϯϬϮϰϯ<ϭ͕͟͞ϯϬϮϰϯWϭ͕͟͞ϯϬϮϰϯdϭ͕͟͞ϯϬϮϰϯsϭ͟΃
AND
D50.0 
 Iron deficiency anemia secondary to blood loss (chronic)
D62 
 Acute posthemorrhagic anemia
I85.11 
 Secondary esophageal varices with bleeding
K20 
 Esophagitis
K20.0 
 Eosinophilic esophagitis
K20.8 
 Other esophagitis
K20.9 
 Esophagitis, unspecified
K21.0 
 Gastro-esophageal reflux disease with esophagitis
K22.11 
 Ulcer of esophagus with bleeding
K25.1 
 Acute gastric ulcer with perforation
K25.2 
 Acute gastric ulcer with both hemorrhage and perforation
K25.4 
 Chronic or unspecified gastric ulcer with hemorrhage
K25.5 
 Chronic or unspecified gastric ulcer with perforation
Appendix A

K26.2 
 Acute duodenal ulcer with both hemorrhage and perforation
K26.4 
 Chronic or unspecified duodenal ulcer with hemorrhage
K26.6 
 Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.4 
 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.5 
 Chronic or unspecified peptic ulcer, site unspecified, with perforation
K27.6 
 Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.1 
 Acute gastrojejunal ulcer with perforation
K28.2 
 Acute gastrojejunal ulcer with both hemorrhage and perforation
K29.31 
 Chronic superficial gastritis with bleeding
K29.91 
 Gastroduodenitis, unspecified, with bleeding
K57.11 
 Diverticulosis of small intestine without perforation or abscess with bleeding
K57.21 
 Diverticulitis of large intestine with perforation and abscess with bleeding
K57.51 
 Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53 
 Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.93 
 Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5 
 Hemorrhage of anus and rectum
K64.1 
 Second degree hemorrhoids
K64.3 
 Fourth degree hemorrhoids
K64.9 
 Unspecified hemorrhoids
K92.0 
 Hematemesis
K92.1 
 Melena
N89.7 
 Hematocolpos
N92.1 
 Excessive and frequent menstruation with irregular cycle
N93.8 
 Other specified abnormal uterine and vaginal bleeding
R04.0 
 Epistaxis
R31.0 
 Gross hematuria
R31.9 
 Hematuria, unspecified
R58 
 Hemorrhage, not elsewhere classified
I85.01 
 Esophageal varices with bleeding
K22.6 
 Gastro-esophageal laceration-hemorrhage syndrome
K25.0 
 Acute gastric ulcer with hemorrhage
K25.6 
 Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 
 Acute duodenal ulcer with hemorrhage
K26.1 
 Acute duodenal ulcer with perforation
K26.5 
 Chronic or unspecified duodenal ulcer with perforation
K27.0 
 Acute peptic ulcer, site unspecified, with hemorrhage
K27.1 
 Acute peptic ulcer, site unspecified, with perforation
K27.2 
 Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 
 Acute gastrojejunal ulcer with hemorrhage
K28.4 
 Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.5 
 Chronic or unspecified gastrojejunal ulcer with perforation
K28.6 
 Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K29.01 
 Acute gastritis with bleeding
K29.21 
 Alcoholic gastritis with bleeding
K29.41 
 Chronic atrophic gastritis with bleeding
K29.51 
 Unspecified chronic gastritis with bleeding
K29.61 
 Other gastritis with bleeding
K29.71 
 Gastritis, unspecified, with bleeding
K29.81 
 Duodenitis with bleeding
K31.811 
 Angiodysplasia of stomach and duodenum with bleeding
K55.21 
 Angiodysplasia of colon with hemorrhage
K57.01 
 Diverticulitis of small intestine with perforation and abscess with bleeding
K57.31 
 Diverticulosis of large intestine without perforation or abscess with bleeding
K57.41 
 Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.81 
 Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 
 Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K64.0 
 First degree hemorrhoids
K64.2 
 Third degree hemorrhoids
K64.4 
 Residual hemorrhoidal skin tags
K64.5 
 Perianal venous thrombosis
Appendix A

K64.8 
 Other hemorrhoids
K92.2 
 Gastrointestinal hemorrhage, unspecified
N89.8 
 Other specified noninflammatory disorders of vagina
N93.9 
 Abnormal uterine and vaginal bleeding, unspecified
R04.1 
 Hemorrhage from throat
R04.2 
 Hemoptysis
Appendix A

Inpatient, Primary Diagnosis: ICD-9 Codes
280.0 - IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS 
(CHRONIC)
455.7 - UNSPECIFIED THROMBOSED HEMORRHOIDS
459.0 - HEMORRHAGE UNSPECIFIED
530.10 - ESOPHAGITIS UNSPECIFIED
530.13 - EOSINOPHILIC ESOPHAGITIS
531.0 - ACUTE GASTRIC ULCER WITH HEMORRHAGE
531.1 - ACUTE GASTRIC ULCER WITH PERFORATION
531.2 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND 
PERFORATION
531.20 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND 
PERFORATION WITHOUT OBSTRUCTION
531.3 - ACUTE GASTRIC ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
531.4 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE
531.6 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE AND PERFORATION
531.61 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.9 - GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC 
WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
532.0 - ACUTE DUODENAL ULCER WITH HEMORRHAGE
532.00 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT 
OBSTRUCTION
532.01 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH 
OBSTRUCTION
532.2 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND 
PERFORATION
532.20 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITHOUT OBSTRUCTION
532.3 - ACUTE DUODENAL ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
Appendix A

532.4 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE
532.41 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE WITH OBSTRUCTION
532.5 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
PERFORATION
532.61 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.0 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE
533.00 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE WITHOUT OBSTRUCTION
533.01 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE WITH OBSTRUCTION
533.1 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
PERFORATION
533.2 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE AND PERFORATION
533.20 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.3 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT 
MENTION OF HEMORRHAGE AND PERFORATION
533.6 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.60 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
WITHOUT OBSTRUCTION
533.7 - CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT 
MENTION OF HEMORRHAGE OR PERFORATION
534.00 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE 
WITHOUT OBSTRUCTION
534.01 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE 
WITH OBSTRUCTION
534.20 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITHOUT OBSTRUCTION
Appendix A

534.3 - ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
534.40 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE WITHOUT OBSTRUCTION
534.41 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE WITH OBSTRUCTION
534.61 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.7 - CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
534.9 - GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR 
CHRONIC WITHOUT MENTION OF HEMORRHAGE OR 
PERFORATION
535.00 - ACUTE GASTRITIS (WITHOUT HEMORRHAGE)
535.01 - ACUTE GASTRITIS WITH HEMORRHAGE
535.10 - ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE)
535.20 - GASTRIC MUCOSAL HYPERTROPHY (WITHOUT 
HEMORRHAGE)
535.21 - GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE
535.31 - ALCOHOLIC GASTRITIS WITH HEMORRHAGE
535.40 - OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE)
535.41 - OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE
562.00 - DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT 
HEMORRHAGE)
562.01 - DIVERTICULITIS OF SMALL INTESTINE (WITHOUT 
HEMORRHAGE)
562.03 - DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.11 - DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE)
562.13 - DIVERTICULITIS OF COLON WITH HEMORRHAGE
569.85 - ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
Appendix A

578.0 - HEMATEMESIS
578.1 - BLOOD IN STOOL
578.9 - HEMORRHAGE OF GASTROINTESTINAL TRACT 
UNSPECIFIED
593.81 - VASCULAR DISORDERS OF KIDNEY
599.70 - HEMATURIA UNSPECIFIED
599.71 - GROSS HEMATURIA
623.6 - VAGINAL HEMATOMA
626.6 - METRORRHAGIA
784.7 - EPISTAXIS
784.8 - HEMORRHAGE FROM THROAT
786.31 - ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN 
INFANTS
285.1 - ACUTE POSTHEMORRHAGIC ANEMIA
455.1 - INTERNAL THROMBOSED HEMORRHOIDS
455.2 - INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.4 - EXTERNAL THROMBOSED HEMORRHOIDS
455.5 - EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION
455.6 - UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION
455.8 - UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION
455.9 - RESIDUAL HEMORRHOIDAL SKIN TAGS
456.0 - ESOPHAGEAL VARICES WITH BLEEDING
456.20 - ESOPHAGEAL VARICES IN DISEASES CLASSIFIED 
ELSEWHERE WITH BLEEDING
530.1 - ESOPHAGITIS
530.11 - REFLUX ESOPHAGITIS
530.12 - ACUTE ESOPHAGITIS
530.19 - OTHER ESOPHAGITIS
530.7 - GASTROESOPHAGEAL LACERATION-HEMORRHAGE 
SYNDROME
530.82 - ESOPHAGEAL HEMORRHAGE
Appendix A

531.00 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT 
OBSTRUCTION
531.01 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH 
OBSTRUCTION
531.21 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND 
PERFORATION WITH OBSTRUCTION
531.40 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE WITHOUT OBSTRUCTION
531.41 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE WITH OBSTRUCTION
531.5 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
PERFORATION
531.60 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH 
HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.7 - CHRONIC GASTRIC ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
532.1 - ACUTE DUODENAL ULCER WITH PERFORATION
532.21 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITH OBSTRUCTION
532.40 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE WITHOUT OBSTRUCTION
532.6 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE AND PERFORATION
532.60 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH 
HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.7 - CHRONIC DUODENAL ULCER WITHOUT MENTION OF 
HEMORRHAGE OR PERFORATION
532.9 - DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC 
WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
533.21 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH 
HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE
Appendix A

533.40 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.5 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH PERFORATION
533.61 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF 
UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH 
OBSTRUCTION
533.9 - PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS 
ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR 
PERFORATION
534.0 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.1 - ACUTE GASTROJEJUNAL ULCER WITH PERFORATION
534.2 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION
534.21 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND 
PERFORATION WITH OBSTRUCTION
534.4 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE
534.5 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
PERFORATION
534.6 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE AND PERFORATION
534.60 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH 
HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
535.11 - ATROPHIC GASTRITIS WITH HEMORRHAGE
535.30 - ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE)
535.50 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS 
(WITHOUT HEMORRHAGE)
535.51 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH 
HEMORRHAGE
535.60 - DUODENITIS (WITHOUT HEMORRHAGE)
Appendix A

535.61 - DUODENITIS WITH HEMORRHAGE
537.83 - ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH 
HEMORRHAGE
562.02 - DIVERTICULOSIS OF SMALL INTESTINE WITH 
HEMORRHAGE
562.10 - DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE)
562.12 - DIVERTICULOSIS OF COLON WITH HEMORRHAGE
569.3 - HEMORRHAGE OF RECTUM AND ANUS
623.8 - OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF 
VAGINA
626.8 - OTHER DISORDERS OF MENSTRUATION AND OTHER 
ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT
786.3 - HEMOPTYSIS
786.30 - HEMOPTYSIS UNSPECIFIED
786.39 - OTHER HEMOPTYSIS
285.9 - ANEMIA UNSPECIFIED
790.92 - ABNORMAL COAGULATION PROFILE
363.63 - CHOROIDAL RUPTURE
626.2 - EXCESSIVE OR FREQUENT MENSTRUATION
372.72 - CONJUNCTIVAL HEMORRHAGE
Inpatient, Primary Diagnosis: ICD-10 Codes
D50.0 - Iron deficiency anemia secondary to blood loss (chronic)
D62 - Acute posthemorrhagic anemia
I85.01 - Esophageal varices with bleeding
I85.11 - Secondary esophageal varices with bleeding
K20.0 - Eosinophilic esophagitis
K20.8 - Other esophagitis
K22.11 - Ulcer of esophagus with bleeding
K22.6 - Gastro-esophageal laceration-hemorrhage syndrome
K25.0 - Acute gastric ulcer with hemorrhage
K25.1 - Acute gastric ulcer with perforation
K25.2 - Acute gastric ulcer with both hemorrhage and perforation
Appendix A

K25.4 - Chronic or unspecified gastric ulcer with hemorrhage
K25.5 - Chronic or unspecified gastric ulcer with perforation
K26.1 - Acute duodenal ulcer with perforation
K26.2 - Acute duodenal ulcer with both hemorrhage and perforation
K26.4 - Chronic or unspecified duodenal ulcer with hemorrhage
K27.1 - Acute peptic ulcer, site unspecified, with perforation
K27.2 - Acute peptic ulcer, site unspecified, with both hemorrhage and 
perforation
K27.5 - Chronic or unspecified peptic ulcer, site unspecified, with 
perforation
K27.6 - Chronic or unspecified peptic ulcer, site unspecified, with both 
hemorrhage and perforation
K28.0 - Acute gastrojejunal ulcer with hemorrhage
K28.4 - Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 - Chronic or unspecified gastrojejunal ulcer with both hemorrhage 
and perforation
K29.01 - Acute gastritis with bleeding
K29.31 - Chronic superficial gastritis with bleeding
K29.41 - Chronic atrophic gastritis with bleeding
K29.51 - Unspecified chronic gastritis with bleeding
K29.71 - Gastritis, unspecified, with bleeding
K57.11 - Diverticulosis of small intestine without perforation or abscess 
with bleeding
K57.21 - Diverticulitis of large intestine with perforation and abscess with 
bleeding
K57.41 - Diverticulitis of both small and large intestine with perforation and 
abscess with bleeding
K57.51 - Diverticulosis of both small and large intestine without perforation 
or abscess with bleeding
K57.81 - Diverticulitis of intestine, part unspecified, with perforation and 
abscess with bleeding
K57.91 - Diverticulosis of intestine, part unspecified, without perforation or 
abscess with bleeding
K57.93 - Diverticulitis of intestine, part unspecified, without perforation or 
abscess with bleeding
Appendix A

K62.5 - Hemorrhage of anus and rectum
K64.0 - First degree hemorrhoids
K64.5 - Perianal venous thrombosis
K64.8 - Other hemorrhoids
K64.9 - Unspecified hemorrhoids
K92.0 - Hematemesis
K92.2 - Gastrointestinal hemorrhage, unspecified
N89.7 - Hematocolpos
N93.8 - Other specified abnormal uterine and vaginal bleeding
R04.2 - Hemoptysis
R31.0 - Gross hematuria
K20 - Esophagitis
K20.9 - Esophagitis, unspecified
K21.0 - Gastro-esophageal reflux disease with esophagitis
K25.6 - Chronic or unspecified gastric ulcer with both hemorrhage and 
perforation
K26.0 - Acute duodenal ulcer with hemorrhage
K26.5 - Chronic or unspecified duodenal ulcer with perforation
K26.6 - Chronic or unspecified duodenal ulcer with both hemorrhage and 
perforation
K27.0 - Acute peptic ulcer, site unspecified, with hemorrhage
K27.4 - Chronic or unspecified peptic ulcer, site unspecified, with 
hemorrhage
K28.1 - Acute gastrojejunal ulcer with perforation
K28.2 - Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.5 - Chronic or unspecified gastrojejunal ulcer with perforation
K29.21 - Alcoholic gastritis with bleeding
K29.61 - Other gastritis with bleeding
K29.81 - Duodenitis with bleeding
K29.91 - Gastroduodenitis, unspecified, with bleeding
K31.811 - Angiodysplasia of stomach and duodenum with bleeding
K55.21 - Angiodysplasia of colon with hemorrhage
Appendix A

K57.01 - Diverticulitis of small intestine with perforation and abscess with 
bleeding
K57.31 - Diverticulosis of large intestine without perforation or abscess 
with bleeding
K57.53 - Diverticulitis of both small and large intestine without perforation 
or abscess with bleeding
K64.1 - Second degree hemorrhoids
K64.2 - Third degree hemorrhoids
K64.3 - Fourth degree hemorrhoids
K64.4 - Residual hemorrhoidal skin tags
K92.1 - Melena
N89.8 - Other specified noninflammatory disorders of vagina
N93.9 - Abnormal uterine and vaginal bleeding, unspecified
R04.0 - Epistaxis
R04.1 - Hemorrhage from throat
R58 - Hemorrhage, not elsewhere classified
D64.9 - Anemia, unspecified
R79.1 - Abnormal coagulation profile
H11.30 - Conjunctival hemorrhage, unspecified eye
H11.31 - Conjunctival hemorrhage, right eye
H11.32 - Conjunctival hemorrhage, left eye
H11.33 - Conjunctival hemorrhage, bilateral
H31.321 - Choroidal rupture, right eye
H31.322 - Choroidal rupture, left eye
H31.323 - Choroidal rupture, bilateral
H31.329 - Choroidal rupture, unspecified eye
N92.1 - Excessive and frequent menstruation with irregular cycle
R31.1 - Benign essential microscopic hematuria
R31.2 - Other microscopic hematuria
R31.29 - Other microscopic hematuria
N92.0 - Excessive and frequent menstruation with regular cycle
R31.21 - Asymptomatic microscopic hematuria
R31.9 - Hematuria, unspecified
Appendix A

Cancer - ICD-9
Cancer - ICD-10
140.0 - MALIGNANT NEOPLASM OF UPPER LIP 
VERMILION BORDER
C00.0 - Malignant neoplasm of external upper lip
140.3 - MALIGNANT NEOPLASM OF UPPER LIP 
INNER ASPECT
C00.1 - Malignant neoplasm of external lower lip
140.6 - MALIGNANT NEOPLASM OF 
COMMISSURE OF LIP
C00.4 - Malignant neoplasm of lower lip, inner aspect
140.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF LIP
C00.5 - Malignant neoplasm of lip, unspecified, inner 
aspect
140.9 - MALIGNANT NEOPLASM OF LIP 
UNSPECIFIED VERMILION BORDER
C00.6 - Malignant neoplasm of commissure of lip, 
unspecified
141.0 - MALIGNANT NEOPLASM OF BASE OF 
TONGUE
C00.9 - Malignant neoplasm of lip, unspecified
141.3 - MALIGNANT NEOPLASM OF VENTRAL 
SURFACE OF TONGUE
C01 - Malignant neoplasm of base of tongue
141.5 - MALIGNANT NEOPLASM OF JUNCTIONAL 
ZONE OF TONGUE
C02 - Malignant neoplasm of other and unspecified parts 
of tongue
141.6 - MALIGNANT NEOPLASM OF LINGUAL 
TONSIL
C02.1 - Malignant neoplasm of border of tongue
141.9 - MALIGNANT NEOPLASM OF TONGUE 
UNSPECIFIED
C02.2 - Malignant neoplasm of ventral surface of tongue
142.0 - MALIGNANT NEOPLASM OF PAROTID 
GLAND
C02.3 - Malignant neoplasm of anterior two-thirds of 
tongue, part unspecified
142.1 - MALIGNANT NEOPLASM OF 
SUBMANDIBULAR GLAND
C02.4 - Malignant neoplasm of lingual tonsil
142.9 - MALIGNANT NEOPLASM OF SALIVARY 
GLAND UNSPECIFIED
C02.8 - Malignant neoplasm of overlapping sites of tongue
143.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF GUM
C02.9 - Malignant neoplasm of tongue, unspecified
144.1 - MALIGNANT NEOPLASM OF LATERAL 
PORTION OF FLOOR OF MOUTH
C03 - Malignant neoplasm of gum
144.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF FLOOR OF MOUTH
C03.0 - Malignant neoplasm of upper gum
144.9 - MALIGNANT NEOPLASM OF FLOOR OF 
MOUTH PART UNSPECIFIED
C04 - Malignant neoplasm of floor of mouth
Appendix A

145.3 - MALIGNANT NEOPLASM OF SOFT 
PALATE
C04.1 - Malignant neoplasm of lateral floor of mouth
145.5 - MALIGNANT NEOPLASM OF PALATE 
UNSPECIFIED
C04.8 - Malignant neoplasm of overlapping sites of floor of 
mouth
145.9 - MALIGNANT NEOPLASM OF MOUTH 
UNSPECIFIED
C05 - Malignant neoplasm of palate
146 - MALIGNANT NEOPLASM OF OROPHARYNX C05.2 - Malignant neoplasm of uvula
146.3 - MALIGNANT NEOPLASM OF VALLECULA 
EPIGLOTTICA
C05.9 - Malignant neoplasm of palate, unspecified
146.4 - MALIGNANT NEOPLASM OF ANTERIOR 
ASPECT OF EPIGLOTTIS
C06 - Malignant neoplasm of other and unspecified parts 
of mouth
146.6 - MALIGNANT NEOPLASM OF LATERAL 
WALL OF OROPHARYNX
C06.0 - Malignant neoplasm of cheek mucosa
146.7 - MALIGNANT NEOPLASM OF POSTERIOR 
WALL OF OROPHARYNX
C06.2 - Malignant neoplasm of retromolar area
146.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF OROPHARYNX
C06.8 - Malignant neoplasm of overlapping sites of other 
and unspecified parts of mouth
146.9 - MALIGNANT NEOPLASM OF 
OROPHARYNX UNSPECIFIED SITE
C06.89 - Malignant neoplasm of overlapping sites of other 
parts of mouth
147 - MALIGNANT NEOPLASM OF 
NASOPHARYNX
C07 - Malignant neoplasm of parotid gland
147.0 - MALIGNANT NEOPLASM OF SUPERIOR 
WALL OF NASOPHARYNX
C08 - Malignant neoplasm of other and unspecified major 
salivary glands
147.2 - MALIGNANT NEOPLASM OF LATERAL 
WALL OF NASOPHARYNX
C08.0 - Malignant neoplasm of submandibular gland
147.9 - MALIGNANT NEOPLASM OF 
NASOPHARYNX UNSPECIFIED SITE
C08.9 - Malignant neoplasm of major salivary gland, 
unspecified
148 - MALIGNANT NEOPLASM OF 
HYPOPHARYNX
C09.0 - Malignant neoplasm of tonsillar fossa
148.2 - MALIGNANT NEOPLASM OF 
ARYEPIGLOTTIC FOLD HYPOPHARYNGEAL 
ASPECT
C10 - Malignant neoplasm of oropharynx
148.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF HYPOPHARYNX
C10.0 - Malignant neoplasm of vallecula
Appendix A

148.9 - MALIGNANT NEOPLASM OF 
HYPOPHARYNX UNSPECIFIED SITE
C10.2 - Malignant neoplasm of lateral wall of oropharynx
149.0 - MALIGNANT NEOPLASM OF PHARYNX 
UNSPECIFIED
C10.3 - Malignant neoplasm of posterior wall of 
oropharynx
149.8 - MALIGNANT NEOPLASM OF OTHER 
SITES WITHIN THE LIP AND ORAL CAVITY
C10.9 - Malignant neoplasm of oropharynx, unspecified
150.1 - MALIGNANT NEOPLASM OF THORACIC 
ESOPHAGUS
C11 - Malignant neoplasm of nasopharynx
150.2 - MALIGNANT NEOPLASM OF ABDOMINAL 
ESOPHAGUS
C11.0 - Malignant neoplasm of superior wall of 
nasopharynx
150.4 - MALIGNANT NEOPLASM OF MIDDLE 
THIRD OF ESOPHAGUS
C11.1 - Malignant neoplasm of posterior wall of 
nasopharynx
150.5 - MALIGNANT NEOPLASM OF LOWER 
THIRD OF ESOPHAGUS
C11.2 - Malignant neoplasm of lateral wall of nasopharynx
150.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED PART OF ESOPHAGUS
C11.8 - Malignant neoplasm of overlapping sites of 
nasopharynx
150.9 - MALIGNANT NEOPLASM OF ESOPHAGUS 
UNSPECIFIED SITE
C11.9 - Malignant neoplasm of nasopharynx, unspecified
151.0 - MALIGNANT NEOPLASM OF CARDIA
C13 - Malignant neoplasm of hypopharynx
151.2 - MALIGNANT NEOPLASM OF PYLORIC 
ANTRUM
C13.1 - Malignant neoplasm of aryepiglottic fold, 
hypopharyngeal aspect
151.3 - MALIGNANT NEOPLASM OF FUNDUS OF 
STOMACH
C14.2 - Malignant neoplasm of Waldeyer's ring
151.5 - MALIGNANT NEOPLASM OF LESSER 
CURVATURE OF STOMACH UNSPECIFIED
C15.4 - Malignant neoplasm of middle third of esophagus
151.6 - MALIGNANT NEOPLASM OF GREATER 
CURVATURE OF STOMACH UNSPECIFIED
C15.8 - Malignant neoplasm of overlapping sites of 
esophagus
151.9 - MALIGNANT NEOPLASM OF STOMACH 
UNSPECIFIED SITE
C15.9 - Malignant neoplasm of esophagus, unspecified
152 - MALIGNANT NEOPLASM OF SMALL 
INTESTINE INCLUDING DUODENUM
C16.0 - Malignant neoplasm of cardia
152.0 - MALIGNANT NEOPLASM OF DUODENUM
C16.2 - Malignant neoplasm of body of stomach
Appendix A

152.3 - MALIGNANT NEOPLASM OF MECKEL'S 
DIVERTICULUM
C16.3 - Malignant neoplasm of pyloric antrum
152.9 - MALIGNANT NEOPLASM OF SMALL 
INTESTINE UNSPECIFIED SITE
C17.3 - Meckel's diverticulum, malignant
153.1 - MALIGNANT NEOPLASM OF 
TRANSVERSE COLON
C18.2 - Malignant neoplasm of ascending colon
153.4 - MALIGNANT NEOPLASM OF CECUM
C18.3 - Malignant neoplasm of hepatic flexure
153.5 - MALIGNANT NEOPLASM OF APPENDIX 
VERMIFORMIS
C18.4 - Malignant neoplasm of transverse colon
153.7 - MALIGNANT NEOPLASM OF SPLENIC 
FLEXURE
C21.8 - Malignant neoplasm of overlapping sites of 
rectum, anus and anal canal
153.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF LARGE INTESTINE
C22 - Malignant neoplasm of liver and intrahepatic bile 
ducts
154.0 - MALIGNANT NEOPLASM OF 
RECTOSIGMOID JUNCTION
C22.1 - Intrahepatic bile duct carcinoma
154.2 - MALIGNANT NEOPLASM OF ANAL CANAL C22.3 - Angiosarcoma of liver
154.3 - MALIGNANT NEOPLASM OF ANUS 
UNSPECIFIED SITE
C22.4 - Other sarcomas of liver
155 - MALIGNANT NEOPLASM OF LIVER AND 
INTRAHEPATIC BILE DUCTS
C22.8 - Malignant neoplasm of liver, primary, unspecified 
as to type
155.0 - MALIGNANT NEOPLASM OF LIVER 
PRIMARY
C24.0 - Malignant neoplasm of extrahepatic bile duct
155.2 - MALIGNANT NEOPLASM OF LIVER NOT 
SPECIFIED AS PRIMARY OR SECONDARY
C24.9 - Malignant neoplasm of biliary tract, unspecified
156 - MALIGNANT NEOPLASM OF 
GALLBLADDER AND EXTRAHEPATIC BILE 
DUCTS
C25.0 - Malignant neoplasm of head of pancreas
156.0 - MALIGNANT NEOPLASM OF 
GALLBLADDER
C25.3 - Malignant neoplasm of pancreatic duct
156.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF GALLBLADDER AND 
EXTRAHEPATIC BILE DUCTS
C25.7 - Malignant neoplasm of other parts of pancreas
Appendix A

157.0 - MALIGNANT NEOPLASM OF HEAD OF 
PANCREAS
C25.8 - Malignant neoplasm of overlapping sites of 
pancreas
157.2 - MALIGNANT NEOPLASM OF TAIL OF 
PANCREAS
C26 - Malignant neoplasm of other and ill-defined digestive 
organs
157.9 - MALIGNANT NEOPLASM OF PANCREAS 
PART UNSPECIFIED
C26.0 - Malignant neoplasm of intestinal tract, part 
unspecified
158.8 - MALIGNANT NEOPLASM OF SPECIFIED 
PARTS OF PERITONEUM
C26.1 - Malignant neoplasm of spleen
158.9 - MALIGNANT NEOPLASM OF 
PERITONEUM UNSPECIFIED
C31.1 - Malignant neoplasm of ethmoidal sinus
159.0 - MALIGNANT NEOPLASM OF INTESTINAL 
TRACT PART UNSPECIFIED
C31.3 - Malignant neoplasm of sphenoid sinus
160 - MALIGNANT NEOPLASM OF NASAL 
CAVITIES MIDDLE EAR AND ACCESSORY 
SINUSES
C31.8 - Malignant neoplasm of overlapping sites of 
accessory sinuses
160.1 - MALIGNANT NEOPLASM OF AUDITORY 
TUBE MIDDLE EAR AND MASTOID AIR CELLS
C31.9 - Malignant neoplasm of accessory sinus, 
unspecified
160.9 - MALIGNANT NEOPLASM OF ACCESSORY 
SINUS UNSPECIFIED
C32.0 - Malignant neoplasm of glottis
161 - MALIGNANT NEOPLASM OF LARYNX
C33 - Malignant neoplasm of trachea
161.0 - MALIGNANT NEOPLASM OF GLOTTIS
C34 - Malignant neoplasm of bronchus and lung
161.1 - MALIGNANT NEOPLASM OF 
SUPRAGLOTTIS
C34.0 - Malignant neoplasm of main bronchus
161.2 - MALIGNANT NEOPLASM OF SUBGLOTTIS C34.01 - Malignant neoplasm of right main bronchus
161.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF LARYNX
C34.02 - Malignant neoplasm of left main bronchus
162 - MALIGNANT NEOPLASM OF TRACHEA 
BRONCHUS AND LUNG
C34.1 - Malignant neoplasm of upper lobe, bronchus or 
lung
162.0 - MALIGNANT NEOPLASM OF TRACHEA
C34.10 - Malignant neoplasm of upper lobe, unspecified 
bronchus or lung
162.2 - MALIGNANT NEOPLASM OF MAIN 
BRONCHUS
C34.11 - Malignant neoplasm of upper lobe, right bronchus 
or lung
Appendix A

162.8 - MALIGNANT NEOPLASM OF OTHER 
PARTS OF BRONCHUS OR LUNG
C34.12 - Malignant neoplasm of upper lobe, left bronchus 
or lung
163 - MALIGNANT NEOPLASM OF PLEURA
C34.31 - Malignant neoplasm of lower lobe, right bronchus 
or lung
163.0 - MALIGNANT NEOPLASM OF PARIETAL 
PLEURA
C34.32 - Malignant neoplasm of lower lobe, left bronchus 
or lung
163.9 - MALIGNANT NEOPLASM OF PLEURA 
UNSPECIFIED
C34.80 - Malignant neoplasm of overlapping sites of 
unspecified bronchus and lung
164 - MALIGNANT NEOPLASM OF THYMUS 
HEART AND MEDIASTINUM
C34.92 - Malignant neoplasm of unspecified part of left 
bronchus or lung
164.1 - MALIGNANT NEOPLASM OF HEART
C37 - Malignant neoplasm of thymus
164.8 - MALIGNANT NEOPLASM OF OTHER 
PARTS OF MEDIASTINUM
C38.1 - Malignant neoplasm of anterior mediastinum
164.9 - MALIGNANT NEOPLASM OF 
MEDIASTINUM PART UNSPECIFIED
C38.2 - Malignant neoplasm of posterior mediastinum
170.1 - MALIGNANT NEOPLASM OF MANDIBLE
C39.0 - Malignant neoplasm of upper respiratory tract, part 
unspecified
170.2 - MALIGNANT NEOPLASM OF VERTEBRAL 
COLUMN EXCLUDING SACRUM AND COCCYX
C40 - Malignant neoplasm of bone and articular cartilage 
of limbs
170.5 - MALIGNANT NEOPLASM OF SHORT 
BONES OF UPPER LIMB
C40.0 - Malignant neoplasm of scapula and long bones of 
upper limb
170.8 - MALIGNANT NEOPLASM OF SHORT 
BONES OF LOWER LIMB
C40.01 - Malignant neoplasm of scapula and long bones of 
right upper limb
170.9 - MALIGNANT NEOPLASM OF BONE AND 
ARTICULAR CARTILAGE SITE UNSPECIFIED
C40.10 - Malignant neoplasm of short bones of 
unspecified upper limb
171 - MALIGNANT NEOPLASM OF CONNECTIVE 
AND OTHER SOFT TISSUE
C40.12 - Malignant neoplasm of short bones of left upper 
limb
171.0 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
HEAD FACE AND NECK
C40.2 - Malignant neoplasm of long bones of lower limb
171.2 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
UPPER LIMB INCLUDING SHOULDER
C40.20 - Malignant neoplasm of long bones of unspecified 
lower limb
Appendix A

171.4 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
THORAX
C40.22 - Malignant neoplasm of long bones of left lower 
limb
171.7 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
TRUNK UNSPECIFIED
C40.3 - Malignant neoplasm of short bones of lower limb
171.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF CONNECTIVE AND OTHER 
SOFT TISSUE
C40.8 - Malignant neoplasm of overlapping sites of bone 
and articular cartilage of limb
172 - MALIGNANT MELANOMA OF SKIN
C40.80 - Malignant neoplasm of overlapping sites of bone 
and articular cartilage of unspecified limb
172.1 - MALIGNANT MELANOMA OF SKIN OF 
EYELID INCLUDING CANTHUS
C40.90 - Malignant neoplasm of unspecified bones and 
articular cartilage of unspecified limb
172.2 - MALIGNANT MELANOMA OF SKIN OF 
EAR AND EXTERNAL AUDITORY CANAL
C40.91 - Malignant neoplasm of unspecified bones and 
articular cartilage of right limb
172.3 - MALIGNANT MELANOMA OF SKIN OF 
OTHER AND UNSPECIFIED PARTS OF FACE
C40.92 - Malignant neoplasm of unspecified bones and 
articular cartilage of left limb
174 - MALIGNANT NEOPLASM OF FEMALE 
BREAST
C41 - Malignant neoplasm of bone and articular cartilage 
of other and unspecified sites
174.1 - MALIGNANT NEOPLASM OF CENTRAL 
PORTION OF FEMALE BREAST
C41.0 - Malignant neoplasm of bones of skull and face
174.2 - MALIGNANT NEOPLASM OF UPPER-
INNER QUADRANT OF FEMALE BREAST
C41.1 - Malignant neoplasm of mandible
174.4 - MALIGNANT NEOPLASM OF UPPER-
OUTER QUADRANT OF FEMALE BREAST
C41.2 - Malignant neoplasm of vertebral column
174.5 - MALIGNANT NEOPLASM OF LOWER-
OUTER QUADRANT OF FEMALE BREAST
C41.3 - Malignant neoplasm of ribs, sternum and clavicle
174.6 - MALIGNANT NEOPLASM OF AXILLARY 
TAIL OF FEMALE BREAST
C41.4 - Malignant neoplasm of pelvic bones, sacrum and 
coccyx
174.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF FEMALE BREAST
C43.1 - Malignant melanoma of eyelid, including canthus
174.9 - MALIGNANT NEOPLASM OF BREAST 
(FEMALE) UNSPECIFIED SITE
C43.11 - Malignant melanoma of right eyelid, including 
canthus
175 - MALIGNANT NEOPLASM OF MALE BREAST
C43.111 - Malignant melanoma of right upper eyelid, 
including canthus
Appendix A

175.9 - MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED SITES OF MALE BREAST
C43.122 - Malignant melanoma of left lower eyelid, 
including canthus
176 - KAPOSI'S SARCOMA
C43.2 - Malignant melanoma of ear and external auricular 
canal
176.0 - KAPOSI'S SARCOMA SKIN
C43.22 - Malignant melanoma of left ear and external 
auricular canal
176.2 - KAPOSI'S SARCOMA PALATE
C43.39 - Malignant melanoma of other parts of face
176.4 - KAPOSI'S SARCOMA LUNG
C43.51 - Malignant melanoma of anal skin
176.5 - KAPOSI'S SARCOMA LYMPH NODES
C43.59 - Malignant melanoma of other part of trunk
176.9 - KAPOSI'S SARCOMA UNSPECIFIED SITE
C43.61 - Malignant melanoma of right upper limb, 
including shoulder
180 - MALIGNANT NEOPLASM OF CERVIX UTERI
C43.71 - Malignant melanoma of right lower limb, including 
hip
180.0 - MALIGNANT NEOPLASM OF 
ENDOCERVIX
C43.9 - Malignant melanoma of skin, unspecified
180.1 - MALIGNANT NEOPLASM OF EXOCERVIX
C45 - Mesothelioma
181 - MALIGNANT NEOPLASM OF PLACENTA
C45.0 - Mesothelioma of pleura
182 - MALIGNANT NEOPLASM OF BODY OF 
UTERUS
C45.2 - Mesothelioma of pericardium
182.0 - MALIGNANT NEOPLASM OF CORPUS 
UTERI EXCEPT ISTHMUS
C46.51 - Kaposi's sarcoma of right lung
182.1 - MALIGNANT NEOPLASM OF ISTHMUS
C46.52 - Kaposi's sarcoma of left lung
182.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF BODY OF UTERUS
C46.9 - Kaposi's sarcoma, unspecified
183 - MALIGNANT NEOPLASM OF OVARY AND 
OTHER UTERINE ADNEXA
C47.10 - Malignant neoplasm of peripheral nerves of 
unspecified upper limb, including shoulder
183.2 - MALIGNANT NEOPLASM OF FALLOPIAN 
TUBE
C47.12 - Malignant neoplasm of peripheral nerves of left 
upper limb, including shoulder
183.3 - MALIGNANT NEOPLASM OF BROAD 
LIGAMENT OF UTERUS
C47.20 - Malignant neoplasm of peripheral nerves of 
unspecified lower limb, including hip
184.0 - MALIGNANT NEOPLASM OF VAGINA
C47.21 - Malignant neoplasm of peripheral nerves of right 
lower limb, including hip
184.3 - MALIGNANT NEOPLASM OF CLITORIS
C47.22 - Malignant neoplasm of peripheral nerves of left 
lower limb, including hip
Appendix A

184.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF FEMALE GENITAL 
ORGANS
C47.4 - Malignant neoplasm of peripheral nerves of 
abdomen
186 - MALIGNANT NEOPLASM OF TESTIS
C47.8 - Malignant neoplasm of overlapping sites of 
peripheral nerves and autonomic nervous system
186.0 - MALIGNANT NEOPLASM OF 
UNDESCENDED TESTIS
C47.9 - Malignant neoplasm of peripheral nerves and 
autonomic nervous system, unspecified
187 - MALIGNANT NEOPLASM OF PENIS AND 
OTHER MALE GENITAL ORGANS
C48.0 - Malignant neoplasm of retroperitoneum
187.1 - MALIGNANT NEOPLASM OF PREPUCE
C48.2 - Malignant neoplasm of peritoneum, unspecified
187.3 - MALIGNANT NEOPLASM OF BODY OF 
PENIS
C48.8 - Malignant neoplasm of overlapping sites of 
retroperitoneum and peritoneum
187.5 - MALIGNANT NEOPLASM OF EPIDIDYMIS
C49 - Malignant neoplasm of other connective and soft 
tissue
187.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF MALE GENITAL ORGANS
C49.10 - Malignant neoplasm of connective and soft tissue 
of unspecified upper limb, including shoulder
188 - MALIGNANT NEOPLASM OF BLADDER
C49.2 - Malignant neoplasm of connective and soft tissue 
of lower limb, including hip
188.1 - MALIGNANT NEOPLASM OF DOME OF 
URINARY BLADDER
C49.20 - Malignant neoplasm of connective and soft tissue 
of unspecified lower limb, including hip
188.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF BLADDER
C49.4 - Malignant neoplasm of connective and soft tissue 
of abdomen
189.2 - MALIGNANT NEOPLASM OF URETER
C49.5 - Malignant neoplasm of connective and soft tissue 
of pelvis
190.0 - MALIGNANT NEOPLASM OF EYEBALL 
EXCEPT CONJUNCTIVA CORNEA RETINA AND 
CHOROID
C49.6 - Malignant neoplasm of connective and soft tissue 
of trunk, unspecified
190.1 - MALIGNANT NEOPLASM OF ORBIT
C49.8 - Malignant neoplasm of overlapping sites of 
connective and soft tissue
190.2 - MALIGNANT NEOPLASM OF LACRIMAL 
GLAND
C49.A - Gastrointestinal stromal tumor
190.5 - MALIGNANT NEOPLASM OF RETINA
C49.A2 - Gastrointestinal stromal tumor of stomach
Appendix A

190.7 - MALIGNANT NEOPLASM OF LACRIMAL 
DUCT
C49.A3 - Gastrointestinal stromal tumor of small intestine
190.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF EYE
C49.A5 - Gastrointestinal stromal tumor of rectum
191 - MALIGNANT NEOPLASM OF BRAIN
C49.A9 - Gastrointestinal stromal tumor of other sites
191.1 - MALIGNANT NEOPLASM OF FRONTAL 
LOBE
C50 - Malignant neoplasm of breast
191.3 - MALIGNANT NEOPLASM OF PARIETAL 
LOBE
C50.012 - Malignant neoplasm of nipple and areola, left 
female breast
191.4 - MALIGNANT NEOPLASM OF OCCIPITAL 
LOBE
C50.02 - Malignant neoplasm of nipple and areola, male
191.7 - MALIGNANT NEOPLASM OF BRAIN STEM
C50.021 - Malignant neoplasm of nipple and areola, right 
male breast
191.9 - MALIGNANT NEOPLASM OF BRAIN 
UNSPECIFIED SITE
C50.029 - Malignant neoplasm of nipple and areola, 
unspecified male breast
192 - MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED PARTS OF NERVOUS SYSTEM
C50.1 - Malignant neoplasm of central portion of breast
192.0 - MALIGNANT NEOPLASM OF CRANIAL 
NERVES
C50.119 - Malignant neoplasm of central portion of 
unspecified female breast
192.2 - MALIGNANT NEOPLASM OF SPINAL 
CORD
C50.12 - Malignant neoplasm of central portion of breast, 
male
192.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF NERVOUS SYSTEM
C50.122 - Malignant neoplasm of central portion of left 
male breast
193 - MALIGNANT NEOPLASM OF THYROID 
GLAND
C50.21 - Malignant neoplasm of upper-inner quadrant of 
breast, female
194 - MALIGNANT NEOPLASM OF OTHER 
ENDOCRINE GLANDS AND RELATED 
STRUCTURES
C50.211 - Malignant neoplasm of upper-inner quadrant of 
right female breast
194.1 - MALIGNANT NEOPLASM OF 
PARATHYROID GLAND
C50.22 - Malignant neoplasm of upper-inner quadrant of 
breast, male
194.3 - MALIGNANT NEOPLASM OF PITUITARY 
GLAND AND CRANIOPHARYNGEAL DUCT
C50.221 - Malignant neoplasm of upper-inner quadrant of 
right male breast
Appendix A

194.4 - MALIGNANT NEOPLASM OF PINEAL 
GLAND
C50.3 - Malignant neoplasm of lower-inner quadrant of 
breast
194.6 - MALIGNANT NEOPLASM OF AORTIC 
BODY AND OTHER PARAGANGLIA
C50.312 - Malignant neoplasm of lower-inner quadrant of 
left female breast
194.8 - MALIGNANT NEOPLASM OF OTHER 
ENDOCRINE GLANDS AND RELATED 
STRUCTURES
C50.32 - Malignant neoplasm of lower-inner quadrant of 
breast, male
194.9 - MALIGNANT NEOPLASM OF ENDOCRINE 
GLAND SITE UNSPECIFIED
C50.322 - Malignant neoplasm of lower-inner quadrant of 
left male breast
195 - MALIGNANT NEOPLASM OF OTHER AND 
ILL-DEFINED SITES
C50.329 - Malignant neoplasm of lower-inner quadrant of 
unspecified male breast
195.2 - MALIGNANT NEOPLASM OF ABDOMEN
C50.4 - Malignant neoplasm of upper-outer quadrant of 
breast
195.3 - MALIGNANT NEOPLASM OF PELVIS
C50.412 - Malignant neoplasm of upper-outer quadrant of 
left female breast
195.4 - MALIGNANT NEOPLASM OF UPPER LIMB
C50.419 - Malignant neoplasm of upper-outer quadrant of 
unspecified female breast
195.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES
C50.51 - Malignant neoplasm of lower-outer quadrant of 
breast, female
196.8 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES OF 
MULTIPLE SITES
C50.522 - Malignant neoplasm of lower-outer quadrant of 
left male breast
197.1 - SECONDARY MALIGNANT NEOPLASM OF 
MEDIASTINUM
C50.6 - Malignant neoplasm of axillary tail of breast
197.2 - SECONDARY MALIGNANT NEOPLASM OF 
PLEURA
C50.61 - Malignant neoplasm of axillary tail of breast, 
female
197.5 - SECONDARY MALIGNANT NEOPLASM OF 
LARGE INTESTINE AND RECTUM
C50.612 - Malignant neoplasm of axillary tail of left female 
breast
197.7 - MALIGNANT NEOPLASM OF LIVER 
SECONDARY
C50.619 - Malignant neoplasm of axillary tail of unspecified 
female breast
197.8 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER DIGESTIVE ORGANS AND SPLEEN
C50.621 - Malignant neoplasm of axillary tail of right male 
breast
Appendix A

198.1 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER URINARY ORGANS
C50.629 - Malignant neoplasm of axillary tail of unspecified 
male breast
198.2 - SECONDARY MALIGNANT NEOPLASM OF 
SKIN
C50.81 - Malignant neoplasm of overlapping sites of 
breast, female
198.5 - SECONDARY MALIGNANT NEOPLASM OF 
BONE AND BONE MARROW
C50.811 - Malignant neoplasm of overlapping sites of right 
female breast
198.8 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITES
C50.812 - Malignant neoplasm of overlapping sites of left 
female breast
198.82 - SECONDARY MALIGNANT NEOPLASM 
OF GENITAL ORGANS
C50.829 - Malignant neoplasm of overlapping sites of 
unspecified male breast
199 - MALIGNANT NEOPLASM WITHOUT 
SPECIFICATION OF SITE
C50.912 - Malignant neoplasm of unspecified site of left 
female breast
199.0 - DISSEMINATED MALIGNANT NEOPLASM
C50.92 - Malignant neoplasm of breast of unspecified site, 
male
200.0 - RETICULOSARCOMA
C50.921 - Malignant neoplasm of unspecified site of right 
male breast
200.01 - RETICULOSARCOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C50.922 - Malignant neoplasm of unspecified site of left 
male breast
200.03 - RETICULOSARCOMA INVOLVING INTRA-
ABDOMINAL LYMPH NODES
C50.929 - Malignant neoplasm of unspecified site of 
unspecified male breast
200.05 - RETICULOSARCOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C51 - Malignant neoplasm of vulva
200.06 - RETICULOSARCOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C51.0 - Malignant neoplasm of labium majus
200.1 - LYMPHOSARCOMA
C51.1 - Malignant neoplasm of labium minus
200.10 - LYMPHOSARCOMA UNSPECIFIED SITE
C51.2 - Malignant neoplasm of clitoris
200.11 - LYMPHOSARCOMA INVOLVING LYMPH 
NODES OF HEAD FACE AND NECK
C51.8 - Malignant neoplasm of overlapping sites of vulva
200.14 - LYMPHOSARCOMA INVOLVING LYMPH 
NODES OF AXILLA AND UPPER LIMB
C51.9 - Malignant neoplasm of vulva, unspecified
200.16 - LYMPHOSARCOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C53.0 - Malignant neoplasm of endocervix
Appendix A

200.17 - LYMPHOSARCOMA INVOLVING SPLEEN C54.1 - Malignant neoplasm of endometrium
200.18 - LYMPHOSARCOMA INVOLVING LYMPH 
NODES OF MULTIPLE SITES
C54.2 - Malignant neoplasm of myometrium
200.2 - BURKITT'S TUMOR OR LYMPHOMA
C54.3 - Malignant neoplasm of fundus uteri
200.20 - BURKITT'S TUMOR OR LYMPHOMA 
UNSPECIFIED SITE
C56 - Malignant neoplasm of ovary
200.22 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C57.00 - Malignant neoplasm of unspecified fallopian tube
200.25 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C57.02 - Malignant neoplasm of left fallopian tube
200.28 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES C57.1 - Malignant neoplasm of broad ligament
200.3 - MARGINAL ZONE LYMPHOMA
C57.11 - Malignant neoplasm of right broad ligament
200.31 - MARGINAL ZONE LYMPHOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C57.12 - Malignant neoplasm of left broad ligament
200.34 - MARGINAL ZONE LYMPHOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C57.8 - Malignant neoplasm of overlapping sites of female 
genital organs
200.36 - MARGINAL ZONE LYMPHOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C57.9 - Malignant neoplasm of female genital organ, 
unspecified
200.37 - MARGINAL ZONE LYMPHOMA 
INVOLVING SPLEEN
C60.0 - Malignant neoplasm of prepuce
200.38 - MARGINAL ZONE LYMPHOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES C60.1 - Malignant neoplasm of glans penis
200.4 - MANTLE CELL LYMPHOMA
C60.9 - Malignant neoplasm of penis, unspecified
200.40 - MANTLE CELL LYMPHOMA 
UNSPECIFIED SITE
C61 - Malignant neoplasm of prostate
200.41 - MANTLE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C62.00 - Malignant neoplasm of unspecified undescended 
testis
Appendix A

200.42 - MANTLE CELL LYMPHOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C62.01 - Malignant neoplasm of undescended right testis
200.46 - MANTLE CELL LYMPHOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C62.02 - Malignant neoplasm of undescended left testis
200.48 - MANTLE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C62.12 - Malignant neoplasm of descended left testis
200.5 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA
C62.9 - Malignant neoplasm of testis, unspecified whether 
descended or undescended
200.51 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING LYMPH NODES OF 
HEAD FACE AND NECK
C62.90 - Malignant neoplasm of unspecified testis, 
unspecified whether descended or undescended
200.52 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING INTRATHORACIC 
LYMPH NODES
C62.92 - Malignant neoplasm of left testis, unspecified 
whether descended or undescended
200.54 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING LYMPH NODES OF 
AXILLA AND UPPER LIMB
C63.02 - Malignant neoplasm of left epididymis
200.55 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C63.2 - Malignant neoplasm of scrotum
200.57 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING SPLEEN
C63.8 - Malignant neoplasm of overlapping sites of male 
genital organs
200.60 - ANAPLASTIC LARGE CELL LYMPHOMA 
UNSPECIFIED SITE
C64 - Malignant neoplasm of kidney, except renal pelvis
200.61 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C64.2 - Malignant neoplasm of left kidney, except renal 
pelvis
200.62 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C65.2 - Malignant neoplasm of left renal pelvis
200.64 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C65.9 - Malignant neoplasm of unspecified renal pelvis
Appendix A

200.66 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C66 - Malignant neoplasm of ureter
200.67 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING SPLEEN
C66.1 - Malignant neoplasm of right ureter
200.7 - LARGE CELL LYMPHOMA
C66.2 - Malignant neoplasm of left ureter
200.71 - LARGE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C67 - Malignant neoplasm of bladder
200.72 - LARGE CELL LYMPHOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C67.2 - Malignant neoplasm of lateral wall of bladder
200.73 - LARGE CELL LYMPHOMA INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C67.3 - Malignant neoplasm of anterior wall of bladder
200.76 - LARGE CELL LYMPHOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C67.6 - Malignant neoplasm of ureteric orifice
200.77 - LARGE CELL LYMPHOMA INVOLVING 
SPLEEN
C68 - Malignant neoplasm of other and unspecified urinary 
organs
200.78 - LARGE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C68.9 - Malignant neoplasm of urinary organ, unspecified
200.8 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA
C69.1 - Malignant neoplasm of cornea
200.80 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
UNSPECIFIED SITE
C69.12 - Malignant neoplasm of left cornea
200.83 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C69.21 - Malignant neoplasm of right retina
Appendix A

200.85 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C69.3 - Malignant neoplasm of choroid
201 - HODGKIN'S DISEASE
C69.30 - Malignant neoplasm of unspecified choroid
201.00 - HODGKIN'S PARAGRANULOMA 
UNSPECIFIED SITE
C69.32 - Malignant neoplasm of left choroid
201.01 - HODGKIN'S PARAGRANULOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C69.5 - Malignant neoplasm of lacrimal gland and duct
201.02 - HODGKIN'S PARAGRANULOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C69.51 - Malignant neoplasm of right lacrimal gland and 
duct
201.03 - HODGKIN'S PARAGRANULOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C69.52 - Malignant neoplasm of left lacrimal gland and 
duct
201.05 - HODGKIN'S PARAGRANULOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C69.60 - Malignant neoplasm of unspecified orbit
201.07 - HODGKIN'S PARAGRANULOMA 
INVOLVING SPLEEN
C69.81 - Malignant neoplasm of overlapping sites of right 
eye and adnexa
201.1 - HODGKIN'S GRANULOMA
C69.82 - Malignant neoplasm of overlapping sites of left 
eye and adnexa
201.14 - HODGKIN'S GRANULOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C69.91 - Malignant neoplasm of unspecified site of right 
eye
201.15 - HODGKIN'S GRANULOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C69.92 - Malignant neoplasm of unspecified site of left eye
201.17 - HODGKIN'S GRANULOMA INVOLVING 
SPLEEN
C70 - Malignant neoplasm of meninges
201.18 - HODGKIN'S GRANULOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C70.0 - Malignant neoplasm of cerebral meninges
Appendix A

201.20 - HODGKIN'S SARCOMA UNSPECIFIED 
SITE
C70.1 - Malignant neoplasm of spinal meninges
201.22 - HODGKIN'S SARCOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C70.9 - Malignant neoplasm of meninges, unspecified
201.23 - HODGKIN'S SARCOMA INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C71 - Malignant neoplasm of brain
201.25 - HODGKIN'S SARCOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C71.2 - Malignant neoplasm of temporal lobe
201.4 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE
C71.3 - Malignant neoplasm of parietal lobe
201.40 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE UNSPECIFIED 
SITE
C71.4 - Malignant neoplasm of occipital lobe
201.46 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
INTRAPELVIC LYMPH NODES
C71.5 - Malignant neoplasm of cerebral ventricle
201.50 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS UNSPECIFIED SITE
C71.6 - Malignant neoplasm of cerebellum
201.52 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING INTRATHORACIC 
LYMPH NODES
C71.7 - Malignant neoplasm of brain stem
201.54 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING LYMPH NODES OF 
AXILLA AND UPPER LIMB
C71.8 - Malignant neoplasm of overlapping sites of brain
201.55 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C71.9 - Malignant neoplasm of brain, unspecified
201.56 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING INTRAPELVIC LYMPH 
NODES
C72 - Malignant neoplasm of spinal cord, cranial nerves 
and other parts of central nervous system
201.57 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING SPLEEN
C72.0 - Malignant neoplasm of spinal cord
Appendix A

201.61 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING LYMPH NODES OF 
HEAD FACE AND NECK
C72.3 - Malignant neoplasm of optic nerve
201.62 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING INTRATHORACIC 
LYMPH NODES
C72.30 - Malignant neoplasm of unspecified optic nerve
201.65 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C72.32 - Malignant neoplasm of left optic nerve
201.66 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING INTRAPELVIC LYMPH 
NODES
C72.4 - Malignant neoplasm of acoustic nerve
201.67 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING SPLEEN
C72.40 - Malignant neoplasm of unspecified acoustic 
nerve
201.68 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING LYMPH NODES OF 
MULTIPLE SITES
C72.41 - Malignant neoplasm of right acoustic nerve
201.7 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION
C72.50 - Malignant neoplasm of unspecified cranial nerve
201.72 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING INTRATHORACIC 
LYMPH NODES
C72.59 - Malignant neoplasm of other cranial nerves
201.73 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING INTRA-ABDOMINAL 
LYMPH NODES
C72.9 - Malignant neoplasm of central nervous system, 
unspecified
201.75 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C73 - Malignant neoplasm of thyroid gland
201.76 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING INTRAPELVIC LYMPH 
NODES
C74 - Malignant neoplasm of adrenal gland
201.78 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING LYMPH NODES OF 
MULTIPLE SITES
C74.00 - Malignant neoplasm of cortex of unspecified 
adrenal gland
Appendix A

201.9 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE
C74.01 - Malignant neoplasm of cortex of right adrenal 
gland
201.90 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE UNSPECIFIED SITE
C74.10 - Malignant neoplasm of medulla of unspecified 
adrenal gland
201.92 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING INTRATHORACIC LYMPH 
NODES
C74.92 - Malignant neoplasm of unspecified part of left 
adrenal gland
201.93 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING INTRA-ABDOMINAL LYMPH 
NODES
C75 - Malignant neoplasm of other endocrine glands and 
related structures
201.96 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING INTRAPELVIC LYMPH NODES
C75.0 - Malignant neoplasm of parathyroid gland
202.0 - NODULAR LYMPHOMA
C75.4 - Malignant neoplasm of carotid body
202.01 - NODULAR LYMPHOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C75.8 - Malignant neoplasm with pluriglandular 
involvement, unspecified
202.03 - NODULAR LYMPHOMA INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C75.9 - Malignant neoplasm of endocrine gland, 
unspecified
202.06 - NODULAR LYMPHOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C76.40 - Malignant neoplasm of unspecified upper limb
202.11 - MYCOSIS FUNGOIDES INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C76.41 - Malignant neoplasm of right upper limb
202.12 - MYCOSIS FUNGOIDES INVOLVING 
INTRATHORACIC LYMPH NODES
C76.42 - Malignant neoplasm of left upper limb
202.13 - MYCOSIS FUNGOIDES INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C76.5 - Malignant neoplasm of lower limb
202.14 - MYCOSIS FUNGOIDES INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C76.50 - Malignant neoplasm of unspecified lower limb
202.15 - MYCOSIS FUNGOIDES INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C76.51 - Malignant neoplasm of right lower limb
202.17 - MYCOSIS FUNGOIDES INVOLVING 
SPLEEN
C76.52 - Malignant neoplasm of left lower limb
202.18 - MYCOSIS FUNGOIDES INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C76.8 - Malignant neoplasm of other specified ill-defined 
sites
Appendix A

202.2 - SEZARY'S DISEASE
C77.0 - Secondary and unspecified malignant neoplasm of 
lymph nodes of head, face and neck
202.22 - SEZARY'S DISEASE INVOLVING 
INTRATHORACIC LYMPH NODES
C77.1 - Secondary and unspecified malignant neoplasm of 
intrathoracic lymph nodes
202.25 - SEZARY'S DISEASE INVOLVING LYMPH 
NODES OF INGUINAL REGION AND LOWER 
LIMB
C77.2 - Secondary and unspecified malignant neoplasm of 
intra-abdominal lymph nodes
202.27 - SEZARY'S DISEASE INVOLVING SPLEEN
C77.9 - Secondary and unspecified malignant neoplasm of 
lymph node, unspecified
202.28 - SEZARY'S DISEASE INVOLVING LYMPH 
NODES OF MULTIPLE SITES
C78 - Secondary malignant neoplasm of respiratory and 
digestive organs
202.3 - MALIGNANT HISTIOCYTOSIS
C78.00 - Secondary malignant neoplasm of unspecified 
lung
202.31 - MALIGNANT HISTIOCYTOSIS 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C78.1 - Secondary malignant neoplasm of mediastinum
202.33 - MALIGNANT HISTIOCYTOSIS 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C78.2 - Secondary malignant neoplasm of pleura
202.34 - MALIGNANT HISTIOCYTOSIS 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C78.30 - Secondary malignant neoplasm of unspecified 
respiratory organ
202.36 - MALIGNANT HISTIOCYTOSIS 
INVOLVING INTRAPELVIC LYMPH NODES
C78.39 - Secondary malignant neoplasm of other 
respiratory organs
202.37 - MALIGNANT HISTIOCYTOSIS 
INVOLVING SPLEEN
C78.5 - Secondary malignant neoplasm of large intestine 
and rectum
202.38 - MALIGNANT HISTIOCYTOSIS 
INVOLVING LYMPH NODES OF MULTIPLE SITES
C78.6 - Secondary malignant neoplasm of retroperitoneum 
and peritoneum
202.4 - LEUKEMIC RETICULOENDOTHELIOSIS
C78.7 - Secondary malignant neoplasm of liver and 
intrahepatic bile duct
202.41 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C78.80 - Secondary malignant neoplasm of unspecified 
digestive organ
Appendix A

202.46 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING INTRAPELVIC LYMPH NODES
C78.89 - Secondary malignant neoplasm of other digestive 
organs
202.47 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING SPLEEN
C79.02 - Secondary malignant neoplasm of left kidney and 
renal pelvis
202.5 - LETTERER-SIWE DISEASE
C79.11 - Secondary malignant neoplasm of bladder
202.50 - LETTERER-SIWE DISEASE 
UNSPECIFIED SITE
C79.2 - Secondary malignant neoplasm of skin
202.51 - LETTERER-SIWE DISEASE INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C79.3 - Secondary malignant neoplasm of brain and 
cerebral meninges
202.54 - LETTERER-SIWE DISEASE INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C79.31 - Secondary malignant neoplasm of brain
202.55 - LETTERER-SIWE DISEASE INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C79.5 - Secondary malignant neoplasm of bone and bone 
marrow
202.58 - LETTERER-SIWE DISEASE INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C79.6 - Secondary malignant neoplasm of ovary
202.65 - MALIGNANT MAST CELL TUMORS 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C79.62 - Secondary malignant neoplasm of left ovary
202.66 - MALIGNANT MAST CELL TUMORS 
INVOLVING INTRAPELVIC LYMPH NODES
C79.7 - Secondary malignant neoplasm of adrenal gland
202.70 - PERIPHERAL T-CELL LYMPHOMA 
UNSPECIFIED SITE
C79.70 - Secondary malignant neoplasm of unspecified 
adrenal gland
202.71 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C79.72 - Secondary malignant neoplasm of left adrenal 
gland
202.72 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C79.8 - Secondary malignant neoplasm of other specified 
sites
Appendix A

202.75 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C79.81 - Secondary malignant neoplasm of breast
202.76 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C79.9 - Secondary malignant neoplasm of unspecified site
202.78 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES C80 - Malignant neoplasm without specification of site
202.80 - OTHER MALIGNANT LYMPHOMAS 
UNSPECIFIED SITE
C81 - Hodgkin lymphoma
202.81 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C81.0 - Nodular lymphocyte predominant Hodgkin 
lymphoma
202.83 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C81.01 - Nodular lymphocyte predominant Hodgkin 
lymphoma, lymph nodes of head, face, and neck
202.84 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C81.02 - Nodular lymphocyte predominant Hodgkin 
lymphoma, intrathoracic lymph nodes
202.90 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE UNSPECIFIED SITE
C81.04 - Nodular lymphocyte predominant Hodgkin 
lymphoma, lymph nodes of axilla and upper limb
202.91 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING LYMPH NODES OF HEAD 
FACE AND NECK
C81.06 - Nodular lymphocyte predominant Hodgkin 
lymphoma, intrapelvic lymph nodes
202.92 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING INTRATHORACIC LYMPH 
NODES
C81.07 - Nodular lymphocyte predominant Hodgkin 
lymphoma, spleen
202.97 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING SPLEEN
C81.09 - Nodular lymphocyte predominant Hodgkin 
lymphoma, extranodal and solid organ sites
Appendix A

202.98 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING LYMPH NODES OF 
MULTIPLE SITES
C81.1 - Nodular sclerosis Hodgkin lymphoma
203.00 - MULTIPLE MYELOMA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C81.12 - Nodular sclerosis Hodgkin lymphoma, 
intrathoracic lymph nodes
203.01 - MULTIPLE MYELOMA IN REMISSION
C81.14 - Nodular sclerosis Hodgkin lymphoma, lymph 
nodes of axilla and upper limb
203.02 - MULTIPLE MYELOMA IN RELAPSE
C81.15 - Nodular sclerosis Hodgkin lymphoma, lymph 
nodes of inguinal region and lower limb
203.10 - PLASMA CELL LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C81.16 - Nodular sclerosis Hodgkin lymphoma, intrapelvic 
lymph nodes
203.11 - PLASMA CELL LEUKEMIA IN REMISSION C81.17 - Nodular sclerosis Hodgkin lymphoma, spleen
203.12 - PLASMA CELL LEUKEMIA IN RELAPSE
C81.18 - Nodular sclerosis Hodgkin lymphoma, lymph 
nodes of multiple sites
203.8 - OTHER IMMUNOPROLIFERATIVE 
NEOPLASMS
C81.19 - Nodular sclerosis Hodgkin lymphoma, extranodal 
and solid organ sites
203.80 - OTHER IMMUNOPROLIFERATIVE 
NEOPLASMS WITHOUT MENTION OF HAVING 
ACHIEVED REMISSION
C81.2 - Mixed cellularity Hodgkin lymphoma
204 - LYMPHOID LEUKEMIA
C81.20 - Mixed cellularity Hodgkin lymphoma, unspecified 
site
204.0 - ACUTE LYMPHOID LEUKEMIA
C81.22 - Mixed cellularity Hodgkin lymphoma, intrathoracic 
lymph nodes
204.01 - ACUTE LYMPHOID LEUKEMIA IN 
REMISSION
C81.24 - Mixed cellularity Hodgkin lymphoma, lymph 
nodes of axilla and upper limb
204.1 - CHRONIC LYMPHOID LEUKEMIA
C81.26 - Mixed cellularity Hodgkin lymphoma, intrapelvic 
lymph nodes
204.10 - CHRONIC LYMPHOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C81.27 - Mixed cellularity Hodgkin lymphoma, spleen
204.12 - CHRONIC LYMPHOID LEUKEMIA IN 
RELAPSE
C81.30 - Lymphocyte depleted Hodgkin lymphoma, 
unspecified site
Appendix A

204.22 - SUBACUTE LYMPHOID LEUKEMIA IN 
RELAPSE
C81.31 - Lymphocyte depleted Hodgkin lymphoma, lymph 
nodes of head, face, and neck
204.8 - OTHER LYMPHOID LEUKEMIA
C81.34 - Lymphocyte depleted Hodgkin lymphoma, lymph 
nodes of axilla and upper limb
204.80 - OTHER LYMPHOID LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C81.36 - Lymphocyte depleted Hodgkin lymphoma, 
intrapelvic lymph nodes
204.81 - OTHER LYMPHOID LEUKEMIA IN 
REMISSION
C81.38 - Lymphocyte depleted Hodgkin lymphoma, lymph 
nodes of multiple sites
204.82 - OTHER LYMPHOID LEUKEMIA IN 
RELAPSE
C81.4 - Lymphocyte-rich Hodgkin lymphoma
204.91 - UNSPECIFIED LYMPHOID LEUKEMIA IN 
REMISSION
C81.41 - Lymphocyte-rich Hodgkin lymphoma, lymph 
nodes of head, face, and neck
204.92 - UNSPECIFIED LYMPHOID LEUKEMIA IN 
RELAPSE
C81.42 - Lymphocyte-rich Hodgkin lymphoma, 
intrathoracic lymph nodes
205.0 - ACUTE MYELOID LEUKEMIA
C81.43 - Lymphocyte-rich Hodgkin lymphoma, intra-
abdominal lymph nodes
205.01 - ACUTE MYELOID LEUKEMIA IN 
REMISSION
C81.44 - Lymphocyte-rich Hodgkin lymphoma, lymph 
nodes of axilla and upper limb
205.02 - ACUTE MYELOID LEUKEMIA IN 
RELAPSE
C81.7 - Other Hodgkin lymphoma
205.1 - CHRONIC MYELOID LEUKEMIA
C81.70 - Other Hodgkin lymphoma, unspecified site
205.12 - CHRONIC MYELOID LEUKEMIA IN 
RELAPSE
C81.71 - Other Hodgkin lymphoma, lymph nodes of head, 
face, and neck
205.2 - SUBACUTE MYELOID LEUKEMIA
C81.72 - Other Hodgkin lymphoma, intrathoracic lymph 
nodes
205.80 - OTHER MYELOID LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C81.73 - Other Hodgkin lymphoma, intra-abdominal lymph 
nodes
205.82 - OTHER MYELOID LEUKEMIA IN 
RELAPSE
C81.75 - Other Hodgkin lymphoma, lymph nodes of 
inguinal region and lower limb
205.9 - UNSPECIFIED MYELOID LEUKEMIA
C81.79 - Other Hodgkin lymphoma, extranodal and solid 
organ sites
Appendix A

205.90 - UNSPECIFIED MYELOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C81.90 - Hodgkin lymphoma, unspecified, unspecified site
205.91 - UNSPECIFIED MYELOID LEUKEMIA IN 
REMISSION
C81.91 - Hodgkin lymphoma, unspecified, lymph nodes of 
head, face, and neck
205.92 - UNSPECIFIED MYELOID LEUKEMIA IN 
RELAPSE
C81.94 - Hodgkin lymphoma, unspecified, lymph nodes of 
axilla and upper limb
206 - MONOCYTIC LEUKEMIA
C81.96 - Hodgkin lymphoma, unspecified, intrapelvic 
lymph nodes
206.00 - ACUTE MONOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C81.97 - Hodgkin lymphoma, unspecified, spleen
206.1 - CHRONIC MONOCYTIC LEUKEMIA
C81.98 - Hodgkin lymphoma, unspecified, lymph nodes of 
multiple sites
206.11 - CHRONIC MONOCYTIC LEUKEMIA IN 
REMISSION
C82 - Follicular lymphoma
206.2 - SUBACUTE MONOCYTIC LEUKEMIA
C82.05 - Follicular lymphoma grade I, lymph nodes of 
inguinal region and lower limb
206.21 - SUBACUTE MONOCYTIC LEUKEMIA IN 
REMISSION
C82.06 - Follicular lymphoma grade I, intrapelvic lymph 
nodes
206.8 - OTHER MONOCYTIC LEUKEMIA
C82.07 - Follicular lymphoma grade I, spleen
206.80 - OTHER MONOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C82.08 - Follicular lymphoma grade I, lymph nodes of 
multiple sites
206.9 - UNSPECIFIED MONOCYTIC LEUKEMIA
C82.09 - Follicular lymphoma grade I, extranodal and solid 
organ sites
207.0 - ACUTE ERYTHREMIA AND 
ERYTHROLEUKEMIA
C82.1 - Follicular lymphoma grade II
207.00 - ACUTE ERYTHREMIA AND 
ERYTHROLEUKEMIA WITHOUT MENTION OF 
HAVING ACHIEVED REMISSION
C82.12 - Follicular lymphoma grade II, intrathoracic lymph 
nodes
207.11 - CHRONIC ERYTHREMIA IN REMISSION
C82.14 - Follicular lymphoma grade II, lymph nodes of 
axilla and upper limb
207.81 - OTHER SPECIFIED LEUKEMIA IN 
REMISSION
C82.15 - Follicular lymphoma grade II, lymph nodes of 
inguinal region and lower limb
Appendix A

208 - LEUKEMIA OF UNSPECIFIED CELL TYPE
C82.18 - Follicular lymphoma grade II, lymph nodes of 
multiple sites
208.0 - ACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE
C82.19 - Follicular lymphoma grade II, extranodal and 
solid organ sites
208.1 - CHRONIC LEUKEMIA OF UNSPECIFIED 
CELL TYPE
C82.2 - Follicular lymphoma grade III, unspecified
208.10 - CHRONIC LEUKEMIA OF UNSPECIFIED 
CELL TYPE WITHOUT MENTION OF HAVING 
ACHIEVED REMISSION
C82.20 - Follicular lymphoma grade III, unspecified, 
unspecified site
208.12 - CHRONIC LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN RELAPSE
C82.21 - Follicular lymphoma grade III, unspecified, lymph 
nodes of head, face, and neck
208.2 - SUBACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE
C82.24 - Follicular lymphoma grade III, unspecified, lymph 
nodes of axilla and upper limb
208.20 - SUBACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE WITHOUT MENTION OF HAVING 
ACHIEVED REMISSION
C82.25 - Follicular lymphoma grade III, unspecified, lymph 
nodes of inguinal region and lower limb
208.21 - SUBACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN REMISSION
C82.28 - Follicular lymphoma grade III, unspecified, lymph 
nodes of multiple sites
208.22 - SUBACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN RELAPSE
C82.29 - Follicular lymphoma grade III, unspecified, 
extranodal and solid organ sites
208.82 - OTHER LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN RELAPSE
C82.32 - Follicular lymphoma grade IIIa, intrathoracic 
lymph nodes
209 - NEUROENDOCRINE TUMORS
C82.33 - Follicular lymphoma grade IIIa, intra-abdominal 
lymph nodes
209.00 - MALIGNANT CARCINOID TUMOR OF 
THE SMALL INTESTINE UNSPECIFIED PORTION
C82.35 - Follicular lymphoma grade IIIa, lymph nodes of 
inguinal region and lower limb
209.01 - MALIGNANT CARCINOID TUMOR OF 
THE DUODENUM
C82.39 - Follicular lymphoma grade IIIa, extranodal and 
solid organ sites
209.02 - MALIGNANT CARCINOID TUMOR OF 
THE JEJUNUM
C82.44 - Follicular lymphoma grade IIIb, lymph nodes of 
axilla and upper limb
209.11 - MALIGNANT CARCINOID TUMOR OF 
THE APPENDIX
C82.46 - Follicular lymphoma grade IIIb, intrapelvic lymph 
nodes
209.12 - MALIGNANT CARCINOID TUMOR OF 
THE CECUM
C82.47 - Follicular lymphoma grade IIIb, spleen
Appendix A

209.17 - MALIGNANT CARCINOID TUMOR OF 
THE RECTUM
C82.51 - Diffuse follicle center lymphoma, lymph nodes of 
head, face, and neck
209.22 - MALIGNANT CARCINOID TUMOR OF 
THE THYMUS
C82.52 - Diffuse follicle center lymphoma, intrathoracic 
lymph nodes
209.25 - MALIGNANT CARCINOID TUMOR OF 
THE FOREGUT NOT OTHERWISE SPECIFIED
C82.55 - Diffuse follicle center lymphoma, lymph nodes of 
inguinal region and lower limb
209.29 - MALIGNANT CARCINOID TUMOR OF 
OTHER SITES
C82.56 - Diffuse follicle center lymphoma, intrapelvic 
lymph nodes
209.3 - MALIGNANT POORLY DIFFERENTIATED 
NEUROENDOCRINE TUMORS
C82.59 - Diffuse follicle center lymphoma, extranodal and 
solid organ sites
209.30 - MALIGNANT POORLY DIFFERENTIATED 
NEUROENDOCRINE CARDINOMA ANY SITE
C82.60 - Cutaneous follicle center lymphoma, unspecified 
site
209.31 - MERKEL CELL CARCINOMA OF THE 
FACE
C82.61 - Cutaneous follicle center lymphoma, lymph 
nodes of head, face, and neck
209.32 - MERKEL CELL CARCINOMA OF THE 
SCALP AND NECK
C82.62 - Cutaneous follicle center lymphoma, intrathoracic 
lymph nodes
209.33 - MERKEL CELL CARCINOMA OF THE 
UPPER LIMB
C82.63 - Cutaneous follicle center lymphoma, intra-
abdominal lymph nodes
209.34 - MERKEL CELL CARCINOMA OF THE 
LOWER LIMB
C82.68 - Cutaneous follicle center lymphoma, lymph 
nodes of multiple sites
209.70 - SECONDARY NEUROENDOCRINE 
TUMOR UNSPECIFIED SITE
C82.69 - Cutaneous follicle center lymphoma, extranodal 
and solid organ sites
209.72 - SECONDARY NEUROENDOCRINE 
TUMOR OF LIVER
C82.8 - Other types of follicular lymphoma
209.75 - SECONDARY MERKEL CELL 
CARCINOMA
C82.80 - Other types of follicular lymphoma, unspecified 
site
209.79 - SECONDARY NEUROENDOCRINE 
TUMOR OF OTHER SITES
C82.86 - Other types of follicular lymphoma, intrapelvic 
lymph nodes
140 - MALIGNANT NEOPLASM OF LIP
C82.87 - Other types of follicular lymphoma, spleen
140.1 - MALIGNANT NEOPLASM OF LOWER LIP 
VERMILION BORDER
C82.89 - Other types of follicular lymphoma, extranodal 
and solid organ sites
Appendix A

140.4 - MALIGNANT NEOPLASM OF LOWER LIP 
INNER ASPECT
C82.92 - Follicular lymphoma, unspecified, intrathoracic 
lymph nodes
140.5 - MALIGNANT NEOPLASM OF LIP 
UNSPECIFIED INNER ASPECT
C82.95 - Follicular lymphoma, unspecified, lymph nodes of 
inguinal region and lower limb
141 - MALIGNANT NEOPLASM OF TONGUE
C82.96 - Follicular lymphoma, unspecified, intrapelvic 
lymph nodes
141.1 - MALIGNANT NEOPLASM OF DORSAL 
SURFACE OF TONGUE
C82.97 - Follicular lymphoma, unspecified, spleen
141.2 - MALIGNANT NEOPLASM OF TIP AND 
LATERAL BORDER OF TONGUE
C82.98 - Follicular lymphoma, unspecified, lymph nodes of 
multiple sites
141.4 - MALIGNANT NEOPLASM OF ANTERIOR 
TWO-THIRDS OF TONGUE PART UNSPECIFIED
C82.99 - Follicular lymphoma, unspecified, extranodal and 
solid organ sites
141.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF TONGUE
C83.00 - Small cell B-cell lymphoma, unspecified site
142 - MALIGNANT NEOPLASM OF MAJOR 
SALIVARY GLANDS
C83.01 - Small cell B-cell lymphoma, lymph nodes of 
head, face, and neck
142.2 - MALIGNANT NEOPLASM OF SUBLINGUAL 
GLAND
C83.02 - Small cell B-cell lymphoma, intrathoracic lymph 
nodes
142.8 - MALIGNANT NEOPLASM OF OTHER 
MAJOR SALIVARY GLANDS
C83.03 - Small cell B-cell lymphoma, intra-abdominal 
lymph nodes
143 - MALIGNANT NEOPLASM OF GUM
C83.06 - Small cell B-cell lymphoma, intrapelvic lymph 
nodes
143.0 - MALIGNANT NEOPLASM OF UPPER GUM C83.07 - Small cell B-cell lymphoma, spleen
143.1 - MALIGNANT NEOPLASM OF LOWER GUM
C83.08 - Small cell B-cell lymphoma, lymph nodes of 
multiple sites
143.9 - MALIGNANT NEOPLASM OF GUM 
UNSPECIFIED
C83.11 - Mantle cell lymphoma, lymph nodes of head, 
face, and neck
144 - MALIGNANT NEOPLASM OF FLOOR OF 
MOUTH
C83.12 - Mantle cell lymphoma, intrathoracic lymph nodes
144.0 - MALIGNANT NEOPLASM OF ANTERIOR 
PORTION OF FLOOR OF MOUTH
C83.14 - Mantle cell lymphoma, lymph nodes of axilla and 
upper limb
145 - MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED PARTS OF MOUTH
C83.17 - Mantle cell lymphoma, spleen
Appendix A

145.0 - MALIGNANT NEOPLASM OF CHEEK 
MUCOSA
C83.18 - Mantle cell lymphoma, lymph nodes of multiple 
sites
145.1 - MALIGNANT NEOPLASM OF VESTIBULE 
OF MOUTH
C83.19 - Mantle cell lymphoma, extranodal and solid organ 
sites
145.2 - MALIGNANT NEOPLASM OF HARD 
PALATE
C83.30 - Diffuse large B-cell lymphoma, unspecified site
145.4 - MALIGNANT NEOPLASM OF UVULA
C83.31 - Diffuse large B-cell lymphoma, lymph nodes of 
head, face, and neck
145.6 - MALIGNANT NEOPLASM OF 
RETROMOLAR AREA
C83.34 - Diffuse large B-cell lymphoma, lymph nodes of 
axilla and upper limb
145.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED PARTS OF MOUTH
C83.35 - Diffuse large B-cell lymphoma, lymph nodes of 
inguinal region and lower limb
146.0 - MALIGNANT NEOPLASM OF TONSIL
C83.36 - Diffuse large B-cell lymphoma, intrapelvic lymph 
nodes
146.1 - MALIGNANT NEOPLASM OF TONSILLAR 
FOSSA
C83.37 - Diffuse large B-cell lymphoma, spleen
146.2 - MALIGNANT NEOPLASM OF TONSILLAR 
PILLARS (ANTERIOR) (POSTERIOR)
C83.38 - Diffuse large B-cell lymphoma, lymph nodes of 
multiple sites
146.5 - MALIGNANT NEOPLASM OF JUNCTIONAL 
REGION OF OROPHARYNX
C83.5 - Lymphoblastic (diffuse) lymphoma
147.1 - MALIGNANT NEOPLASM OF POSTERIOR 
WALL OF NASOPHARYNX
C83.50 - Lymphoblastic (diffuse) lymphoma, unspecified 
site
147.3 - MALIGNANT NEOPLASM OF ANTERIOR 
WALL OF NASOPHARYNX
C83.52 - Lymphoblastic (diffuse) lymphoma, intrathoracic 
lymph nodes
147.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF NASOPHARYNX
C83.53 - Lymphoblastic (diffuse) lymphoma, intra-
abdominal lymph nodes
148.0 - MALIGNANT NEOPLASM OF 
POSTCRICOID REGION OF HYPOPHARYNX
C83.56 - Lymphoblastic (diffuse) lymphoma, intrapelvic 
lymph nodes
148.1 - MALIGNANT NEOPLASM OF PYRIFORM 
SINUS
C83.58 - Lymphoblastic (diffuse) lymphoma, lymph nodes 
of multiple sites
148.3 - MALIGNANT NEOPLASM OF POSTERIOR 
HYPOPHARYNGEAL WALL
C83.59 - Lymphoblastic (diffuse) lymphoma, extranodal 
and solid organ sites
Appendix A

149 - MALIGNANT NEOPLASM OF OTHER AND 
ILL-DEFINED SITES WITHIN THE LIP ORAL 
CAVITY AND PHARYNX
C83.72 - Burkitt lymphoma, intrathoracic lymph nodes
149.1 - MALIGNANT NEOPLASM OF 
WALDEYER'S RING
C83.76 - Burkitt lymphoma, intrapelvic lymph nodes
149.9 - MALIGNANT NEOPLASM OF ILL-DEFINED 
SITES WITHIN THE LIP AND ORAL CAVITY
C83.77 - Burkitt lymphoma, spleen
150 - MALIGNANT NEOPLASM OF ESOPHAGUS
C83.79 - Burkitt lymphoma, extranodal and solid organ 
sites
150.0 - MALIGNANT NEOPLASM OF CERVICAL 
ESOPHAGUS
C83.8 - Other non-follicular lymphoma
150.3 - MALIGNANT NEOPLASM OF UPPER 
THIRD OF ESOPHAGUS
C83.80 - Other non-follicular lymphoma, unspecified site
151 - MALIGNANT NEOPLASM OF STOMACH
C83.83 - Other non-follicular lymphoma, intra-abdominal 
lymph nodes
151.1 - MALIGNANT NEOPLASM OF PYLORUS
C83.84 - Other non-follicular lymphoma, lymph nodes of 
axilla and upper limb
151.4 - MALIGNANT NEOPLASM OF BODY OF 
STOMACH
C83.89 - Other non-follicular lymphoma, extranodal and 
solid organ sites
151.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF STOMACH
C83.9 - Non-follicular (diffuse) lymphoma, unspecified
152.1 - MALIGNANT NEOPLASM OF JEJUNUM
C83.90 - Non-follicular (diffuse) lymphoma, unspecified, 
unspecified site
152.2 - MALIGNANT NEOPLASM OF ILEUM
C83.92 - Non-follicular (diffuse) lymphoma, unspecified, 
intrathoracic lymph nodes
152.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF SMALL INTESTINE
C83.93 - Non-follicular (diffuse) lymphoma, unspecified, 
intra-abdominal lymph nodes
153 - MALIGNANT NEOPLASM OF COLON
C83.95 - Non-follicular (diffuse) lymphoma, unspecified, 
lymph nodes of inguinal region and lower limb
153.0 - MALIGNANT NEOPLASM OF HEPATIC 
FLEXURE
C84.02 - Mycosis fungoides, intrathoracic lymph nodes
153.2 - MALIGNANT NEOPLASM OF 
DESCENDING COLON
C84.07 - Mycosis fungoides, spleen
Appendix A

153.3 - MALIGNANT NEOPLASM OF SIGMOID 
COLON
C84.11 - Sezary disease, lymph nodes of head, face, and 
neck
153.6 - MALIGNANT NEOPLASM OF ASCENDING 
COLON
C84.13 - Sezary disease, intra-abdominal lymph nodes
153.9 - MALIGNANT NEOPLASM OF COLON 
UNSPECIFIED SITE
C84.15 - Sezary disease, lymph nodes of inguinal region 
and lower limb
154 - MALIGNANT NEOPLASM OF RECTUM 
RECTOSIGMOID JUNCTION AND ANUS
C84.17 - Sezary disease, spleen
154.1 - MALIGNANT NEOPLASM OF RECTUM
C84.18 - Sezary disease, lymph nodes of multiple sites
154.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF RECTUM RECTOSIGMOID JUNCTION 
AND ANUS
C84.4 - Peripheral T-cell lymphoma, not classified
155.1 - MALIGNANT NEOPLASM OF 
INTRAHEPATIC BILE DUCTS
C84.41 - Peripheral T-cell lymphoma, not classified, lymph 
nodes of head, face, and neck
156.1 - MALIGNANT NEOPLASM OF 
EXTRAHEPATIC BILE DUCTS
C84.42 - Peripheral T-cell lymphoma, not classified, 
intrathoracic lymph nodes
156.2 - MALIGNANT NEOPLASM OF AMPULLA OF 
VATER
C84.43 - Peripheral T-cell lymphoma, not classified, intra-
abdominal lymph nodes
156.9 - MALIGNANT NEOPLASM OF BILIARY 
TRACT PART UNSPECIFIED SITE
C84.44 - Peripheral T-cell lymphoma, not classified, lymph 
nodes of axilla and upper limb
157 - MALIGNANT NEOPLASM OF PANCREAS
C84.45 - Peripheral T-cell lymphoma, not classified, lymph 
nodes of inguinal region and lower limb
157.1 - MALIGNANT NEOPLASM OF BODY OF 
PANCREAS
C84.48 - Peripheral T-cell lymphoma, not classified, lymph 
nodes of multiple sites
157.3 - MALIGNANT NEOPLASM OF 
PANCREATIC DUCT
C84.49 - Peripheral T-cell lymphoma, not classified, 
extranodal and solid organ sites
157.4 - MALIGNANT NEOPLASM OF ISLETS OF 
LANGERHANS
C84.61 - Anaplastic large cell lymphoma, ALK-positive, 
lymph nodes of head, face, and neck
157.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF PANCREAS
C84.66 - Anaplastic large cell lymphoma, ALK-positive, 
intrapelvic lymph nodes
158 - MALIGNANT NEOPLASM OF 
RETROPERITONEUM AND PERITONEUM
C84.7 - Anaplastic large cell lymphoma, ALK-negative
158.0 - MALIGNANT NEOPLASM OF 
RETROPERITONEUM
C84.71 - Anaplastic large cell lymphoma, ALK-negative, 
lymph nodes of head, face, and neck
Appendix A

159 - MALIGNANT NEOPLASM OF OTHER AND 
ILL-DEFINED SITES WITHIN THE DIGESTIVE 
ORGANS AND PERITONEUM
C84.74 - Anaplastic large cell lymphoma, ALK-negative, 
lymph nodes of axilla and upper limb
159.1 - MALIGNANT NEOPLASM OF SPLEEN NOT 
ELSEWHERE CLASSIFIED
C84.75 - Anaplastic large cell lymphoma, ALK-negative, 
lymph nodes of inguinal region and lower limb
159.8 - MALIGNANT NEOPLASM OF OTHER 
SITES OF DIGESTIVE SYSTEM AND INTRA-
ABDOMINAL ORGANS
C84.76 - Anaplastic large cell lymphoma, ALK-negative, 
intrapelvic lymph nodes
159.9 - MALIGNANT NEOPLASM OF ILL-DEFINED 
SITES WITHIN THE DIGESTIVE ORGANS AND 
PERITONEUM
C84.79 - Anaplastic large cell lymphoma, ALK-negative, 
extranodal and solid organ sites
160.0 - MALIGNANT NEOPLASM OF NASAL 
CAVITIES
C84.9 - Mature T/NK-cell lymphomas, unspecified
160.2 - MALIGNANT NEOPLASM OF MAXILLARY 
SINUS
C84.93 - Mature T/NK-cell lymphomas, unspecified, intra-
abdominal lymph nodes
160.3 - MALIGNANT NEOPLASM OF ETHMOIDAL 
SINUS
C84.94 - Mature T/NK-cell lymphomas, unspecified, lymph 
nodes of axilla and upper limb
160.4 - MALIGNANT NEOPLASM OF FRONTAL 
SINUS
C84.95 - Mature T/NK-cell lymphomas, unspecified, lymph 
nodes of inguinal region and lower limb
160.5 - MALIGNANT NEOPLASM OF 
SPHENOIDAL SINUS
C84.96 - Mature T/NK-cell lymphomas, unspecified, 
intrapelvic lymph nodes
160.8 - MALIGNANT NEOPLASM OF OTHER 
ACCESSORY SINUSES
C84.97 - Mature T/NK-cell lymphomas, unspecified, spleen
161.3 - MALIGNANT NEOPLASM OF LARYNGEAL 
CARTILAGES
C84.98 - Mature T/NK-cell lymphomas, unspecified, lymph 
nodes of multiple sites
161.9 - MALIGNANT NEOPLASM OF LARYNX 
UNSPECIFIED
C84.99 - Mature T/NK-cell lymphomas, unspecified, 
extranodal and solid organ sites
162.3 - MALIGNANT NEOPLASM OF UPPER LOBE 
BRONCHUS OR LUNG
C84.A - Cutaneous T-cell lymphoma, unspecified
162.4 - MALIGNANT NEOPLASM OF MIDDLE 
LOBE BRONCHUS OR LUNG
C84.A4 - Cutaneous T-cell lymphoma, unspecified, lymph 
nodes of axilla and upper limb
162.5 - MALIGNANT NEOPLASM OF LOWER 
LOBE BRONCHUS OR LUNG
C84.A6 - Cutaneous T-cell lymphoma, unspecified, 
intrapelvic lymph nodes
Appendix A

162.9 - MALIGNANT NEOPLASM OF BRONCHUS 
AND LUNG UNSPECIFIED
C84.A8 - Cutaneous T-cell lymphoma, unspecified, lymph 
nodes of multiple sites
163.1 - MALIGNANT NEOPLASM OF VISCERAL 
PLEURA
C84.A9 - Cutaneous T-cell lymphoma, unspecified, 
extranodal and solid organ sites
163.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF PLEURA
C84.Z0 - Other mature T/NK-cell lymphomas, unspecified 
site
164.0 - MALIGNANT NEOPLASM OF THYMUS
C84.Z2 - Other mature T/NK-cell lymphomas, intrathoracic 
lymph nodes
164.2 - MALIGNANT NEOPLASM OF ANTERIOR 
MEDIASTINUM
C84.Z3 - Other mature T/NK-cell lymphomas, intra-
abdominal lymph nodes
164.3 - MALIGNANT NEOPLASM OF POSTERIOR 
MEDIASTINUM
C84.Z5 - Other mature T/NK-cell lymphomas, lymph nodes 
of inguinal region and lower limb
165 - MALIGNANT NEOPLASM OF OTHER AND 
ILL-DEFINED SITES WITHIN THE RESPIRATORY 
SYSTEM AND INTRATHORACIC ORGANS
C84.Z7 - Other mature T/NK-cell lymphomas, spleen
165.0 - MALIGNANT NEOPLASM OF UPPER 
RESPIRATORY TRACT PART UNSPECIFIED
C84.Z9 - Other mature T/NK-cell lymphomas, extranodal 
and solid organ sites
165.8 - MALIGNANT NEOPLASM OF OTHER 
SITES WITHIN THE RESPIRATORY SYSTEM AND 
INTRATHORACIC ORGANS
C85 - Other specified and unspecified types of non-
Hodgkin lymphoma
165.9 - MALIGNANT NEOPLASM OF ILL-DEFINED 
SITES WITHIN THE RESPIRATORY SYSTEM
C85.10 - Unspecified B-cell lymphoma, unspecified site
170 - MALIGNANT NEOPLASM OF BONE AND 
ARTICULAR CARTILAGE
C85.11 - Unspecified B-cell lymphoma, lymph nodes of 
head, face, and neck
170.0 - MALIGNANT NEOPLASM OF BONES OF 
SKULL AND FACE EXCEPT MANDIBLE
C85.14 - Unspecified B-cell lymphoma, lymph nodes of 
axilla and upper limb
170.3 - MALIGNANT NEOPLASM OF RIBS 
STERNUM AND CLAVICLE
C85.16 - Unspecified B-cell lymphoma, intrapelvic lymph 
nodes
170.4 - MALIGNANT NEOPLASM OF SCAPULA 
AND LONG BONES OF UPPER LIMB
C85.2 - Mediastinal (thymic) large B-cell lymphoma
170.6 - MALIGNANT NEOPLASM OF PELVIC 
BONES SACRUM AND COCCYX
C85.20 - Mediastinal (thymic) large B-cell lymphoma, 
unspecified site
Appendix A

170.7 - MALIGNANT NEOPLASM OF LONG 
BONES OF LOWER LIMB
C85.21 - Mediastinal (thymic) large B-cell lymphoma, 
lymph nodes of head, face, and neck
171.3 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
LOWER LIMB INCLUDING HIP
C85.23 - Mediastinal (thymic) large B-cell lymphoma, intra-
abdominal lymph nodes
171.5 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
ABDOMEN
C85.24 - Mediastinal (thymic) large B-cell lymphoma, 
lymph nodes of axilla and upper limb
171.6 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE OF 
PELVIS
C85.25 - Mediastinal (thymic) large B-cell lymphoma, 
lymph nodes of inguinal region and lower limb
171.9 - MALIGNANT NEOPLASM OF 
CONNECTIVE AND OTHER SOFT TISSUE SITE 
UNSPECIFIED
C85.27 - Mediastinal (thymic) large B-cell lymphoma, 
spleen
172.0 - MALIGNANT MELANOMA OF SKIN OF LIP
C85.28 - Mediastinal (thymic) large B-cell lymphoma, 
lymph nodes of multiple sites
172.4 - MALIGNANT MELANOMA OF SKIN OF 
SCALP AND NECK
C85.29 - Mediastinal (thymic) large B-cell lymphoma, 
extranodal and solid organ sites
172.5 - MALIGNANT MELANOMA OF SKIN OF 
TRUNK EXCEPT SCROTUM
C85.81 - Other specified types of non-Hodgkin lymphoma, 
lymph nodes of head, face, and neck
172.6 - MALIGNANT MELANOMA OF SKIN OF 
UPPER LIMB INCLUDING SHOULDER
C85.82 - Other specified types of non-Hodgkin lymphoma, 
intrathoracic lymph nodes
172.7 - MALIGNANT MELANOMA OF SKIN OF 
LOWER LIMB INCLUDING HIP
C85.83 - Other specified types of non-Hodgkin lymphoma, 
intra-abdominal lymph nodes
172.8 - MALIGNANT MELANOMA OF OTHER 
SPECIFIED SITES OF SKIN
C85.84 - Other specified types of non-Hodgkin lymphoma, 
lymph nodes of axilla and upper limb
172.9 - MELANOMA OF SKIN SITE UNSPECIFIED
C85.85 - Other specified types of non-Hodgkin lymphoma, 
lymph nodes of inguinal region and lower limb
174.0 - MALIGNANT NEOPLASM OF NIPPLE AND 
AREOLA OF FEMALE BREAST
C85.88 - Other specified types of non-Hodgkin lymphoma, 
lymph nodes of multiple sites
174.3 - MALIGNANT NEOPLASM OF LOWER-
INNER QUADRANT OF FEMALE BREAST
C85.9 - Non-Hodgkin lymphoma, unspecified
175.0 - MALIGNANT NEOPLASM OF NIPPLE AND 
AREOLA OF MALE BREAST
C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified 
site
Appendix A

176.1 - KAPOSI'S SARCOMA SOFT TISSUE
C85.94 - Non-Hodgkin lymphoma, unspecified, lymph 
nodes of axilla and upper limb
176.3 - KAPOSI'S SARCOMA 
GASTROINTESTINAL SITES
C85.95 - Non-Hodgkin lymphoma, unspecified, lymph 
nodes of inguinal region and lower limb
176.8 - KAPOSI'S SARCOMA OTHER SPECIFIED 
SITES
C86.1 - Hepatosplenic T-cell lymphoma
179 - MALIGNANT NEOPLASM OF UTERUS-PART 
UNS
C86.2 - Enteropathy-type (intestinal) T-cell lymphoma
180.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF CERVIX
C88 - Malignant immunoproliferative diseases and certain 
other B-cell lymphomas
180.9 - MALIGNANT NEOPLASM OF CERVIX 
UTERI UNSPECIFIED SITE
C88.3 - Immunoproliferative small intestinal disease
183.0 - MALIGNANT NEOPLASM OF OVARY
C88.9 - Malignant immunoproliferative disease, 
unspecified
183.4 - MALIGNANT NEOPLASM OF 
PARAMETRIUM
C90.0 - Multiple myeloma
183.5 - MALIGNANT NEOPLASM OF ROUND 
LIGAMENT OF UTERUS
C90.01 - Multiple myeloma in remission
183.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF UTERINE ADNEXA
C90.11 - Plasma cell leukemia in remission
183.9 - MALIGNANT NEOPLASM OF UTERINE 
ADNEXA UNSPECIFIED SITE
C90.2 - Extramedullary plasmacytoma
184 - MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED FEMALE GENITAL ORGANS
C90.20 - Extramedullary plasmacytoma not having 
achieved remission
184.1 - MALIGNANT NEOPLASM OF LABIA 
MAJORA
C90.3 - Solitary plasmacytoma
184.2 - MALIGNANT NEOPLASM OF LABIA 
MINORA
C90.30 - Solitary plasmacytoma not having achieved 
remission
184.4 - MALIGNANT NEOPLASM OF VULVA 
UNSPECIFIED SITE
C91.0 - Acute lymphoblastic leukemia [ALL]
184.9 - MALIGNANT NEOPLASM OF FEMALE 
GENITAL ORGAN SITE UNSPECIFIED
C91.00 - Acute lymphoblastic leukemia not having 
achieved remission
185 - MALIGNANT NEOPLASM OF PROSTATE
C91.11 - Chronic lymphocytic leukemia of B-cell type in 
remission
Appendix A

186.9 - MALIGNANT NEOPLASM OF OTHER AND 
UNSPECIFIED TESTIS
C91.3 - Prolymphocytic leukemia of B-cell type
187.2 - MALIGNANT NEOPLASM OF GLANS 
PENIS
C91.31 - Prolymphocytic leukemia of B-cell type, in 
remission
187.4 - MALIGNANT NEOPLASM OF PENIS PART 
UNSPECIFIED
C91.4 - Hairy cell leukemia
187.6 - MALIGNANT NEOPLASM OF SPERMATIC 
CORD
C91.40 - Hairy cell leukemia not having achieved 
remission
187.7 - MALIGNANT NEOPLASM OF SCROTUM
C91.41 - Hairy cell leukemia, in remission
187.9 - MALIGNANT NEOPLASM OF MALE 
GENITAL ORGAN SITE UNSPECIFIED
C91.5 - Adult T-cell lymphoma/leukemia (HTLV-1-
associated)
188.0 - MALIGNANT NEOPLASM OF TRIGONE OF 
URINARY BLADDER
C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-
associated) not having achieved remission
188.2 - MALIGNANT NEOPLASM OF LATERAL 
WALL OF URINARY BLADDER
C91.6 - Prolymphocytic leukemia of T-cell type
188.3 - MALIGNANT NEOPLASM OF ANTERIOR 
WALL OF URINARY BLADDER
C91.60 - Prolymphocytic leukemia of T-cell type not having 
achieved remission
188.4 - MALIGNANT NEOPLASM OF POSTERIOR 
WALL OF URINARY BLADDER
C91.61 - Prolymphocytic leukemia of T-cell type, in 
remission
188.5 - MALIGNANT NEOPLASM OF BLADDER 
NECK
C91.91 - Lymphoid leukemia, unspecified, in remission
188.6 - MALIGNANT NEOPLASM OF URETERIC 
ORIFICE
C91.A1 - Mature B-cell leukemia Burkitt-type, in remission
188.7 - MALIGNANT NEOPLASM OF URACHUS
C91.Z - Other lymphoid leukemia
188.9 - MALIGNANT NEOPLASM OF BLADDER 
PART UNSPECIFIED
C91.Z2 - Other lymphoid leukemia, in relapse
189 - MALIGNANT NEOPLASM OF KIDNEY AND 
OTHER AND UNSPECIFIED URINARY ORGANS
C92.00 - Acute myeloblastic leukemia, not having 
achieved remission
189.0 - MALIGNANT NEOPLASM OF KIDNEY 
EXCEPT PELVIS
C92.01 - Acute myeloblastic leukemia, in remission
189.1 - MALIGNANT NEOPLASM OF RENAL 
PELVIS
C92.02 - Acute myeloblastic leukemia, in relapse
Appendix A

189.3 - MALIGNANT NEOPLASM OF URETHRA
C92.1 - Chronic myeloid leukemia, BCR/ABL-positive
189.4 - MALIGNANT NEOPLASM OF 
PARAURETHRAL GLANDS
C92.11 - Chronic myeloid leukemia, BCR/ABL-positive, in 
remission
189.8 - MALIGNANT NEOPLASM OF OTHER 
SPECIFIED SITES OF URINARY ORGANS
C92.21 - Atypical chronic myeloid leukemia, BCR/ABL-
negative, in remission
189.9 - MALIGNANT NEOPLASM OF URINARY 
ORGAN SITE UNSPECIFIED
C92.3 - Myeloid sarcoma
190 - MALIGNANT NEOPLASM OF EYE
C92.30 - Myeloid sarcoma, not having achieved remission
190.3 - MALIGNANT NEOPLASM OF 
CONJUNCTIVA
C92.4 - Acute promyelocytic leukemia
190.4 - MALIGNANT NEOPLASM OF CORNEA
C92.41 - Acute promyelocytic leukemia, in remission
190.6 - MALIGNANT NEOPLASM OF CHOROID
C92.42 - Acute promyelocytic leukemia, in relapse
190.9 - MALIGNANT NEOPLASM OF EYE PART 
UNSPECIFIED
C92.60 - Acute myeloid leukemia with 11q23-abnormality 
not having achieved remission
191.0 - MALIGNANT NEOPLASM OF CEREBRUM 
EXCEPT LOBES AND VENTRICLES
C92.61 - Acute myeloid leukemia with 11q23-abnormality 
in remission
191.2 - MALIGNANT NEOPLASM OF TEMPORAL 
LOBE
C92.9 - Myeloid leukemia, unspecified
191.5 - MALIGNANT NEOPLASM OF VENTRICLES
C92.90 - Myeloid leukemia, unspecified, not having 
achieved remission
191.6 - MALIGNANT NEOPLASM OF 
CEREBELLUM NOT OTHERWISE SPECIFIED
C92.91 - Myeloid leukemia, unspecified in remission
191.8 - MALIGNANT NEOPLASM OF OTHER 
PARTS OF BRAIN
C92.A0 - Acute myeloid leukemia with multilineage 
dysplasia, not having achieved remission
192.1 - MALIGNANT NEOPLASM OF CEREBRAL 
MENINGES
C92.A1 - Acute myeloid leukemia with multilineage 
dysplasia, in remission
192.3 - MALIGNANT NEOPLASM OF SPINAL 
MENINGES
C92.A2 - Acute myeloid leukemia with multilineage 
dysplasia, in relapse
192.9 - MALIGNANT NEOPLASM OF NERVOUS 
SYSTEM PART UNSPECIFIED
C92.Z - Other myeloid leukemia
Appendix A

194.0 - MALIGNANT NEOPLASM OF ADRENAL 
GLAND
C92.Z0 - Other myeloid leukemia not having achieved 
remission
194.5 - MALIGNANT NEOPLASM OF CAROTID 
BODY
C93.0 - Acute monoblastic/monocytic leukemia
195.0 - MALIGNANT NEOPLASM OF HEAD FACE 
AND NECK
C93.01 - Acute monoblastic/monocytic leukemia, in 
remission
195.1 - MALIGNANT NEOPLASM OF THORAX
C93.1 - Chronic myelomonocytic leukemia
195.5 - MALIGNANT NEOPLASM OF LOWER LIMB C93.12 - Chronic myelomonocytic leukemia, in relapse
196 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES
C93.3 - Juvenile myelomonocytic leukemia
196.0 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES OF 
HEAD FACE AND NECK
C93.30 - Juvenile myelomonocytic leukemia, not having 
achieved remission
196.1 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF INTRATHORACIC 
LYMPH NODES
C93.31 - Juvenile myelomonocytic leukemia, in remission
196.2 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF INTRA-ABDOMINAL 
LYMPH NODES
C93.32 - Juvenile myelomonocytic leukemia, in relapse
196.3 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES OF 
AXILLA AND UPPER LIMB
C93.90 - Monocytic leukemia, unspecified, not having 
achieved remission
196.5 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C93.92 - Monocytic leukemia, unspecified in relapse
196.6 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF INTRAPELVIC 
LYMPH NODES
C93.Z - Other monocytic leukemia
196.9 - SECONDARY AND UNSPECIFIED 
MALIGNANT NEOPLASM OF LYMPH NODES SITE 
UNSPECIFIED
C93.Z1 - Other monocytic leukemia, in remission
197 - SECONDARY MALIGNANT NEOPLASM OF 
RESPIRATORY AND DIGESTIVE SYSTEMS
C94.0 - Acute erythroid leukemia
Appendix A

197.0 - SECONDARY MALIGNANT NEOPLASM OF 
LUNG
C94.20 - Acute megakaryoblastic leukemia not having 
achieved remission
197.3 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER RESPIRATORY ORGANS
C94.21 - Acute megakaryoblastic leukemia, in remission
197.4 - SECONDARY MALIGNANT NEOPLASM OF 
SMALL INTESTINE INCLUDING DUODENUM
C94.22 - Acute megakaryoblastic leukemia, in relapse
197.6 - SECONDARY MALIGNANT NEOPLASM OF 
RETROPERITONEUM AND PERITONEUM
C94.3 - Mast cell leukemia
198 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER SPECIFIED SITES
C94.4 - Acute panmyelosis with myelofibrosis
198.0 - SECONDARY MALIGNANT NEOPLASM OF 
KIDNEY
C94.40 - Acute panmyelosis with myelofibrosis not having 
achieved remission
198.3 - SECONDARY MALIGNANT NEOPLASM OF 
BRAIN AND SPINAL CORD
C94.42 - Acute panmyelosis with myelofibrosis, in relapse
198.4 - SECONDARY MALIGNANT NEOPLASM OF 
OTHER PARTS OF NERVOUS SYSTEM
C94.6 - Myelodysplastic disease, not classified
198.6 - SECONDARY MALIGNANT NEOPLASM OF 
OVARY
C95 - Leukemia of unspecified cell type
198.7 - SECONDARY MALIGNANT NEOPLASM OF 
ADRENAL GLAND
C95.0 - Acute leukemia of unspecified cell type
198.81 - SECONDARY MALIGNANT NEOPLASM 
OF BREAST
C95.1 - Chronic leukemia of unspecified cell type
198.89 - SECONDARY MALIGNANT NEOPLASM 
OF OTHER SPECIFIED SITES
C95.90 - Leukemia, unspecified not having achieved 
remission
199.1 - OTHER MALIGNANT NEOPLASM OF 
UNSPECIFIED SITE
C95.92 - Leukemia, unspecified, in relapse
199.2 - MALIGNANT NEOPLASM ASSOCIATED 
WITH TRANSPLANTED ORGAN
C96 - Other and unspecified malignant neoplasms of 
lymphoid, hematopoietic and related tissue
Appendix A

200 - LYMPHOSARCOMA AND 
RETICULOSARCOMA AND OTHER SPECIFIED 
MALIGNANT TUMORS OF LYMPHATIC TISSUE
C96.20 - Malignant mast cell neoplasm, unspecified
200.00 - RETICULOSARCOMA UNSPECIFIED 
SITE
C96.21 - Aggressive systemic mastocytosis
200.02 - RETICULOSARCOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C96.22 - Mast cell sarcoma
200.04 - RETICULOSARCOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
D45 - Polycythemia vera
200.07 - RETICULOSARCOMA INVOLVING 
SPLEEN
C00 - Malignant neoplasm of lip
200.08 - RETICULOSARCOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C00.2 - Malignant neoplasm of external lip, unspecified
200.12 - LYMPHOSARCOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C00.3 - Malignant neoplasm of upper lip, inner aspect
200.13 - LYMPHOSARCOMA INVOLVING INTRA-
ABDOMINAL LYMPH NODES
C00.8 - Malignant neoplasm of overlapping sites of lip
200.15 - LYMPHOSARCOMA INVOLVING LYMPH 
NODES OF INGUINAL REGION AND LOWER 
LIMB
C02.0 - Malignant neoplasm of dorsal surface of tongue
200.21 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C03.1 - Malignant neoplasm of lower gum
200.23 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C03.9 - Malignant neoplasm of gum, unspecified
200.24 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C04.0 - Malignant neoplasm of anterior floor of mouth
200.26 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C04.9 - Malignant neoplasm of floor of mouth, unspecified
200.27 - BURKITT'S TUMOR OR LYMPHOMA 
INVOLVING SPLEEN
C05.0 - Malignant neoplasm of hard palate
Appendix A

200.30 - MARGINAL ZONE LYMPHOMA 
UNSPECIFIED SITE
C05.1 - Malignant neoplasm of soft palate
200.32 - MARGINAL ZONE LYMPHOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C05.8 - Malignant neoplasm of overlapping sites of palate
200.33 - MARGINAL ZONE LYMPHOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C06.1 - Malignant neoplasm of vestibule of mouth
200.35 - MARGINAL ZONE LYMPHOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C06.80 - Malignant neoplasm of overlapping sites of 
unspecified parts of mouth
200.43 - MANTLE CELL LYMPHOMA INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C06.9 - Malignant neoplasm of mouth, unspecified
200.44 - MANTLE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C08.1 - Malignant neoplasm of sublingual gland
200.45 - MANTLE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C09 - Malignant neoplasm of tonsil
200.47 - MANTLE CELL LYMPHOMA INVOLVING 
SPLEEN
C09.1 - Malignant neoplasm of tonsillar pillar (anterior) 
(posterior)
200.50 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA UNSPECIFIED SITE
C09.8 - Malignant neoplasm of overlapping sites of tonsil
200.53 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING INTRA-ABDOMINAL 
LYMPH NODES
C09.9 - Malignant neoplasm of tonsil, unspecified
200.56 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING INTRAPELVIC LYMPH 
NODES
C10.1 - Malignant neoplasm of anterior surface of 
epiglottis
200.58 - PRIMARY CENTRAL NERVOUS SYSTEM 
LYMPHOMA INVOLVING LYMPH NODES OF 
MULTIPLE SITES
C10.4 - Malignant neoplasm of branchial cleft
200.6 - ANAPLASTIC LARGE CELL LYMPHOMA
C10.8 - Malignant neoplasm of overlapping sites of 
oropharynx
Appendix A

200.63 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C11.3 - Malignant neoplasm of anterior wall of 
nasopharynx
200.65 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C12 - Malignant neoplasm of pyriform sinus
200.68 - ANAPLASTIC LARGE CELL LYMPHOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES C13.0 - Malignant neoplasm of postcricoid region
200.70 - LARGE CELL LYMPHOMA UNSPECIFIED 
SITE
C13.2 - Malignant neoplasm of posterior wall of 
hypopharynx
200.74 - LARGE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C13.8 - Malignant neoplasm of overlapping sites of 
hypopharynx
200.75 - LARGE CELL LYMPHOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C13.9 - Malignant neoplasm of hypopharynx, unspecified
200.81 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C14 - Malignant neoplasm of other and ill-defined sites in 
the lip, oral cavity and pharynx
200.82 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING INTRATHORACIC LYMPH NODES
C14.0 - Malignant neoplasm of pharynx, unspecified
200.84 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C14.8 - Malignant neoplasm of overlapping sites of lip, oral 
cavity and pharynx
200.86 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C15 - Malignant neoplasm of esophagus
Appendix A

200.87 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING SPLEEN
C15.3 - Malignant neoplasm of upper third of esophagus
200.88 - OTHER NAMED VARIANTS OF 
LYMPHOSARCOMA AND RETICULOSARCOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES C15.5 - Malignant neoplasm of lower third of esophagus
201.0 - HODGKIN'S PARAGRANULOMA
C16 - Malignant neoplasm of stomach
201.04 - HODGKIN'S PARAGRANULOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C16.1 - Malignant neoplasm of fundus of stomach
201.06 - HODGKIN'S PARAGRANULOMA 
INVOLVING INTRAPELVIC LYMPH NODES
C16.4 - Malignant neoplasm of pylorus
201.08 - HODGKIN'S PARAGRANULOMA 
INVOLVING LYMPH NODES OF MULTIPLE SITES
C16.5 - Malignant neoplasm of lesser curvature of 
stomach, unspecified
201.10 - HODGKIN'S GRANULOMA UNSPECIFIED 
SITE
C16.6 - Malignant neoplasm of greater curvature of 
stomach, unspecified
201.11 - HODGKIN'S GRANULOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C16.8 - Malignant neoplasm of overlapping sites of 
stomach
201.12 - HODGKIN'S GRANULOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C16.9 - Malignant neoplasm of stomach, unspecified
201.13 - HODGKIN'S GRANULOMA INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C17 - Malignant neoplasm of small intestine
201.16 - HODGKIN'S GRANULOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C17.0 - Malignant neoplasm of duodenum
201.2 - HODGKIN'S SARCOMA
C17.1 - Malignant neoplasm of jejunum
201.21 - HODGKIN'S SARCOMA INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C17.2 - Malignant neoplasm of ileum
201.24 - HODGKIN'S SARCOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C17.8 - Malignant neoplasm of overlapping sites of small 
intestine
201.26 - HODGKIN'S SARCOMA INVOLVING 
INTRAPELVIC LYMPH NODES
C17.9 - Malignant neoplasm of small intestine, unspecified
Appendix A

201.27 - HODGKIN'S SARCOMA INVOLVING 
SPLEEN
C18 - Malignant neoplasm of colon
201.28 - HODGKIN'S SARCOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C18.0 - Malignant neoplasm of cecum
201.41 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
LYMPH NODES OF HEAD FACE AND NECK
C18.1 - Malignant neoplasm of appendix
201.42 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
INTRATHORACIC LYMPH NODES
C18.5 - Malignant neoplasm of splenic flexure
201.43 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C18.6 - Malignant neoplasm of descending colon
201.44 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C18.7 - Malignant neoplasm of sigmoid colon
201.45 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C18.8 - Malignant neoplasm of overlapping sites of colon
201.47 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
SPLEEN
C18.9 - Malignant neoplasm of colon, unspecified
201.48 - HODGKIN'S DISEASE LYMPHOCYTIC-
HISTIOCYTIC PREDOMINANCE INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C19 - Malignant neoplasm of rectosigmoid junction
201.5 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS
C20 - Malignant neoplasm of rectum
Appendix A

201.51 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING LYMPH NODES OF 
HEAD FACE AND NECK
C21 - Malignant neoplasm of anus and anal canal
201.53 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING INTRA-ABDOMINAL 
LYMPH NODES
C21.0 - Malignant neoplasm of anus, unspecified
201.58 - HODGKIN'S DISEASE NODULAR 
SCLEROSIS INVOLVING LYMPH NODES OF 
MULTIPLE SITES
C21.1 - Malignant neoplasm of anal canal
201.6 - HODGKIN'S DISEASE MIXED 
CELLULARITY
C21.2 - Malignant neoplasm of cloacogenic zone
201.60 - HODGKIN'S DISEASE MIXED 
CELLULARITY UNSPECIFIED SITE
C22.0 - Liver cell carcinoma
201.63 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING INTRA-ABDOMINAL 
LYMPH NODES
C22.2 - Hepatoblastoma
201.64 - HODGKIN'S DISEASE MIXED 
CELLULARITY INVOLVING LYMPH NODES OF 
AXILLA AND UPPER LIMB
C22.7 - Other specified carcinomas of liver
201.70 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION UNSPECIFIED SITE
C22.9 - Malignant neoplasm of liver, not specified as 
primary or secondary
201.71 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING LYMPH NODES OF 
HEAD FACE AND NECK
C23 - Malignant neoplasm of gallbladder
201.74 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING LYMPH NODES OF 
AXILLA AND UPPER LIMB
C24 - Malignant neoplasm of other and unspecified parts 
of biliary tract
201.77 - HODGKIN'S DISEASE LYMPHOCYTIC 
DEPLETION INVOLVING SPLEEN
C24.1 - Malignant neoplasm of ampulla of Vater
201.91 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING LYMPH NODES OF HEAD 
FACE AND NECK
C24.8 - Malignant neoplasm of overlapping sites of biliary 
tract
Appendix A

201.94 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING LYMPH NODES OF AXILLA 
AND UPPER LIMB
C25 - Malignant neoplasm of pancreas
201.95 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C25.1 - Malignant neoplasm of body of pancreas
201.97 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING SPLEEN
C25.2 - Malignant neoplasm of tail of pancreas
201.98 - HODGKIN'S DISEASE UNSPECIFIED 
TYPE INVOLVING LYMPH NODES OF MULTIPLE 
SITES
C25.4 - Malignant neoplasm of endocrine pancreas
202 - OTHER MALIGNANT NEOPLASMS OF 
LYMPHOID AND HISTIOCYTIC TISSUE
C25.9 - Malignant neoplasm of pancreas, unspecified
202.00 - NODULAR LYMPHOMA UNSPECIFIED 
SITE
C26.9 - Malignant neoplasm of ill-defined sites within the 
digestive system
202.02 - NODULAR LYMPHOMA INVOLVING 
INTRATHORACIC LYMPH NODES
C30 - Malignant neoplasm of nasal cavity and middle ear
202.04 - NODULAR LYMPHOMA INVOLVING 
LYMPH NODES OF AXILLA AND UPPER LIMB
C30.0 - Malignant neoplasm of nasal cavity
202.05 - NODULAR LYMPHOMA INVOLVING 
LYMPH NODES OF INGUINAL REGION AND 
LOWER LIMB
C30.1 - Malignant neoplasm of middle ear
202.07 - NODULAR LYMPHOMA INVOLVING 
SPLEEN
C31 - Malignant neoplasm of accessory sinuses
202.08 - NODULAR LYMPHOMA INVOLVING 
LYMPH NODES OF MULTIPLE SITES
C31.0 - Malignant neoplasm of maxillary sinus
202.1 - MYCOSIS FUNGOIDES
C31.2 - Malignant neoplasm of frontal sinus
202.10 - MYCOSIS FUNGOIDES UNSPECIFIED 
SITE
C32 - Malignant neoplasm of larynx
202.16 - MYCOSIS FUNGOIDES INVOLVING 
INTRAPELVIC LYMPH NODES
C32.1 - Malignant neoplasm of supraglottis
202.20 - SEZARY'S DISEASE UNSPECIFIED SITE
C32.2 - Malignant neoplasm of subglottis
202.21 - SEZARY'S DISEASE INVOLVING LYMPH 
NODES OF HEAD FACE AND NECK
C32.3 - Malignant neoplasm of laryngeal cartilage
Appendix A

202.23 - SEZARY'S DISEASE INVOLVING INTRA-
ABDOMINAL LYMPH NODES
C32.8 - Malignant neoplasm of overlapping sites of larynx
202.24 - SEZARY'S DISEASE INVOLVING LYMPH 
NODES OF AXILLA AND UPPER LIMB
C32.9 - Malignant neoplasm of larynx, unspecified
202.26 - SEZARY'S DISEASE INVOLVING 
INTRAPELVIC LYMPH NODES
C34.00 - Malignant neoplasm of unspecified main 
bronchus
202.30 - MALIGNANT HISTIOCYTOSIS 
UNSPECIFIED SITE
C34.2 - Malignant neoplasm of middle lobe, bronchus or 
lung
202.32 - MALIGNANT HISTIOCYTOSIS 
INVOLVING INTRATHORACIC LYMPH NODES
C34.3 - Malignant neoplasm of lower lobe, bronchus or 
lung
202.35 - MALIGNANT HISTIOCYTOSIS 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C34.30 - Malignant neoplasm of lower lobe, unspecified 
bronchus or lung
202.40 - LEUKEMIC RETICULOENDOTHELIOSIS 
UNSPECIFIED SITE
C34.8 - Malignant neoplasm of overlapping sites of 
bronchus and lung
202.42 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING INTRATHORACIC LYMPH NODES
C34.81 - Malignant neoplasm of overlapping sites of right 
bronchus and lung
202.43 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C34.82 - Malignant neoplasm of overlapping sites of left 
bronchus and lung
202.44 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER ARM
C34.9 - Malignant neoplasm of unspecified part of 
bronchus or lung
202.45 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C34.90 - Malignant neoplasm of unspecified part of 
unspecified bronchus or lung
202.48 - LEUKEMIC RETICULOENDOTHELIOSIS 
INVOLVING LYMPH NODES OF MULTIPLE SITES
C34.91 - Malignant neoplasm of unspecified part of right 
bronchus or lung
202.52 - LETTERER-SIWE DISEASE INVOLVING 
INTRATHORACIC LYMPH NODES
C38 - Malignant neoplasm of heart, mediastinum and 
pleura
Appendix A

202.53 - LETTERER-SIWE DISEASE INVOLVING 
INTRA-ABDOMINAL LYMPH NODES
C38.0 - Malignant neoplasm of heart
202.56 - LETTERER-SIWE DISEASE INVOLVING 
INTRAPELVIC LYMPH NODES
C38.3 - Malignant neoplasm of mediastinum, part 
unspecified
202.57 - LETTERER-SIWE DISEASE INVOLVING 
SPLEEN
C38.4 - Malignant neoplasm of pleura
202.6 - MALIGNANT MAST CELL TUMORS
C38.8 - Malignant neoplasm of overlapping sites of heart, 
mediastinum and pleura
202.60 - MALIGNANT MAST CELL TUMORS 
UNSPECIFIED SITE
C39 - Malignant neoplasm of other and ill-defined sites in 
the respiratory system and intrathoracic organs
202.61 - MALIGNANT MAST CELL TUMORS 
INVOLVING LYMPH NODES OF HEAD FACE AND 
NECK
C39.9 - Malignant neoplasm of lower respiratory tract, part 
unspecified
202.62 - MALIGNANT MAST CELL TUMORS 
INVOLVING INTRATHORACIC LYMPH NODES
C40.00 - Malignant neoplasm of scapula and long bones of 
unspecified upper limb
202.63 - MALIGNANT MAST CELL TUMORS 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C40.02 - Malignant neoplasm of scapula and long bones of 
left upper limb
202.64 - MALIGNANT MAST CELL TUMORS 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C40.1 - Malignant neoplasm of short bones of upper limb
202.67 - MALIGNANT MAST CELL TUMORS 
INVOLVING SPLEEN
C40.11 - Malignant neoplasm of short bones of right upper 
limb
202.68 - MALIGNANT MAST CELL TUMORS 
INVOLVING LYMPH NODES OF MULTIPLE SITES
C40.21 - Malignant neoplasm of long bones of right lower 
limb
202.7 - PERIPHERAL T-CELL LYMPHOMA
C40.30 - Malignant neoplasm of short bones of 
unspecified lower limb
202.73 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING INTRA-ABDOMINAL LYMPH NODES
C40.31 - Malignant neoplasm of short bones of right lower 
limb
Appendix A

202.74 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING LYMPH NODES OF AXILLA AND 
UPPER LIMB
C40.32 - Malignant neoplasm of short bones of left lower 
limb
202.77 - PERIPHERAL T-CELL LYMPHOMA 
INVOLVING SPLEEN
C40.81 - Malignant neoplasm of overlapping sites of bone 
and articular cartilage of right limb
202.8 - OTHER MALIGNANT LYMPHOMAS
C40.82 - Malignant neoplasm of overlapping sites of bone 
and articular cartilage of left limb
202.82 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING INTRATHORACIC LYMPH NODES
C40.9 - Malignant neoplasm of unspecified bones and 
articular cartilage of limb
202.85 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING LYMPH NODES OF INGUINAL 
REGION AND LOWER LIMB
C41.9 - Malignant neoplasm of bone and articular 
cartilage, unspecified
202.86 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING INTRAPELVIC LYMPH NODES
C43 - Malignant melanoma of skin
202.87 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING SPLEEN
C43.0 - Malignant melanoma of lip
202.88 - OTHER MALIGNANT LYMPHOMAS 
INVOLVING LYMPH NODES OF MULTIPLE SITES
C43.10 - Malignant melanoma of unspecified eyelid, 
including canthus
202.9 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE
C43.112 - Malignant melanoma of right lower eyelid, 
including canthus
202.93 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING INTRA-ABDOMINAL LYMPH 
NODES
C43.12 - Malignant melanoma of left eyelid, including 
canthus
202.94 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING LYMPH NODES OF AXILLA 
AND UPPER LIMB
C43.121 - Malignant melanoma of left upper eyelid, 
including canthus
202.95 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING LYMPH NODES OF 
INGUINAL REGION AND LOWER LIMB
C43.20 - Malignant melanoma of unspecified ear and 
external auricular canal
Appendix A

202.96 - OTHER AND UNSPECIFIED MALIGNANT 
NEOPLASMS OF LYMPHOID AND HISTIOCYTIC 
TISSUE INVOLVING INTRAPELVIC LYMPH 
NODES
C43.21 - Malignant melanoma of right ear and external 
auricular canal
203 - MULTIPLE MYELOMA AND 
IMMUNOPROLIFERATIVE NEOPLASMS
C43.3 - Malignant melanoma of other and unspecified 
parts of face
203.0 - MULTIPLE MYELOMA
C43.30 - Malignant melanoma of unspecified part of face
203.1 - PLASMA CELL LEUKEMIA
C43.31 - Malignant melanoma of nose
203.81 - OTHER IMMUNOPROLIFERATIVE 
NEOPLASMS IN REMISSION
C43.4 - Malignant melanoma of scalp and neck
203.82 - OTHER IMMUNOPROLIFERATIVE 
NEOPLASMS IN RELAPSE
C43.5 - Malignant melanoma of trunk
204.00 - ACUTE LYMPHOID LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C43.52 - Malignant melanoma of skin of breast
204.02 - ACUTE LYMPHOID LEUKEMIA IN 
RELAPSE
C43.6 - Malignant melanoma of upper limb, including 
shoulder
204.11 - CHRONIC LYMPHOID LEUKEMIA IN 
REMISSION
C43.60 - Malignant melanoma of unspecified upper limb, 
including shoulder
204.2 - SUBACUTE LYMPHOID LEUKEMIA
C43.62 - Malignant melanoma of left upper limb, including 
shoulder
204.20 - SUBACUTE LYMPHOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C43.7 - Malignant melanoma of lower limb, including hip
204.21 - SUBACUTE LYMPHOID LEUKEMIA IN 
REMISSION
C43.70 - Malignant melanoma of unspecified lower limb, 
including hip
204.9 - UNSPECIFIED LYMPHOID LEUKEMIA
C43.72 - Malignant melanoma of left lower limb, including 
hip
204.90 - UNSPECIFIED LYMPHOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C43.8 - Malignant melanoma of overlapping sites of skin
205 - MYELOID LEUKEMIA
C45.1 - Mesothelioma of peritoneum
Appendix A

205.00 - ACUTE MYELOID LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C45.7 - Mesothelioma of other sites
205.10 - CHRONIC MYELOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C45.9 - Mesothelioma, unspecified
205.11 - CHRONIC MYELOID LEUKEMIA IN 
REMISSION
C46 - Kaposi's sarcoma
205.20 - SUBACUTE MYELOID LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C46.0 - Kaposi's sarcoma of skin
205.21 - SUBACUTE MYELOID LEUKEMIA IN 
REMISSION
C46.1 - Kaposi's sarcoma of soft tissue
205.22 - SUBACUTE MYELOID LEUKEMIA IN 
RELAPSE
C46.2 - Kaposi's sarcoma of palate
205.3 - MYELOID SARCOMA
C46.3 - Kaposi's sarcoma of lymph nodes
205.30 - MYELOID SARCOMA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C46.4 - Kaposi's sarcoma of gastrointestinal sites
205.31 - MYELOID SARCOMA IN REMISSION
C46.5 - Kaposi's sarcoma of lung
205.32 - MYELOID SARCOMA IN RELAPSE
C46.50 - Kaposi's sarcoma of unspecified lung
205.8 - OTHER MYELOID LEUKEMIA
C46.7 - Kaposi's sarcoma of other sites
205.81 - OTHER MYELOID LEUKEMIA IN 
REMISSION
C47 - Malignant neoplasm of peripheral nerves and 
autonomic nervous system
206.0 - ACUTE MONOCYTIC LEUKEMIA
C47.0 - Malignant neoplasm of peripheral nerves of head, 
face and neck
206.01 - ACUTE MONOCYTIC LEUKEMIA IN 
REMISSION
C47.1 - Malignant neoplasm of peripheral nerves of upper 
limb, including shoulder
206.02 - ACUTE MONOCYTIC LEUKEMIA IN 
RELAPSE
C47.11 - Malignant neoplasm of peripheral nerves of right 
upper limb, including shoulder
206.10 - CHRONIC MONOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C47.2 - Malignant neoplasm of peripheral nerves of lower 
limb, including hip
206.12 - CHRONIC MONOCYTIC LEUKEMIA IN 
RELAPSE
C47.3 - Malignant neoplasm of peripheral nerves of thorax
Appendix A

206.20 - SUBACUTE MONOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C47.5 - Malignant neoplasm of peripheral nerves of pelvis
206.22 - SUBACUTE MONOCYTIC LEUKEMIA IN 
RELAPSE
C47.6 - Malignant neoplasm of peripheral nerves of trunk, 
unspecified
206.81 - OTHER MONOCYTIC LEUKEMIA IN 
REMISSION
C48 - Malignant neoplasm of retroperitoneum and 
peritoneum
206.82 - OTHER MONOCYTIC LEUKEMIA IN 
RELAPSE
C48.1 - Malignant neoplasm of specified parts of 
peritoneum
206.90 - UNSPECIFIED MONOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C49.0 - Malignant neoplasm of connective and soft tissue 
of head, face and neck
206.91 - UNSPECIFIED MONOCYTIC LEUKEMIA 
IN REMISSION
C49.1 - Malignant neoplasm of connective and soft tissue 
of upper limb, including shoulder
206.92 - UNSPECIFIED MONOCYTIC LEUKEMIA 
IN RELAPSE
C49.11 - Malignant neoplasm of connective and soft tissue 
of right upper limb, including shoulder
207 - OTHER SPECIFIED LEUKEMIA
C49.12 - Malignant neoplasm of connective and soft tissue 
of left upper limb, including shoulder
207.01 - ACUTE ERYTHREMIA AND 
ERYTHROLEUKEMIA IN REMISSION
C49.21 - Malignant neoplasm of connective and soft tissue 
of right lower limb, including hip
207.02 - ACUTE ERYTHREMIA AND 
ERYTHROLEUKEMIA IN RELAPSE
C49.22 - Malignant neoplasm of connective and soft tissue 
of left lower limb, including hip
207.1 - CHRONIC ERYTHREMIA
C49.3 - Malignant neoplasm of connective and soft tissue 
of thorax
207.10 - CHRONIC ERYTHREMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C49.9 - Malignant neoplasm of connective and soft tissue, 
unspecified
207.12 - CHRONIC ERYTHREMIA IN RELAPSE
C49.A0 - Gastrointestinal stromal tumor, unspecified site
207.2 - MEGAKARYOCYTIC LEUKEMIA
C49.A1 - Gastrointestinal stromal tumor of esophagus
207.20 - MEGAKARYOCYTIC LEUKEMIA 
WITHOUT MENTION OF HAVING ACHIEVED 
REMISSION
C49.A4 - Gastrointestinal stromal tumor of large intestine
207.21 - MEGAKARYOCYTIC LEUKEMIA IN 
REMISSION
C50.0 - Malignant neoplasm of nipple and areola
Appendix A

207.22 - MEGAKARYOCYTIC LEUKEMIA IN 
RELAPSE
C50.01 - Malignant neoplasm of nipple and areola, female
207.8 - OTHER SPECIFIED LEUKEMIA
C50.011 - Malignant neoplasm of nipple and areola, right 
female breast
207.80 - OTHER SPECIFIED LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C50.019 - Malignant neoplasm of nipple and areola, 
unspecified female breast
207.82 - OTHER SPECIFIED LEUKEMIA IN 
RELAPSE
C50.022 - Malignant neoplasm of nipple and areola, left 
male breast
208.00 - ACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE WITHOUT MENTION OF HAVING 
ACHIEVED REMISSION
C50.11 - Malignant neoplasm of central portion of breast, 
female
208.01 - ACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN REMISSION
C50.111 - Malignant neoplasm of central portion of right 
female breast
208.02 - ACUTE LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN RELAPSE
C50.112 - Malignant neoplasm of central portion of left 
female breast
208.11 - CHRONIC LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN REMISSION
C50.121 - Malignant neoplasm of central portion of right 
male breast
208.8 - OTHER LEUKEMIA OF UNSPECIFIED 
CELL TYPE
C50.129 - Malignant neoplasm of central portion of 
unspecified male breast
208.80 - OTHER LEUKEMIA OF UNSPECIFIED 
CELL TYPE WITHOUT MENTION OF HAVING 
ACHIEVED REMISSION
C50.2 - Malignant neoplasm of upper-inner quadrant of 
breast
208.81 - OTHER LEUKEMIA OF UNSPECIFIED 
CELL TYPE IN REMISSION
C50.212 - Malignant neoplasm of upper-inner quadrant of 
left female breast
208.9 - UNSPECIFIED LEUKEMIA
C50.219 - Malignant neoplasm of upper-inner quadrant of 
unspecified female breast
208.90 - UNSPECIFIED LEUKEMIA WITHOUT 
MENTION OF HAVING ACHIEVED REMISSION
C50.222 - Malignant neoplasm of upper-inner quadrant of 
left male breast
208.91 - UNSPECIFIED LEUKEMIA IN REMISSION
C50.229 - Malignant neoplasm of upper-inner quadrant of 
unspecified male breast
208.92 - UNSPECIFIED LEUKEMIA IN RELAPSE
C50.31 - Malignant neoplasm of lower-inner quadrant of 
breast, female
209.0 - MALIGNANT CARCINOID TUMORS OF 
THE SMALL INTESTINE
C50.311 - Malignant neoplasm of lower-inner quadrant of 
right female breast
Appendix A

209.03 - MALIGNANT CARCINOID TUMOR OF 
THE ILEUM
C50.319 - Malignant neoplasm of lower-inner quadrant of 
unspecified female breast
209.1 - MALIGNANT CARCINOID TUMORS OF 
THE APPENDIX LARGE INTESTINE AND 
RECTUM
C50.321 - Malignant neoplasm of lower-inner quadrant of 
right male breast
209.10 - MALIGNANT CARCINOID TUMOR OF 
THE LARGE INTESTINE UNSPECIFIED PORTION
C50.41 - Malignant neoplasm of upper-outer quadrant of 
breast, female
209.13 - MALIGNANT CARCINOID TUMOR OF 
THE ASCENDING COLON
C50.411 - Malignant neoplasm of upper-outer quadrant of 
right female breast
209.14 - MALIGNANT CARCINOID TUMOR OF 
THE TRANSVERSE COLON
C50.42 - Malignant neoplasm of upper-outer quadrant of 
breast, male
209.15 - MALIGNANT CARCINOID TUMOR OF 
THE DESCENDING COLON
C50.421 - Malignant neoplasm of upper-outer quadrant of 
right male breast
209.16 - MALIGNANT CARCINOID TUMOR OF 
THE SIGMOID COLON
C50.422 - Malignant neoplasm of upper-outer quadrant of 
left male breast
209.2 - MALIGNANT CARCINOID TUMOR OF 
OTHER AND UNSPECIFIED SITES
C50.429 - Malignant neoplasm of upper-outer quadrant of 
unspecified male breast
209.20 - MALIGNANT CARCINOID TUMOR OF 
UNKNOWN PRIMARY SITE
C50.5 - Malignant neoplasm of lower-outer quadrant of 
breast
209.21 - MALIGNANT CARCINOID TUMOR OF 
THE BRONCHUS AND LUNG
C50.511 - Malignant neoplasm of lower-outer quadrant of 
right female breast
209.23 - MALIGNANT CARCINOID TUMOR OF 
THE STOMACH
C50.512 - Malignant neoplasm of lower-outer quadrant of 
left female breast
209.24 - MALIGNANT CARCINOID TUMOR OF 
THE KIDNEY
C50.519 - Malignant neoplasm of lower-outer quadrant of 
unspecified female breast
209.26 - MALIGNANT CARCINOID TUMOR OF 
THE MIDGUT NOT OTHERWISE SPECIFIED
C50.52 - Malignant neoplasm of lower-outer quadrant of 
breast, male
209.27 - MALIGNANT CARCINOID TUMOR OF 
THE HINDGUT NOT OTHERWISE SPECIFIED
C50.521 - Malignant neoplasm of lower-outer quadrant of 
right male breast
209.35 - MERKEL CELL CARCINOMA OF THE 
TRUNK
C50.529 - Malignant neoplasm of lower-outer quadrant of 
unspecified male breast
209.36 - MERKEL CELL CARCINOMA OF OTHER 
SITES
C50.611 - Malignant neoplasm of axillary tail of right 
female breast
Appendix A

209.7 - SECONDARY NEUROENDOCRINE 
TUMORS
C50.62 - Malignant neoplasm of axillary tail of breast, male
209.71 - SECONDARY NEUROENDOCRINE 
TUMOR OF DISTANT LYMPH NODES
C50.622 - Malignant neoplasm of axillary tail of left male 
breast
209.73 - SECONDARY NEUROENDOCRINE 
TUMOR OF BONE
C50.8 - Malignant neoplasm of overlapping sites of breast
209.74 - SECONDARY NEUROENDOCRINE 
TUMOR OF PERITONEUM
C50.819 - Malignant neoplasm of overlapping sites of 
unspecified female breast
C50.82 - Malignant neoplasm of overlapping sites of 
breast, male
C50.821 - Malignant neoplasm of overlapping sites of right 
male breast
C50.822 - Malignant neoplasm of overlapping sites of left 
male breast
C50.9 - Malignant neoplasm of breast of unspecified site
C50.91 - Malignant neoplasm of breast of unspecified site, 
female
C50.911 - Malignant neoplasm of unspecified site of right 
female breast
C50.919 - Malignant neoplasm of unspecified site of 
unspecified female breast
C52 - Malignant neoplasm of vagina
C53 - Malignant neoplasm of cervix uteri
C53.1 - Malignant neoplasm of exocervix
C53.8 - Malignant neoplasm of overlapping sites of cervix 
uteri
C53.9 - Malignant neoplasm of cervix uteri, unspecified
C54 - Malignant neoplasm of corpus uteri
C54.0 - Malignant neoplasm of isthmus uteri
C54.8 - Malignant neoplasm of overlapping sites of corpus 
uteri
C54.9 - Malignant neoplasm of corpus uteri, unspecified
Appendix A

C55 - Malignant neoplasm of uterus, part unspecified
C56.1 - Malignant neoplasm of right ovary
C56.2 - Malignant neoplasm of left ovary
C56.9 - Malignant neoplasm of unspecified ovary
C57 - Malignant neoplasm of other and unspecified female 
genital organs
C57.0 - Malignant neoplasm of fallopian tube
C57.01 - Malignant neoplasm of right fallopian tube
C57.10 - Malignant neoplasm of unspecified broad 
ligament
C57.2 - Malignant neoplasm of round ligament
C57.20 - Malignant neoplasm of unspecified round 
ligament
C57.21 - Malignant neoplasm of right round ligament
C57.22 - Malignant neoplasm of left round ligament
C57.3 - Malignant neoplasm of parametrium
C57.4 - Malignant neoplasm of uterine adnexa, unspecified
C57.7 - Malignant neoplasm of other specified female 
genital organs
C58 - Malignant neoplasm of placenta
C60 - Malignant neoplasm of penis
C60.2 - Malignant neoplasm of body of penis
C60.8 - Malignant neoplasm of overlapping sites of penis
C62 - Malignant neoplasm of testis
C62.0 - Malignant neoplasm of undescended testis
C62.1 - Malignant neoplasm of descended testis
C62.10 - Malignant neoplasm of unspecified descended 
testis
C62.11 - Malignant neoplasm of descended right testis
C62.91 - Malignant neoplasm of right testis, unspecified 
whether descended or undescended
Appendix A

C63 - Malignant neoplasm of other and unspecified male 
genital organs
C63.0 - Malignant neoplasm of epididymis
C63.00 - Malignant neoplasm of unspecified epididymis
C63.01 - Malignant neoplasm of right epididymis
C63.1 - Malignant neoplasm of spermatic cord
C63.10 - Malignant neoplasm of unspecified spermatic 
cord
C63.11 - Malignant neoplasm of right spermatic cord
C63.12 - Malignant neoplasm of left spermatic cord
C63.7 - Malignant neoplasm of other specified male genital 
organs
C63.9 - Malignant neoplasm of male genital organ, 
unspecified
C64.1 - Malignant neoplasm of right kidney, except renal 
pelvis
C64.9 - Malignant neoplasm of unspecified kidney, except 
renal pelvis
C65 - Malignant neoplasm of renal pelvis
C65.1 - Malignant neoplasm of right renal pelvis
C66.9 - Malignant neoplasm of unspecified ureter
C67.0 - Malignant neoplasm of trigone of bladder
C67.1 - Malignant neoplasm of dome of bladder
C67.4 - Malignant neoplasm of posterior wall of bladder
C67.5 - Malignant neoplasm of bladder neck
C67.7 - Malignant neoplasm of urachus
C67.8 - Malignant neoplasm of overlapping sites of bladder
C67.9 - Malignant neoplasm of bladder, unspecified
C68.0 - Malignant neoplasm of urethra
C68.1 - Malignant neoplasm of paraurethral glands
C68.8 - Malignant neoplasm of overlapping sites of urinary 
organs
Appendix A

C69 - Malignant neoplasm of eye and adnexa
C69.0 - Malignant neoplasm of conjunctiva
C69.00 - Malignant neoplasm of unspecified conjunctiva
C69.01 - Malignant neoplasm of right conjunctiva
C69.02 - Malignant neoplasm of left conjunctiva
C69.10 - Malignant neoplasm of unspecified cornea
C69.11 - Malignant neoplasm of right cornea
C69.2 - Malignant neoplasm of retina
C69.20 - Malignant neoplasm of unspecified retina
C69.22 - Malignant neoplasm of left retina
C69.31 - Malignant neoplasm of right choroid
C69.4 - Malignant neoplasm of ciliary body
C69.40 - Malignant neoplasm of unspecified ciliary body
C69.41 - Malignant neoplasm of right ciliary body
C69.42 - Malignant neoplasm of left ciliary body
C69.50 - Malignant neoplasm of unspecified lacrimal gland 
and duct
C69.6 - Malignant neoplasm of orbit
C69.61 - Malignant neoplasm of right orbit
C69.62 - Malignant neoplasm of left orbit
C69.8 - Malignant neoplasm of overlapping sites of eye 
and adnexa
C69.80 - Malignant neoplasm of overlapping sites of 
unspecified eye and adnexa
C69.9 - Malignant neoplasm of unspecified site of eye
C69.90 - Malignant neoplasm of unspecified site of 
unspecified eye
C71.0 - Malignant neoplasm of cerebrum, except lobes 
and ventricles
C71.1 - Malignant neoplasm of frontal lobe
C72.1 - Malignant neoplasm of cauda equina
C72.2 - Malignant neoplasm of olfactory nerve
Appendix A

C72.20 - Malignant neoplasm of unspecified olfactory 
nerve
C72.21 - Malignant neoplasm of right olfactory nerve
C72.22 - Malignant neoplasm of left olfactory nerve
C72.31 - Malignant neoplasm of right optic nerve
C72.42 - Malignant neoplasm of left acoustic nerve
C72.5 - Malignant neoplasm of other and unspecified 
cranial nerves
C74.0 - Malignant neoplasm of cortex of adrenal gland
C74.02 - Malignant neoplasm of cortex of left adrenal 
gland
C74.1 - Malignant neoplasm of medulla of adrenal gland
C74.11 - Malignant neoplasm of medulla of right adrenal 
gland
C74.12 - Malignant neoplasm of medulla of left adrenal 
gland
C74.9 - Malignant neoplasm of unspecified part of adrenal 
gland
C74.90 - Malignant neoplasm of unspecified part of 
unspecified adrenal gland
C74.91 - Malignant neoplasm of unspecified part of right 
adrenal gland
C75.1 - Malignant neoplasm of pituitary gland
C75.2 - Malignant neoplasm of craniopharyngeal duct
C75.3 - Malignant neoplasm of pineal gland
C75.5 - Malignant neoplasm of aortic body and other 
paraganglia
C76 - Malignant neoplasm of other and ill-defined sites
C76.0 - Malignant neoplasm of head, face and neck
C76.1 - Malignant neoplasm of thorax
C76.2 - Malignant neoplasm of abdomen
C76.3 - Malignant neoplasm of pelvis
Appendix A

C76.4 - Malignant neoplasm of upper limb
C77 - Secondary and unspecified malignant neoplasm of 
lymph nodes
C77.3 - Secondary and unspecified malignant neoplasm of 
axilla and upper limb lymph nodes
C77.4 - Secondary and unspecified malignant neoplasm of 
inguinal and lower limb lymph nodes
C77.5 - Secondary and unspecified malignant neoplasm of 
intrapelvic lymph nodes
C77.8 - Secondary and unspecified malignant neoplasm of 
lymph nodes of multiple regions
C78.0 - Secondary malignant neoplasm of lung
C78.01 - Secondary malignant neoplasm of right lung
C78.02 - Secondary malignant neoplasm of left lung
C78.3 - Secondary malignant neoplasm of other and 
unspecified respiratory organs
C78.4 - Secondary malignant neoplasm of small intestine
C78.8 - Secondary malignant neoplasm of other and 
unspecified digestive organs
C79 - Secondary malignant neoplasm of other and 
unspecified sites
C79.0 - Secondary malignant neoplasm of kidney and 
renal pelvis
C79.00 - Secondary malignant neoplasm of unspecified 
kidney and renal pelvis
C79.01 - Secondary malignant neoplasm of right kidney 
and renal pelvis
C79.1 - Secondary malignant neoplasm of bladder and 
other and unspecified urinary organs
C79.10 - Secondary malignant neoplasm of unspecified 
urinary organs
C79.19 - Secondary malignant neoplasm of other urinary 
organs
Appendix A

C79.32 - Secondary malignant neoplasm of cerebral 
meninges
C79.4 - Secondary malignant neoplasm of other and 
unspecified parts of nervous system
C79.40 - Secondary malignant neoplasm of unspecified 
part of nervous system
C79.49 - Secondary malignant neoplasm of other parts of 
nervous system
C79.51 - Secondary malignant neoplasm of bone
C79.52 - Secondary malignant neoplasm of bone marrow
C79.60 - Secondary malignant neoplasm of unspecified 
ovary
C79.61 - Secondary malignant neoplasm of right ovary
C79.71 - Secondary malignant neoplasm of right adrenal 
gland
C79.82 - Secondary malignant neoplasm of genital organs
C79.89 - Secondary malignant neoplasm of other specified 
sites
C80.0 - Disseminated malignant neoplasm, unspecified
C80.1 - Malignant (primary) neoplasm, unspecified
C80.2 - Malignant neoplasm associated with transplanted 
organ
C81.00 - Nodular lymphocyte predominant Hodgkin 
lymphoma, unspecified site
C81.03 - Nodular lymphocyte predominant Hodgkin 
lymphoma, intra-abdominal lymph nodes
C81.05 - Nodular lymphocyte predominant Hodgkin 
lymphoma, lymph nodes of inguinal region and lower limb
C81.08 - Nodular lymphocyte predominant Hodgkin 
lymphoma, lymph nodes of multiple sites
Appendix A

C81.10 - Nodular sclerosis Hodgkin lymphoma, 
unspecified site
C81.11 - Nodular sclerosis Hodgkin lymphoma, lymph 
nodes of head, face, and neck
C81.13 - Nodular sclerosis Hodgkin lymphoma, intra-
abdominal lymph nodes
C81.21 - Mixed cellularity Hodgkin lymphoma, lymph 
nodes of head, face, and neck
C81.23 - Mixed cellularity Hodgkin lymphoma, intra-
abdominal lymph nodes
C81.25 - Mixed cellularity Hodgkin lymphoma, lymph 
nodes of inguinal region and lower limb
C81.28 - Mixed cellularity Hodgkin lymphoma, lymph 
nodes of multiple sites
C81.29 - Mixed cellularity Hodgkin lymphoma, extranodal 
and solid organ sites
C81.3 - Lymphocyte depleted Hodgkin lymphoma
C81.32 - Lymphocyte depleted Hodgkin lymphoma, 
intrathoracic lymph nodes
C81.33 - Lymphocyte depleted Hodgkin lymphoma, intra-
abdominal lymph nodes
C81.35 - Lymphocyte depleted Hodgkin lymphoma, lymph 
nodes of inguinal region and lower limb
C81.37 - Lymphocyte depleted Hodgkin lymphoma, spleen
C81.39 - Lymphocyte depleted Hodgkin lymphoma, 
extranodal and solid organ sites
C81.40 - Lymphocyte-rich Hodgkin lymphoma, unspecified 
site
C81.45 - Lymphocyte-rich Hodgkin lymphoma, lymph 
nodes of inguinal region and lower limb
C81.46 - Lymphocyte-rich Hodgkin lymphoma, intrapelvic 
lymph nodes
C81.47 - Lymphocyte-rich Hodgkin lymphoma, spleen
Appendix A

C81.48 - Lymphocyte-rich Hodgkin lymphoma, lymph 
nodes of multiple sites
C81.49 - Lymphocyte-rich Hodgkin lymphoma, extranodal 
and solid organ sites
C81.74 - Other Hodgkin lymphoma, lymph nodes of axilla 
and upper limb
C81.76 - Other Hodgkin lymphoma, intrapelvic lymph 
nodes
C81.77 - Other Hodgkin lymphoma, spleen
C81.78 - Other Hodgkin lymphoma, lymph nodes of 
multiple sites
C81.9 - Hodgkin lymphoma, unspecified
C81.92 - Hodgkin lymphoma, unspecified, intrathoracic 
lymph nodes
C81.93 - Hodgkin lymphoma, unspecified, intra-abdominal 
lymph nodes
C81.95 - Hodgkin lymphoma, unspecified, lymph nodes of 
inguinal region and lower limb
C81.99 - Hodgkin lymphoma, unspecified, extranodal and 
solid organ sites
C82.0 - Follicular lymphoma grade I
C82.00 - Follicular lymphoma grade I, unspecified site
C82.01 - Follicular lymphoma grade I, lymph nodes of 
head, face, and neck
C82.02 - Follicular lymphoma grade I, intrathoracic lymph 
nodes
C82.03 - Follicular lymphoma grade I, intra-abdominal 
lymph nodes
C82.04 - Follicular lymphoma grade I, lymph nodes of 
axilla and upper limb
C82.10 - Follicular lymphoma grade II, unspecified site
C82.11 - Follicular lymphoma grade II, lymph nodes of 
head, face, and neck
Appendix A

C82.13 - Follicular lymphoma grade II, intra-abdominal 
lymph nodes
C82.16 - Follicular lymphoma grade II, intrapelvic lymph 
nodes
C82.17 - Follicular lymphoma grade II, spleen
C82.22 - Follicular lymphoma grade III, unspecified, 
intrathoracic lymph nodes
C82.23 - Follicular lymphoma grade III, unspecified, intra-
abdominal lymph nodes
C82.26 - Follicular lymphoma grade III, unspecified, 
intrapelvic lymph nodes
C82.27 - Follicular lymphoma grade III, unspecified, spleen
C82.3 - Follicular lymphoma grade IIIa
C82.30 - Follicular lymphoma grade IIIa, unspecified site
C82.31 - Follicular lymphoma grade IIIa, lymph nodes of 
head, face, and neck
C82.34 - Follicular lymphoma grade IIIa, lymph nodes of 
axilla and upper limb
C82.36 - Follicular lymphoma grade IIIa, intrapelvic lymph 
nodes
C82.37 - Follicular lymphoma grade IIIa, spleen
C82.38 - Follicular lymphoma grade IIIa, lymph nodes of 
multiple sites
C82.4 - Follicular lymphoma grade IIIb
C82.40 - Follicular lymphoma grade IIIb, unspecified site
C82.41 - Follicular lymphoma grade IIIb, lymph nodes of 
head, face, and neck
C82.42 - Follicular lymphoma grade IIIb, intrathoracic 
lymph nodes
C82.43 - Follicular lymphoma grade IIIb, intra-abdominal 
lymph nodes
Appendix A

C82.45 - Follicular lymphoma grade IIIb, lymph nodes of 
inguinal region and lower limb
C82.48 - Follicular lymphoma grade IIIb, lymph nodes of 
multiple sites
C82.49 - Follicular lymphoma grade IIIb, extranodal and 
solid organ sites
C82.5 - Diffuse follicle center lymphoma
C82.50 - Diffuse follicle center lymphoma, unspecified site
C82.53 - Diffuse follicle center lymphoma, intra-abdominal 
lymph nodes
C82.54 - Diffuse follicle center lymphoma, lymph nodes of 
axilla and upper limb
C82.57 - Diffuse follicle center lymphoma, spleen
C82.58 - Diffuse follicle center lymphoma, lymph nodes of 
multiple sites
C82.6 - Cutaneous follicle center lymphoma
C82.64 - Cutaneous follicle center lymphoma, lymph 
nodes of axilla and upper limb
C82.65 - Cutaneous follicle center lymphoma, lymph 
nodes of inguinal region and lower limb
C82.66 - Cutaneous follicle center lymphoma, intrapelvic 
lymph nodes
C82.67 - Cutaneous follicle center lymphoma, spleen
C82.81 - Other types of follicular lymphoma, lymph nodes 
of head, face, and neck
C82.82 - Other types of follicular lymphoma, intrathoracic 
lymph nodes
C82.83 - Other types of follicular lymphoma, intra-
abdominal lymph nodes
C82.84 - Other types of follicular lymphoma, lymph nodes 
of axilla and upper limb
C82.85 - Other types of follicular lymphoma, lymph nodes 
of inguinal region and lower limb
Appendix A

C82.88 - Other types of follicular lymphoma, lymph nodes 
of multiple sites
C82.9 - Follicular lymphoma, unspecified
C82.90 - Follicular lymphoma, unspecified, unspecified site
C82.91 - Follicular lymphoma, unspecified, lymph nodes of 
head, face, and neck
C82.93 - Follicular lymphoma, unspecified, intra-abdominal 
lymph nodes
C82.94 - Follicular lymphoma, unspecified, lymph nodes of 
axilla and upper limb
C83 - Non-follicular lymphoma
C83.0 - Small cell B-cell lymphoma
C83.04 - Small cell B-cell lymphoma, lymph nodes of axilla 
and upper limb
C83.05 - Small cell B-cell lymphoma, lymph nodes of 
inguinal region and lower limb
C83.09 - Small cell B-cell lymphoma, extranodal and solid 
organ sites
C83.1 - Mantle cell lymphoma
C83.10 - Mantle cell lymphoma, unspecified site
C83.13 - Mantle cell lymphoma, intra-abdominal lymph 
nodes
C83.15 - Mantle cell lymphoma, lymph nodes of inguinal 
region and lower limb
C83.16 - Mantle cell lymphoma, intrapelvic lymph nodes
C83.3 - Diffuse large B-cell lymphoma
C83.32 - Diffuse large B-cell lymphoma, intrathoracic 
lymph nodes
C83.33 - Diffuse large B-cell lymphoma, intra-abdominal 
lymph nodes
C83.39 - Diffuse large B-cell lymphoma, extranodal and 
solid organ sites
Appendix A

C83.51 - Lymphoblastic (diffuse) lymphoma, lymph nodes 
of head, face, and neck
C83.54 - Lymphoblastic (diffuse) lymphoma, lymph nodes 
of axilla and upper limb
C83.55 - Lymphoblastic (diffuse) lymphoma, lymph nodes 
of inguinal region and lower limb
C83.57 - Lymphoblastic (diffuse) lymphoma, spleen
C83.7 - Burkitt lymphoma
C83.70 - Burkitt lymphoma, unspecified site
C83.71 - Burkitt lymphoma, lymph nodes of head, face, 
and neck
C83.73 - Burkitt lymphoma, intra-abdominal lymph nodes
C83.74 - Burkitt lymphoma, lymph nodes of axilla and 
upper limb
C83.75 - Burkitt lymphoma, lymph nodes of inguinal region 
and lower limb
C83.78 - Burkitt lymphoma, lymph nodes of multiple sites
C83.81 - Other non-follicular lymphoma, lymph nodes of 
head, face, and neck
C83.82 - Other non-follicular lymphoma, intrathoracic 
lymph nodes
C83.85 - Other non-follicular lymphoma, lymph nodes of 
inguinal region and lower limb
C83.86 - Other non-follicular lymphoma, intrapelvic lymph 
nodes
C83.87 - Other non-follicular lymphoma, spleen
C83.88 - Other non-follicular lymphoma, lymph nodes of 
multiple sites
C83.91 - Non-follicular (diffuse) lymphoma, unspecified, 
lymph nodes of head, face, and neck
C83.94 - Non-follicular (diffuse) lymphoma, unspecified, 
lymph nodes of axilla and upper limb
Appendix A

C83.96 - Non-follicular (diffuse) lymphoma, unspecified, 
intrapelvic lymph nodes
C83.97 - Non-follicular (diffuse) lymphoma, unspecified, 
spleen
C83.98 - Non-follicular (diffuse) lymphoma, unspecified, 
lymph nodes of multiple sites
C83.99 - Non-follicular (diffuse) lymphoma, unspecified, 
extranodal and solid organ sites
C84 - Mature T/NK-cell lymphomas
C84.0 - Mycosis fungoides
C84.00 - Mycosis fungoides, unspecified site
C84.01 - Mycosis fungoides, lymph nodes of head, face, 
and neck
C84.03 - Mycosis fungoides, intra-abdominal lymph nodes
C84.04 - Mycosis fungoides, lymph nodes of axilla and 
upper limb
C84.05 - Mycosis fungoides, lymph nodes of inguinal 
region and lower limb
C84.06 - Mycosis fungoides, intrapelvic lymph nodes
C84.08 - Mycosis fungoides, lymph nodes of multiple sites
C84.09 - Mycosis fungoides, extranodal and solid organ 
sites
C84.1 - Sezary disease
C84.10 - Sezary disease, unspecified site
C84.12 - Sezary disease, intrathoracic lymph nodes
C84.14 - Sezary disease, lymph nodes of axilla and upper 
limb
C84.16 - Sezary disease, intrapelvic lymph nodes
C84.19 - Sezary disease, extranodal and solid organ sites
C84.40 - Peripheral T-cell lymphoma, not classified, 
unspecified site
Appendix A

C84.46 - Peripheral T-cell lymphoma, not classified, 
intrapelvic lymph nodes
C84.47 - Peripheral T-cell lymphoma, not classified, spleen
C84.6 - Anaplastic large cell lymphoma, ALK-positive
C84.60 - Anaplastic large cell lymphoma, ALK-positive, 
unspecified site
C84.62 - Anaplastic large cell lymphoma, ALK-positive, 
intrathoracic lymph nodes
C84.63 - Anaplastic large cell lymphoma, ALK-positive, 
intra-abdominal lymph nodes
C84.64 - Anaplastic large cell lymphoma, ALK-positive, 
lymph nodes of axilla and upper limb
C84.65 - Anaplastic large cell lymphoma, ALK-positive, 
lymph nodes of inguinal region and lower limb
C84.67 - Anaplastic large cell lymphoma, ALK-positive, 
spleen
C84.68 - Anaplastic large cell lymphoma, ALK-positive, 
lymph nodes of multiple sites
C84.69 - Anaplastic large cell lymphoma, ALK-positive, 
extranodal and solid organ sites
C84.70 - Anaplastic large cell lymphoma, ALK-negative, 
unspecified site
C84.72 - Anaplastic large cell lymphoma, ALK-negative, 
intrathoracic lymph nodes
C84.73 - Anaplastic large cell lymphoma, ALK-negative, 
intra-abdominal lymph nodes
C84.77 - Anaplastic large cell lymphoma, ALK-negative, 
spleen
C84.78 - Anaplastic large cell lymphoma, ALK-negative, 
lymph nodes of multiple sites
C84.90 - Mature T/NK-cell lymphomas, unspecified, 
unspecified site
Appendix A

C84.91 - Mature T/NK-cell lymphomas, unspecified, lymph 
nodes of head, face, and neck
C84.92 - Mature T/NK-cell lymphomas, unspecified, 
intrathoracic lymph nodes
C84.A0 - Cutaneous T-cell lymphoma, unspecified, 
unspecified site
C84.A1 - Cutaneous T-cell lymphoma, unspecified lymph 
nodes of head, face, and neck
C84.A2 - Cutaneous T-cell lymphoma, unspecified, 
intrathoracic lymph nodes
C84.A3 - Cutaneous T-cell lymphoma, unspecified, intra-
abdominal lymph nodes
C84.A5 - Cutaneous T-cell lymphoma, unspecified, lymph 
nodes of inguinal region and lower limb
C84.A7 - Cutaneous T-cell lymphoma, unspecified, spleen
C84.Z - Other mature T/NK-cell lymphomas
C84.Z1 - Other mature T/NK-cell lymphomas, lymph nodes 
of head, face, and neck
C84.Z4 - Other mature T/NK-cell lymphomas, lymph nodes 
of axilla and upper limb
C84.Z6 - Other mature T/NK-cell lymphomas, intrapelvic 
lymph nodes
C84.Z8 - Other mature T/NK-cell lymphomas, lymph nodes 
of multiple sites
C85.1 - Unspecified B-cell lymphoma
C85.12 - Unspecified B-cell lymphoma, intrathoracic lymph 
nodes
C85.13 - Unspecified B-cell lymphoma, intra-abdominal 
lymph nodes
C85.15 - Unspecified B-cell lymphoma, lymph nodes of 
inguinal region and lower limb
C85.17 - Unspecified B-cell lymphoma, spleen
C85.18 - Unspecified B-cell lymphoma, lymph nodes of 
multiple sites
Appendix A

C85.19 - Unspecified B-cell lymphoma, extranodal and 
solid organ sites
C85.22 - Mediastinal (thymic) large B-cell lymphoma, 
intrathoracic lymph nodes
C85.26 - Mediastinal (thymic) large B-cell lymphoma, 
intrapelvic lymph nodes
C85.8 - Other specified types of non-Hodgkin lymphoma
C85.80 - Other specified types of non-Hodgkin lymphoma, 
unspecified site
C85.86 - Other specified types of non-Hodgkin lymphoma, 
intrapelvic lymph nodes
C85.87 - Other specified types of non-Hodgkin lymphoma, 
spleen
C85.89 - Other specified types of non-Hodgkin lymphoma, 
extranodal and solid organ sites
C85.91 - Non-Hodgkin lymphoma, unspecified, lymph 
nodes of head, face, and neck
C85.92 - Non-Hodgkin lymphoma, unspecified, 
intrathoracic lymph nodes
C85.93 - Non-Hodgkin lymphoma, unspecified, intra-
abdominal lymph nodes
C85.96 - Non-Hodgkin lymphoma, unspecified, intrapelvic 
lymph nodes
C85.97 - Non-Hodgkin lymphoma, unspecified, spleen
C85.98 - Non-Hodgkin lymphoma, unspecified, lymph 
nodes of multiple sites
C85.99 - Non-Hodgkin lymphoma, unspecified, extranodal 
and solid organ sites
C86 - Other specified types of T/NK-cell lymphoma
C86.0 - Extranodal NK/T-cell lymphoma, nasal type
C86.3 - Subcutaneous panniculitis-like T-cell lymphoma
C86.4 - Blastic NK-cell lymphoma
Appendix A

C86.5 - Angioimmunoblastic T-cell lymphoma
C86.6 - Primary cutaneous CD30-positive T-cell 
proliferations
C88.0 - Waldenstrom macroglobulinemia
C88.2 - Heavy chain disease
C88.4 - Extranodal marginal zone B-cell lymphoma of 
mucosa-associated lymphoid tissue [MALT-lymphoma]
C88.8 - Other malignant immunoproliferative diseases
C90 - Multiple myeloma and malignant plasma cell 
neoplasms
C90.00 - Multiple myeloma not having achieved remission
C90.02 - Multiple myeloma in relapse
C90.1 - Plasma cell leukemia
C90.10 - Plasma cell leukemia not having achieved 
remission
C90.12 - Plasma cell leukemia in relapse
C90.21 - Extramedullary plasmacytoma in remission
C90.22 - Extramedullary plasmacytoma in relapse
C90.31 - Solitary plasmacytoma in remission
C90.32 - Solitary plasmacytoma in relapse
C91 - Lymphoid leukemia
C91.01 - Acute lymphoblastic leukemia, in remission
C91.02 - Acute lymphoblastic leukemia, in relapse
C91.1 - Chronic lymphocytic leukemia of B-cell type
C91.10 - Chronic lymphocytic leukemia of B-cell type not 
having achieved remission
C91.12 - Chronic lymphocytic leukemia of B-cell type in 
relapse
C91.30 - Prolymphocytic leukemia of B-cell type not having 
achieved remission
C91.32 - Prolymphocytic leukemia of B-cell type, in relapse
Appendix A

C91.42 - Hairy cell leukemia, in relapse
C91.51 - Adult T-cell lymphoma/leukemia (HTLV-1-
associated), in remission
C91.52 - Adult T-cell lymphoma/leukemia (HTLV-1-
associated), in relapse
C91.62 - Prolymphocytic leukemia of T-cell type, in relapse
C91.9 - Lymphoid leukemia, unspecified
C91.90 - Lymphoid leukemia, unspecified not having 
achieved remission
C91.92 - Lymphoid leukemia, unspecified, in relapse
C91.A - Mature B-cell leukemia Burkitt-type
C91.A0 - Mature B-cell leukemia Burkitt-type not having 
achieved remission
C91.A2 - Mature B-cell leukemia Burkitt-type, in relapse
C91.Z0 - Other lymphoid leukemia not having achieved 
remission
C91.Z1 - Other lymphoid leukemia, in remission
C92 - Myeloid leukemia
C92.0 - Acute myeloblastic leukemia
C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not 
having achieved remission
C92.12 - Chronic myeloid leukemia, BCR/ABL-positive, in 
relapse
C92.2 - Atypical chronic myeloid leukemia, BCR/ABL-
negative
C92.20 - Atypical chronic myeloid leukemia, BCR/ABL-
negative, not having achieved remission
C92.22 - Atypical chronic myeloid leukemia, BCR/ABL-
negative, in relapse
C92.31 - Myeloid sarcoma, in remission
C92.32 - Myeloid sarcoma, in relapse
C92.40 - Acute promyelocytic leukemia, not having 
achieved remission
Appendix A

C92.5 - Acute myelomonocytic leukemia
C92.50 - Acute myelomonocytic leukemia, not having 
achieved remission
C92.51 - Acute myelomonocytic leukemia, in remission
C92.52 - Acute myelomonocytic leukemia, in relapse
C92.6 - Acute myeloid leukemia with 11q23-abnormality
C92.62 - Acute myeloid leukemia with 11q23-abnormality 
in relapse
C92.92 - Myeloid leukemia, unspecified in relapse
C92.A - Acute myeloid leukemia with multilineage 
dysplasia
C92.Z1 - Other myeloid leukemia, in remission
C92.Z2 - Other myeloid leukemia, in relapse
C93 - Monocytic leukemia
C93.00 - Acute monoblastic/monocytic leukemia, not 
having achieved remission
C93.02 - Acute monoblastic/monocytic leukemia, in 
relapse
C93.10 - Chronic myelomonocytic leukemia not having 
achieved remission
C93.11 - Chronic myelomonocytic leukemia, in remission
C93.9 - Monocytic leukemia, unspecified
C93.91 - Monocytic leukemia, unspecified in remission
C93.Z0 - Other monocytic leukemia, not having achieved 
remission
C93.Z2 - Other monocytic leukemia, in relapse
C94 - Other leukemias of specified cell type
C94.00 - Acute erythroid leukemia, not having achieved 
remission
C94.01 - Acute erythroid leukemia, in remission
C94.02 - Acute erythroid leukemia, in relapse
Appendix A

C94.2 - Acute megakaryoblastic leukemia
C94.30 - Mast cell leukemia not having achieved remission
C94.31 - Mast cell leukemia, in remission
C94.32 - Mast cell leukemia, in relapse
C94.41 - Acute panmyelosis with myelofibrosis, in 
remission
C94.8 - Other specified leukemias
C94.80 - Other specified leukemias not having achieved 
remission
C94.81 - Other specified leukemias, in remission
C94.82 - Other specified leukemias, in relapse
C95.00 - Acute leukemia of unspecified cell type not 
having achieved remission
C95.01 - Acute leukemia of unspecified cell type, in 
remission
C95.02 - Acute leukemia of unspecified cell type, in 
relapse
C95.10 - Chronic leukemia of unspecified cell type not 
having achieved remission
C95.11 - Chronic leukemia of unspecified cell type, in 
remission
C95.12 - Chronic leukemia of unspecified cell type, in 
relapse
C95.9 - Leukemia, unspecified
C95.91 - Leukemia, unspecified, in remission
C96.0 - Multifocal and multisystemic (disseminated) 
Langerhans-cell histiocytosis
C96.2 - Malignant mast cell neoplasm
C96.29 - Other malignant mast cell neoplasm
C96.4 - Sarcoma of dendritic cells (accessory cells)
C96.5 - Multifocal and unisystemic Langerhans-cell 
histiocytosis
C96.6 - Unifocal Langerhans-cell histiocytosis
Appendix A

C96.9 - Malignant neoplasm of lymphoid, hematopoietic 
and related tissue, unspecified
C96.A - Histiocytic sarcoma
C96.Z - Other specified malignant neoplasms of lymphoid, 
hematopoietic and related tissue
Appendix A

Dialysis Codes 
90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session
90999, Unlisted dialysis procedure, inpatient or outpatient
99512, Home visit for hemodialysis
- HCPCS codes:
G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD facility
90989, Dialysis training, patient, including helper where applicable, any mode, completed course
90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician visits per 
month
90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits per 
90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per month
90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over
90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over
90935, Hemodialysis procedure with single physician evaluation
90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription
90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), 
with single physician evaluation
90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) 
requiring repeated physician evaluations, with or without substantial revision of dialysis prescription
90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older
90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and older
- CPT4 codes:
Codes include:
- ICD9 prox codes:
39.95, Hemodialysis
54.98, Peritoneal dialysis
- ICD9 dx codes:
585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis)
585.6x, End stage renal disease (for ESRD with dialysis)
V56.0x, encounter for dialysis NOS
V56.8x, encounter for peritoneal dialysis
V45.1x, renal dialysis status
Appendix A

 50365, Renal allotransplantation, implantation, graft, w/ donor & recipient nephrectomy
V42.0x, Kidney transplant status
996.81 Complications of transplanted kidney
-ICD9 prox codes:
55.6x, Transplant of kidney (Exclude 55.61)
- CPT4 codes:
50360, Renal allotransplantation, implantation, graft, w/o donor & recipient nephrectomy
OR
Kidney transplant, defined as either 1 inpatient or 1 outpatient code
Codes include:
-ICD9 dx codes:
G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include monitoring for 
the adequacy of nutrition, etc. w/2 or 3 physician visit per month
G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring for 
the adequacy of nutrition, etc. w/1 physician visit per month
G0322, G0323, ESRD related services for home dialysis patients per full month: for patients 12-19 and 20 yrs of age and over to include 
monitoring for adequacy of nutrition and etc.
G0326, G0327, ESRD related services for home dialysis (less than full month), per day; for patients 12-19 and 20 yrs of age and over
S9335, Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and 
equipment (drugs and nursing services coded separately), per diem
S9339, Home therapy, peritoneal dialysis, administrative services, care coordination and all necessary supplies and equipment, per diem
G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age an over to include monitoring for 
the adequacy of nutrition, etc. w/4 or more physician visit per month
Appendix A

Liver Bypass ICD-10 Procedure Codes
06100Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Open Approach
0610496 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06104Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Percutaneous Endoscopic Approach
06104ZY - Bypass Inferior Vena Cava to Lower Vein, Percutaneous Endoscopic Approach
061107B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach
0611099 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach
06110AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06110J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Open Approach
0611479 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061147Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06114J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06120ZY - Bypass Gastric Vein to Lower Vein, Open Approach
06140AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061507Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061509Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061549Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06154AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061647Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061709Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061807Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061809B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach
061809Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06180J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Open Approach
06180Z9 - Bypass Portal Vein to Right Renal Vein, Open Approach
0618479 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061849B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184ZB - Bypass Portal Vein to Left Renal Vein, Percutaneous Endoscopic Approach
06190ZY - Bypass Right Renal Vein to Lower Vein, Open Approach
061947Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061949Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061B0ZY - Bypass Left Renal Vein to Lower Vein, Open Approach
061B4AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061B4KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061J09Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061J0KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06L30ZZ - Occlusion of Esophageal Vein, Open Approach
061007Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Open Approach
06100A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Open Approach
06100J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Open Approach
06100K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach
06110JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Open Approach
06110KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach
06114JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061207Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061407Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061409Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Open Approach
Appendix A

061449Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06144AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06150KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06154ZY - Bypass Superior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach
061607Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06160ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Open Approach
06164AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061749Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06174AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06174KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
0618099 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach
06180K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach
06184J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06184Z9 - Bypass Portal Vein to Right Renal Vein, Percutaneous Endoscopic Approach
061909Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061J4JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06L34CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Endoscopic Approach
0610075 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Open Approach
06100A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Open Approach
06100K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach
06100KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06100ZY - Bypass Inferior Vena Cava to Lower Vein, Open Approach
061049Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Percutaneous Endoscopic Approach
061107Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06110KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06110ZB - Bypass Splenic Vein to Left Renal Vein, Open Approach
061149Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06114A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06114ZB - Bypass Splenic Vein to Left Renal Vein, Percutaneous Endoscopic Approach
06140KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06140ZY - Bypass Hepatic Vein to Lower Vein, Open Approach
06144ZY - Bypass Hepatic Vein to Lower Vein, Percutaneous Endoscopic Approach
06150AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06150ZY - Bypass Superior Mesenteric Vein to Lower Vein, Open Approach
061609Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061649Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06164JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06164KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06164ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach
06170KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061807B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach
06180JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Open Approach
06180KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
Appendix A

06180ZY - Bypass Portal Vein to Lower Vein, Open Approach
061847Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06184DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Endoscopic Approach
06184KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06190AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06194JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061B07Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061B0AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061B4ZY - Bypass Left Renal Vein to Lower Vein, Percutaneous Endoscopic Approach
061J07Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
061J4ZY - Bypass Left Hypogastric Vein to Lower Vein, Percutaneous Endoscopic Approach
06L33DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Approach
06L34DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Endoscopic Approach
0610096 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Open Approach
061009Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Open Approach
06100Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Open Approach
0610476 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06104AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06104J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06104KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06110JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Open Approach
06110K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach
06110ZY - Bypass Splenic Vein to Lower Vein, Open Approach
0611499 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06114JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06114K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06114Z9 - Bypass Splenic Vein to Right Renal Vein, Percutaneous Endoscopic Approach
06114ZY - Bypass Splenic Vein to Lower Vein, Percutaneous Endoscopic Approach
06120KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061247Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061249Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06124AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06150JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach
06154JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06160KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061747Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06174ZY - Bypass Colic Vein to Lower Vein, Percutaneous Endoscopic Approach
0618079 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach
06180AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06180JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Open Approach
06180KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach
06180ZB - Bypass Portal Vein to Left Renal Vein, Open Approach
06183DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Approach
061847B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
0618499 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
Appendix A

06184ZY - Bypass Portal Vein to Lower Vein, Percutaneous Endoscopic Approach
061907Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06194ZY - Bypass Right Renal Vein to Lower Vein, Percutaneous Endoscopic Approach
061B0JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Open Approach
061B0KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
061B47Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061B4JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
061J0AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
061J0ZY - Bypass Left Hypogastric Vein to Lower Vein, Open Approach
061J47Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06L30CZ - Occlusion of Esophageal Vein with Extraluminal Device, Open Approach
06L30DZ - Occlusion of Esophageal Vein with Intraluminal Device, Open Approach
06L33CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Approach
06L33ZZ - Occlusion of Esophageal Vein, Percutaneous Approach
0610076 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Open Approach
0610095 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Open Approach
06100AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Open Approach
06100J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Open Approach
06100JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Open Approach
0610475 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061047Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
0610495 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06104K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
0611079 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach
061109B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach
061109Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06110A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach
06110AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach
06110Z9 - Bypass Splenic Vein to Right Renal Vein, Open Approach
061147B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
061149B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061209Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach
06120AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06120JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Open Approach
06124JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06124KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06124ZY - Bypass Gastric Vein to Lower Vein, Percutaneous Endoscopic Approach
06140JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Open Approach
061447Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06144JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
06144KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061547Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach
06154KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06160AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06160JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach
061707Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach
06170AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach
06170JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Open Approach
06170ZY - Bypass Colic Vein to Lower Vein, Open Approach
06174JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach
Appendix A

06180A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach
06180AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach
061849Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
06184A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06184KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06190JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Open Approach
06190KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach
06194AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
06194KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
061B09Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach
061B49Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061J0JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Open Approach
061J49Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach
061J4AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach
061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach
06L34ZZ - Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach
Appendix A

Procedure Codes Description 
CPT-4 codes 
1960 
Anesthesia for vaginal delivery only 
1961 
Anesthesia for cesarean delivery only 
1962 
Anesthesia for urgent hysterectomy following delivery 
1963 
Anesthesia for cesarean hysterectomy w/o any labor analgesia/anesthesia care 
1967 
Neuraxial labor analgesia/anesthesia, planned vaginal delivery 
1968 
Anesthesia for cesarean delivery following neuraxial labor analgesia/anesthesia 
1969 
Anes for cesarean hysterectomy following neuraxial labor analgesia/anesthesia 
59050 
Fetal monitoring in labor, physician w/written report; s & i 
59051 
Fetal monitoring in labor, physician w/written report; intrepretation only 
59400 
ROUTINE TOTAL OBSTETRIC CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care. 
59409 
Vaginal delivery only (w/wo episiotomy &/or forceps) 
59410 
Vaginal delivery only (w/wo episiotomy &/or forceps); w/postpartum care 
59412 
Ext cephalic version, w/wo tocolysis 
59414 
Delivery of placenta (separate  proc) 
59430 
Postpartum care only 
59510 
Routine obstetric care w/antepartum care, cesarean delivery, & postpartum care 
59514 
Cesarean delivery only 
59515 
Cesarean delivery only; w/postpartum care 
59525 
Subtotal/total hysterectomy after cesarean delivery 
59610 
Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery 
59612 
Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps) 
59614 
Vaginal delivery only, previous cesarean delivery w/postpartum care 
59618 
Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery 
59620 
Cesarean delivery after failed vaginal delivery, previous cesarean delivery 
59622 
Cesarean delivery after failed vaginal delivery, previous cesarean delivery; w/postpartum care 
99436 
Attendance at delivery, at request of delivering physician, & stabilization of newborn 
99440 
Newborn resuscitation 
ICD-9 procedure 
codes 
72.xx 
Forceps, vacuum, & breech 
73.xx 
Other including manual delivery 
74xx 
Cesarean section 
75.4x 
Manual removal of placenta 
ICD-10 
procedure 
codes 
Normal 
Delivery 
ϭϬϬyථ
Delivery of Products of Conception, External Approach 
C-Section 
ථϭϬϬϬϬථ
Extraction of Products of Conception, High, Open Approach 
ථϭϬϬϬϭථ
Extraction of Products of Conception, Low, Open Approach 
ථϭϬϬϬϮථ
Extraction of Products of Conception, Extraperitoneal, Open Approach 
Other assisted delivery (forceps, vacuum, internal version, other) 
ϭϬϬϳϯථ
Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening 
ϭϬϬϳϰථ
Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening 
ϭϬϬϳϱථ
Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening 
ϭϬϬϳϲථ
Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening 
ϭϬϬϳϳථ
Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening 
ϭϬϬϳϴථ
Extraction of Products of Conception, Other, Via Natural or Artificial Opening 
ICD-9 code 
Definition 
Gestational Age 
Appendix A

ථ 
ථ 
Weeks 
Days 
765.21 
Less than 24 c 24 
168 
765.22 
24 completed weeks of gestation 
765.23 
25-26 comple 26 
182 
765.24 
27-28 comple 28 
196 
765.25 
29-30 comple 30 
210 
765.26 
31-32 comple 32 
224 
765.27 
33-34 comple 34 
238 
765.28 
35-36 comple 36 
252 
ICD-10 code 
Definition 
Gestational Age 
ථ 
ථ 
Weeks 
Days 
P07.21 
Extreme imma23 
161 
P07.22 
Extreme imma23 
161 
P07.23 
Extreme imma24 
168 
P07.24 
Extreme imma25 
175 
P07.25 
Extreme imma26 
182 
P07.26 
Extreme imma27 
189 
P07.31 
Preterm newb28 
196 
P07.32 
Preterm newb29 
203 
P07.33 
Preterm newb30 
210 
P07.34 
Preterm newb31 
217 
P07.35 
Preterm newb32 
224 
P07.36 
Preterm newb33 
231 
P07.37 
Preterm newb34 
238 
P07.38 
Preterm newb35 
245 
P07.39 
Preterm newb36 
252 
Codes indicating extreme prematurity 
ICD-9 code 
Definition 
Gestational Age 
ථ 
ථ 
Weeks 
Days 
765.0 
Disorders rela 28 
196 
ϳϲϱ͘ϬϬථ
Extreme immaturity, unspecified [weight] 
ϳϲϱ͘Ϭϭථ
Extreme immaturity, less than 500 grams 
ϳϲϱ͘ϬϮථ
Extreme immaturity, 500-749 grams 
ϳϲϱ͘Ϭϯථ
Extreme immaturity, 750-999 grams 
ϳϲϱ͘Ϭϰථ
Extreme immaturity, 1,000-1,249 grams 
ϳϲϱ͘Ϭϱථ
Extreme immaturity, 1,250-1,499 grams 
ϳϲϱ͘Ϭϲථ
Extreme immaturity, 1,500-1,749 grams 
ϳϲϱ͘Ϭϳථ
Extreme immaturity, 1,750-1,999 grams 
ϳϲϱ͘Ϭϴථ
Extreme immaturity, 2,000-2,499 grams 
ICD-10 code 
Definition 
Gestational Age 
ථ 
ථ 
Weeks 
Days 
P07.2 
Extreme imma28 
196 
P07.20 
Extreme immaturity of newborn, unspecified weeks of gestation 
O42.012 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, second trimester 
Other preterm 
codes 
ICD-9 code 
Definition 
Gestational Age 
ථ 
ථ 
Weeks 
Days 
765.1 
Disorders rela 35 
245 
ϳϲϱ͘ϭϬථ
Other preterm infants, unspecified [weight] 
ϳϲϱ͘ϭϭථ
Other preterm infants, less than 500 grams 
Appendix A

ϳϲϱ͘ϭϮථ
Other preterm infants, 500-749 grams 
ϳϲϱ͘ϭϯථ
Other preterm infants, 750-999 grams 
ϳϲϱ͘ϭϰථ
Other preterm infants, 1,000-1,249 grams 
ϳϲϱ͘ϭϱථ
Other preterm infants, 1,250-1,499 grams 
ϳϲϱ͘ϭϲථ
Other preterm infants, 1,500-1,749 grams 
ϳϲϱ͘ϭϳථ
Other preterm infants, 1,750-1,999 grams 
ϳϲϱ͘ϭϴථ
Other preterm infants, 2,000-2,499 grams 
644.21 
Onset of delivery before 37 completed weeks of gestation 
ICD-10 code 
Definition 
Gestational Age 
ථ 
ථ 
Weeks 
Days 
WϬϱ͘Ϭϭථ
Disorders of n 35 
245 
P05.02 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 500-749 grams 
P05.03 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 750-999 grams 
P05.04 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1000-1249 grams 
P05.05 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1250-1499 grams 
P05.06 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1500-1749 grams 
P05.07 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1750-1999 grams 
P05.11 
Newborn small for gestational age, less than 500 grams 
P05.12 
Newborn small for gestational age, 500-749 grams 
P05.13 
Newborn small for gestational age, 750-999 grams 
P05.14 
Newborn small for gestational age, 1000-1249 grams 
P05.15 
Newborn small for gestational age, 1250-1499 grams 
P05.16 
Newborn small for gestational age, 1500-1749 grams 
P05.17 
Newborn small for gestational age, 1750-1999 grams 
WϬϳ͘Ϭථ
Extremely low birth weight newborn 
P07.00 
Extremely low birth weight newborn, unspecified weight 
P07.01 
Extremely low birth weight newborn, less than 500 grams 
P07.02 
Extremely low birth weight newborn, 500-749 grams 
P07.03 
Extremely low birth weight newborn, 750-999 grams 
P07.1 
Other low birth weight newborn 
P07.10 
Other low birth weight newborn, unspecified weight 
P07.14 
Other low birth weight newborn,1000-1249 grams 
P07.15 
Other low birth weight newborn,1250-1499 grams 
P07.16 
Other low birth weight newborn,1500-1749 grams 
P07.17 
Other low birth weight newborn,1750-1999 grams 
P07.3 
Preterm [premature] newborn [other] 
WϬϳ͘ϯϬථ
Preterm newborn, unspecified weeks of gestation 
KϲϬ͘ϭථ
Preterm labor with preterm delivery 
O42.01 
ථWƌĞƚĞƌŵƉƌĞŵĂƚƵƌĞƌƵƉƚƵƌĞŽĨŵĞŵďƌĂŶĞƐ͕ŽŶƐĞƚŽĨůĂďŽƌǁŝƚŚŝŶϮϰŚŽƵƌƐŽĨƌƵƉƚƵƌĞ
O42.019 
ථWƌĞƚĞƌŵƉƌĞŵĂƚƵƌĞƌƵƉƚƵƌĞŽĨŵĞŵďƌĂŶĞƐ͕ŽŶƐĞƚŽĨůĂďŽƌǁŝƚŚŝŶϮϰŚŽƵƌƐŽĨƌƵƉƚƵƌĞ͕ƵŶƐƉĞĐŝĨŝĞĚƚƌŝŵĞƐƚĞƌ
O42.013 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester 
644.2 
early onset of delivery 
644.20 
Early onset of delivery, unspecified as to episode of care or not applicable 
644.21 
Early onset of delivery, delivered, with or without mention of antepartum condition 
776.6 
anemia of prematurity 
362.20 
retinopathy of prematurity, unspecified 
362.22 
retinopathy of prematurity, stage 0 
362.23 
retinopathy of prematurity, stage 1 
362.24 
retinopathy of prematurity, stage 2 
362.25 
retinopathy of prematurity, stage 3 
362.26 
retinopathy of prematurity, stage 4 
362.27 
retinopathy of prematurity, stage 5 
CPT 
ථ 
Appendix A

49491 
repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception 
49492 
repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception 
67229 
treatment of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from 
836 
anesthesia for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth 
ICD-10 code 
Definition 
ථ 
ථ 
H35.1 
Retinopathy of prematurity 
P61.2 
Anemia of prematurity 
V27.2 
Twins both liveborn 
V27.3 
Mother with twins one liveborn and one stillborn  
V27.4 
Mother with twins both stillborn 
V27.5  
Other multiple birth, all liveborn 
V27.6 
Other multiple birth, some liveborn 
V31 
Twin, mate liveborn 
V32 
Twin birth mate stillborn  
V33 
Twin, unspecified 
V34 
Other multiple, mates all liveborn 
V35 
Other multiple birth (three or more) mates all stillborn  
V36 
Other multiple, mates live- and stillborn 
V37 
Other multiple, unspecified 
651 
Multiple gestation 
651.0x 
Twin Pregnancy 
651.1x 
Triplet pregnancy 
651.2x 
Quadruplet pregnancy 
651.3x 
Twin pregnancy with fetal loss and retention of one fetusථ
651.4x 
Triplet pregnancy with fetal loss and retention of one or more fetus(es) 
651.5x 
Quadruplet pregnancy with fetal loss and retention of one or more fetus(es) 
651.6x 
Other multiple pregnancy with fetal loss and retention of one or more fetus(es) 
651.7x 
Multiple gestation following (elective) fetal reduction 
651.8x 
Other specified multiple gestation 
651.9x 
Unspecified multiple gestation 
652.6x 
Multiple gestation with malpresentation of one fetus or more 
660.5x 
Locked Twins 
662.3x 
Delayed delivery of second twin, triplet, etc. 
761.5x 
Multiple pregnancy 
ICD10 Code  
Description 
ථKϯϬǆǆǆǆථ
Multiple gestation 
ථKϯϭǆǆǆǆථ
Complications specific to multiple gestation 
ථKϰϯ͘ϬϮථ
Fetus-to-fetus placental transfusion syndrome 
ථKϲϯ͘Ϯථ
Delayed delivery of second twin, triplet, etc. 
ථϯϳ͘Ϯථ
Twins, both liveborn 
ථϯϳ͘ϯථ
Twins, one liveborn and one stillborn 
ථϯϳ͘ϱථ
Other multiple births, all liveborn 
ථϯϳ͘ϱϬථ
Multiple births, unspecified, all liveborn 
ථϯϳ͘ϱϭථ
Triplets, all liveborn 
ථϯϳ͘ϱϮථ
Quadruplets, all liveborn 
ථϯϳ͘ϱϯථ
Quintuplets, all liveborn 
ථϯϳ͘ϱϰථ
Sextuplets, all liveborn 
ථϯϳ͘ϱϵථ
Other multiple births, all liveborn 
ථϯϳ͘ϲථ
Other multiple births, some liveborn 
ථϯϳ͘ϲϬථ
Multiple births, unspecified, some liveborn 
ථϯϳ͘ϲϭථ
Triplets, some liveborn 
Appendix A

ථϯϳ͘ϲϮථ
Quadruplets, some liveborn 
ථϯϳ͘ϲϯථ
Quintuplets, some liveborn 
ථϯϳ͘ϲϰථ
Sextuplets, some liveborn 
ථϯϳ͘ϲϵථ
Other multiple births, some liveborn 
ථϯϴ͘ϯථ
Twin liveborn infant, born in hospital 
ථϯϴ͘ϯϬථ
Twin liveborn infant, delivered vaginally 
ථϯϴ͘ϯϭථ
Twin liveborn infant, delivered by cesarean 
ථϯϴ͘ϰථ
Twin liveborn infant, born outside hospital 
ථϯϴ͘ϱථ
Twin liveborn infant, unspecified as to place of birth 
ථϯϴ͘ϲථ
Other multiple liveborn infant, born in hospital 
ථϯϴ͘ϲϭථ
Triplet liveborn infant, delivered vaginally 
ථϯϴ͘ϲϮථ
Triplet liveborn infant, delivered by cesarean 
ථϯϴ͘ϲϯථ
Quadruplet liveborn infant, delivered vaginally 
ථϯϴ͘ϲϰථ
Quadruplet liveborn infant, delivered by cesarean 
ථϯϴ͘ϲϱථ
Quintuplet liveborn infant, delivered vaginally 
ථϯϴ͘ϲϲථ
Quintuplet liveborn infant, delivered by cesarean 
ථϯϴ͘ϲϴථ
Other multiple liveborn infant, delivered vaginally 
ථϯϴ͘ϲϵථ
Other multiple liveborn infant, delivered by cesarean 
ථϯϴ͘ϳථ
Other multiple liveborn infant, born outside hospital 
ථϯϴ͘ϴථ
Other multiple liveborn infant, unspecified as to place of birth 
ථWϬϭ͘ϱථ
Newborn affected by multiple pregnancy 
ථ 
ථ 
645 
Late Pregnancy 
645.1 
Post term pregnancy 
645.10 
Post term pregnancy, unspecified as to episode of care or not applicable 
645.11 
Post term pregnancy, delivered, with or without mention of antepartum condition 
645.13 
Post term pregnancy, antepartum condition or complication 
645.2 
Prolonged pregnancy 
645.20 
Prolonged pregnancy, unspecified as to episode of care or not applicable 
645.21 
Prolonged pregnancy, delivered, with or without mention of antepartum condition 
645.23 
Prolonged pregnancy, antepartum condition or complication 
766.2 
Late infant, not 'heavy-for-dates' 
766.21 
Post-term infant 
766.22 
Prolonged gestation of infant 
ථKϰϴථ
Late pregnancy 
ථKϰϴ͘Ϭථ
Post-term pregnancy 
ථKϰϴ͘ϭථ
Prolonged pregnancy 
ථWϬϴ͘Ϯථ
Late newborn, not heavy for gestational age 
ථWϬϴ͘Ϯϭථ
Post-term newborn 
ථWϬϴ͘ϮϮථ
Prolonged gestation of newborn 
ථϯ͘ϰϭථ
41 weeks gestation of pregnancy 
ථϯ͘ϰϮථ
42 weeks gestation of pregnancy 
ථϯ͘ϰϵථ
Greater than 42 weeks gestation of pregnancy 
ICD-10 CODES 
INDICATING 
PREGNANCY 
Dx codes: 
KϬϵ͘yzථ^ƵƉĞƌǀŝƐŝŽŶŽĨŚŝŐŚƌŝƐŬƉƌĞŐŶĂŶĐǇ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚŝŶŐĨŝƌƐƚͬƐĞĐŽŶĚͬƚŚŝƌĚͬƵŶƐƉĞĐŝĨŝĞĚƚƌŝŵĞƐƚĞƌͬƵŶƐƉĞĐŝĨŝĞĚĂƐƚŽƚŝŵĞƉĞƌŝŽĚͿ
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
KϭϭථWƌĞͲĞǆŝƐƚŝŶŐŚǇƉĞƌƚĞŶƐŝŽŶǁŝƚŚƉƌĞͲĞĐůĂŵƉƐŝĂ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚŝŶŐĨŝƌƐƚͬƐĞĐŽŶĚͬƚŚŝƌĚͬƵŶƐƉĞĐŝĨŝĞĚƚƌŝŵĞƐƚĞƌͬƵŶƐƉĞĐŝĨŝĞĚĂƐƚŽƚŝŵĞƉĞƌŝŽĚͿ
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O13 Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
Appendix A

O14 Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O20 Hemorrhage in early pregnancy 
O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester) 
O22 Venous complications and hemorrhoids in pregnancy 
O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester) 
O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O25 Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O28 Abnormal findings on antenatal screening of mother 
O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester) 
O30 Multiple gestation (last digit refers to first/second/third/unspecified trimester) 
O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester) 
O32 Maternal care for malpresentation of fetus 
O33 Maternal care for disproportion 
O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester) 
KϯϱථDĂƚĞƌŶĂůĐĂƌĞĨŽƌŬŶŽǁŶŽƌƐƵƐƉĞĐƚĞĚĨĞƚĂůĂďŶŽƌŵĂůŝƚǇĂŶĚĚĂŵĂŐĞ
O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester) 
O40 Polyhydramnios (codes indicate first/second/third/unspecified trimester) 
O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester) 
KϰϮ͘ϭථWƌĞŵĂƚƵƌĞƌƵƉƚƵƌĞŽĨŵĞŵďƌĂŶĞƐ͕ŽŶƐĞƚŽĨůĂďŽƌŵŽƌĞƚŚĂŶϮϰŚŽƵƌƐĨŽůůŽǁŝŶŐƌƵƉƚƵƌĞ
KϰϮ͘ϵථWƌĞŵĂƚƵƌĞƌƵƉƚƵƌĞŽĨŵĞŵďƌĂŶĞƐ͕ƵŶƐƉĞĐŝĨŝĞĚĂƐƚŽůĞŶŐƚŚŽĨƚŝŵĞďĞƚǁĞĞŶƌƵƉƚƵƌĞĂŶĚŽŶƐĞƚŽĨůĂďŽƌ
KϰϯථWůĂĐĞŶƚĂůĚŝƐŽƌĚĞƌƐ;ůĂƐƚĚŝŐŝƚƌĞĨĞƌƐƚŽĨŝƌƐƚͬƐĞĐŽŶĚͬƚŚŝƌĚͬƵŶƐƉĞĐŝĨŝĞĚƚƌŝŵĞƐƚĞƌͿ
O44 Placenta previa (last digit refers to first/second/third/unspecified trimester) 
O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester) 
O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester) 
Kϰϳථ&ĂůƐĞůĂďŽƌ
O60.0 Preterm labor without delivery 
O61 Failed induction of labor 
Kϳϭ͘ϬථZƵƉƚƵƌĞŽĨƵƚĞƌƵƐ;ƐƉŽŶƚĂŶĞŽƵƐͿďĞĨŽƌĞŽŶƐĞƚŽĨůĂďŽƌ
KϳϮථWŽƐƚƉĂƌƚƵŵŚĞŵŽƌƌŚĂŐĞ
KϳϮ͘ϮථĞůĂǇĞĚĂŶĚƐĞĐŽŶĚĂƌǇƉŽƐƚƉĂƌƚƵŵŚĞŵŽƌƌŚĂŐĞ
KϳϮ͘ϯථWŽƐƚƉĂƌƚƵŵĐŽĂŐƵůĂƚŝŽŶĚĞĨĞĐƚƐ
O73 Retained placenta and membranes, without hemorrhage 
O75 Other complications of labor and delivery, not elsewhere classified 
Kϵϰථ^ĞƋƵĞůĂĞŽĨĐŽŵƉůŝĐĂƚŝŽŶŽĨƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚ͕ĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ
KϵϴථDĂƚĞƌŶĂůŝŶĨĞĐƚŝŽƵƐĂŶĚƉĂƌĂƐŝƚŝĐĚŝƐĞĂƐĞƐĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĨŝƌƐƚƚƌŝŵĞƐƚĞƌ͕ƐĞĐŽŶĚƚƌŝŵĞƐƚĞƌ͕ƚŚŝƌĚƚƌŝŵĞƐƚĞƌ͕ƵŶƐƉĞĐŝĨŝĞĚ͕ŽƌŶŽƚŚŝŶŐͿ
KϵϵථKƚŚĞƌŵĂƚĞƌŶĂůĚŝƐĞĂƐĞƐĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĨŝƌƐƚƚƌŝŵĞƐƚĞƌ͕ƐĞĐŽŶĚƚƌŝŵĞƐƚĞƌ͕ƚŚŝƌĚƚƌŝŵĞƐƚĞƌ͕ƵŶƐƉĞĐŝĨŝĞĚ͕ŽƌŶŽƚŚŝŶŐͿ
KϵථDĂƚĞƌŶĂůŵĂůŝŐŶĂŶƚŶĞŽƉůĂƐŵƐ͕ƚƌĂƵŵĂƚŝĐŝŶũƵƌŝĞƐĂŶĚĂďƵƐĞĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĨŝƌƐƚƚƌŝŵĞƐƚĞƌ͕ƐĞĐŽŶĚƚƌŝŵĞƐƚĞƌ͕ƚŚŝƌĚƚƌŝŵĞƐƚĞƌ͕ƵŶƐƉĞĐŝĨŝĞĚ͕ŽƌŶŽƚŚŝŶŐͿ
ϯϮ͘ϬϭථŶĐŽƵŶƚĞƌĨŽƌƉƌĞŐŶĂŶĐǇƚĞƐƚͲƌĞƐƵůƚƉŽƐŝƚŝǀĞ
ϯϯථWƌĞŐŶĂŶƚƐƚĂƚĞ
ϯϰථŶĐŽƵŶƚĞƌĨŽƌƐƵƉĞƌǀŝƐŝŽŶŽĨŶŽƌŵĂůƉƌĞŐŶĂŶĐǇ
ϯϲථŶĐŽƵŶƚĞƌĨŽƌĂŶƚĞŶĂƚĂůƐĐƌĞĞŶŝŶŐŽĨŵŽƚŚĞƌ
ϯϵථŶĐŽƵŶƚĞƌĨŽƌŵĂƚĞƌŶĂůƉŽƐƚƉĂƌƚƵŵĐĂƌĞĂŶĚĞǆĂŵŝŶĂƚŝŽŶ
ϯϵ͘ϭථŶĐŽƵŶƚĞƌĨŽƌĐĂƌĞĂŶĚĞǆĂŵŝŶĂƚŝŽŶŽĨůĂĐƚĂƚŝŶŐŵŽƚŚĞƌ
ϯϵ͘ϮථŶĐŽƵŶƚĞƌĨŽƌƌŽƵƚŝŶĞƉŽƐƚƉĂƌƚƵŵĨŽůůŽǁͲƵƉ
ϯථtĞĞŬƐŽĨŐĞƐƚĂƚŝŽŶ
Proc codes: 
ϭϬϮථŚĂŶŐĞ
ϭϬϵථƌĂŝŶĂŐĞ
ϭϬ,ථ/ŶƐĞƌƚŝŽŶ
ϭϬ:ථ/ŶƐƉĞĐƚŝŽŶ
ϭϬWථZĞŵŽǀĂů
ϭϬYථZĞƉĂŝƌ
Appendix A

ϭϬ^ථZĞƉŽƐŝƚŝŽŶ
ϭϬzථdƌĂŶƐƉůĂŶƚĂƚŝŽŶ
ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify deliveries) 
Dx codes: 
Use the following codes only if the last digit indicates childbirth or puerperium or labor 
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium 
KϭϭථWƌĞͲĞǆŝƐƚŝŶŐŚǇƉĞƌƚĞŶƐŝŽŶǁŝƚŚƉƌĞͲĞĐůĂŵƉƐŝĂ
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension 
O13 Gestational [pregnancy-induced] hypertension without significant proteinuria 
O14 Pre-eclampsia 
O15 Eclampsia 
O16 Unspecified maternal hypertension 
KϮϰථŝĂďĞƚĞƐŵĞůůŝƚƵƐŝŶƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚ͕ĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ
KϮϱථDĂůŶƵƚƌŝƚŝŽŶŝŶƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ
O26 Maternal care for other conditions predominantly related to pregnancy 
KϰϮ͘ϬථWƌĞŵĂƚƵƌĞƌƵƉƚƵƌĞŽĨŵĞŵďƌĂŶĞƐ͕ŽŶƐĞƚŽĨůĂďŽƌǁŝƚŚŝŶϮϰŚŽƵƌƐŽĨƌƵƉƚƵƌĞ͕ĞǆĐĞƉƚϬϰϮ͘Ϭϭϭ;ĨŝƌƐƚƚƌŝŵĞƐƚĞƌͿ
O48 Late pregnancy 
O60.1 Preterm labor with preterm delivery 
O60.2 Term delivery with preterm labor 
O62 Abnormalities of forces of labor 
O63 Long labor 
O64  Obstructed labor due to malposition and malpresentation of fetus 
O65  Obstructed labor due to maternal pelvic abnormality 
O66  Other obstructed labor 
O67  Labor and delivery complicated by intrapartum hemorrhage, not elsewhere classified 
O68  Labor and delivery complicated by abnormality of fetal acid-base balance 
O69  Labor and delivery complicated by umbilical cord complications 
O70  Perineal laceration during delivery 
Kϳϭ͘ϭථZƵƉƚƵƌĞŽĨƵƚĞƌƵƐĚƵƌŝŶŐůĂďŽƌ
Kϳϭ͘ϮථWŽƐƚƉĂƌƚƵŵŝŶǀĞƌƐŝŽŶŽĨƵƚĞƌƵƐ
Kϳϭ͘ϯථKďƐƚĞƚƌŝĐůĂĐĞƌĂƚŝŽŶŽĨĐĞƌǀŝǆ
Kϳϭ͘ϰථKďƐƚĞƚƌŝĐŚŝŐŚǀĂŐŝŶĂůůĂĐĞƌĂƚŝŽŶĂůŽŶĞථ
KϳϮ͘ϬථdŚŝƌĚͲƐƚĂŐĞŚĞŵŽƌƌŚĂŐĞථ
KϳϮ͘ϭථKƚŚĞƌŝŵŵĞĚŝĂƚĞƉŽƐƚƉĂƌƚƵŵŚĞŵŽƌƌŚĂŐĞ
O74 Complications of anesthesia during labor and delivery 
O76  Abnormality in fetal heart rate and rhythm complicating labor and delivery 
O77  Other fetal stress complicating labor and delivery 
O80  Encounter for full-term uncomplicated delivery 
O82  Encounter for cesarean delivery without indication 
KϵϴථDĂƚĞƌŶĂůŝŶĨĞĐƚŝŽƵƐĂŶĚƉĂƌĂƐŝƚŝĐĚŝƐĞĂƐĞƐĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĐŚŝůĚďŝƌƚŚŽƌƉƵĞƌƉĞƌŝƵŵͿ
KϵϵථKƚŚĞƌŵĂƚĞƌŶĂůĚŝƐĞĂƐĞƐĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĐŚŝůĚďŝƌƚŚŽƌƉƵĞƌƉĞƌŝƵŵͿ
KϵථDĂƚĞƌŶĂůŵĂůŝŐŶĂŶƚŶĞŽƉůĂƐŵƐ͕ƚƌĂƵŵĂƚŝĐŝŶũƵƌŝĞƐĂŶĚĂďƵƐĞĐůĂƐƐŝĨŝĂďůĞĞůƐĞǁŚĞƌĞďƵƚĐŽŵƉůŝĐĂƚŝŶŐƉƌĞŐŶĂŶĐǇ͕ĐŚŝůĚďŝƌƚŚĂŶĚƚŚĞƉƵĞƌƉĞƌŝƵŵ;ŝĨůĂƐƚĚŝŐŝƚŝŶĚŝĐĂƚĞƐĐŚŝůĚďŝƌƚŚŽƌƉƵĞƌƉĞƌŝƵŵͿ
ϯϳථKƵƚĐŽŵĞŽĨĚĞůŝǀĞƌǇ;&ŽƌůŝǀĞďŝƌƚŚĐŽŚŽƌƚ͕ĞǆĐůƵĚĞϯϳ͘ϭ͕ϯϳ͘ϰ͕ϯϳ͘ϳͲĂůůƐƚŝůůďŝƌƚŚĐŽĚĞƐͿ
ϯϴථ>ŝǀĞďŽƌŶŝŶĨĂŶƚƐĂĐĐŽƌĚŝŶŐƚŽƉůĂĐĞŽĨďŝƌƚŚĂŶĚƚǇƉĞŽĨĚĞůŝǀĞƌǇ
ϯϵ͘ϬථŶĐŽƵŶƚĞƌĨŽƌĐĂƌĞĂŶĚĞǆĂŵŝŶĂƚŝŽŶŽĨŵŽƚŚĞƌŝŵŵĞĚŝĂƚĞůǇĂĨƚĞƌĚĞůŝǀĞƌǇ
ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES 
Dx codes: 
O00-O08  Pregnancy with abortive outcome 
Proc codes: 
ϭϬථďŽƌƚŝŽŶ
ϭϬϭϳϵථDĂŶƵĂůǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ZĞƚĂŝŶĞĚ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐ
ϭϬϭϳථǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ZĞƚĂŝŶĞĚ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐ
ϭϬϭϴϵථDĂŶƵĂůǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ZĞƚĂŝŶĞĚ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐŶĚŽƐĐŽƉŝĐ
ϭϬϭϴථǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ZĞƚĂŝŶĞĚ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐŶĚŽƐĐŽƉŝĐ
ICD-10 CODES INDICATING ECTOPIC PREGNANCY 
Appendix A

ϭϬϮϳථǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ĐƚŽƉŝĐ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐ
ϭϬϮϴථǆƚƌĂĐƚŝŽŶŽĨWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ĐƚŽƉŝĐ͕sŝĂEĂƚƵƌĂůŽƌƌƚŝĨŝĐŝĂůKƉĞŶŝŶŐŶĚŽƐĐŽƉŝĐ
ϭϬ^ϮථZĞƉŽƐŝƚŝŽŶWƌŽĚƵĐƚƐŽĨŽŶĐĞƉƚŝŽŶ͕ĐƚŽƉŝĐ
ϭϬdථZĞƐĞĐƚŝŽŶ;ĐƚŽƉŝĐͿ
Appendix A

Variable
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Number of patients
4,499
5,087
6,339
4,781
12,786
8,329
23,624
18,197
Age
...mean (sd)
61.83 (16.97)
69.01 (15.57)
-0.44
53.93 (15.65)
57.11 (15.97)
-0.20
70.91 (13.02)
74.18 (12.37)
-0.26
64.62 (14.57)
68.25 (14.31)
-0.25
...median [IQR]
64.00 [51.00, 75.00]
72.00 [61.00, 81.00]
-0.49
55.00 [44.00, 63.00] 57.00 [47.00, 66.00]
-0.13
72.00 [66.00, 80.00] 75.00 [68.00, 83.00 -0.24
65.91 (14.57)
69.43 (14.31)
-0.24
Age categories
...18 - 54; n (%)
1,386 (30.8%)
883 (17.4%)
0.32
3,104 (49.0%)
1,981 (41.4%)
0.15
1,412 (11.0%)
592 (7.1%)
0.14
5,902 (25.0%)
3,456 (19.0%)
0.15
...55 - 64; n (%)
865 (19.2%)
676 (13.3%)
0.16
1,888 (29.8%)
1,536 (32.1%)
-0.05
1,202 (9.4%)
619 (7.4%)
0.07
3,955 (16.7%)
2,831 (15.6%)
0.03
...65 - 74; n (%)
1,095 (24.3%)
1,341 (26.4%)
-0.05
723 (11.4%)
552 (11.5%)
0.00
4,839 (37.8%)
2,798 (33.6%)
0.09
6,657 (28.2%)
4,691 (25.8%)
0.05
...>= 75; n (%)
1,153 (25.6%)
2,187 (43.0%)
-0.37
624 (9.8%)
712 (14.9%)
-0.16
5,333 (41.7%)
4,320 (51.9%)
-0.21
7,110 (30.1%)
7,219 (39.7%)
-0.20
Calendar Year (2014-2020)
...2014; n (%)
295 (6.6%)
23 (0.5%)
0.33
837 (13.2%)
69 (1.4%)
0.47
1,392 (10.9%)
175 (2.1%)
0.36
2,524 (10.7%)
267 (1.5%)
0.39
...2015; n (%)
761 (16.9%)
193 (3.8%)
0.44
1,592 (25.1%)
465 (9.7%)
0.41
3,619 (28.3%)
1,581 (19.0%)
0.22
5,972 (25.3%)
2,239 (12.3%)
0.34
...2016; n (%)
834 (18.5%)
513 (10.1%)
0.24
1,424 (22.5%)
893 (18.7%)
0.09
3,778 (29.5%)
3,246 (39.0%)
-0.20
6,036 (25.6%)
4,652 (25.6%)
0.00
...2017; n (%)
793 (17.6%)
774 (15.2%)
0.06
1,032 (16.3%)
1,069 (22.4%)
-0.15
3,997 (31.3%)
3,327 (39.9%)
-0.18
5,822 (24.6%)
5,170 (28.4%)
-0.09
...2018; n (%)
869 (19.3%)
1,276 (25.1%)
-0.14
823 (13.0%)
1,079 (22.6%)
-0.25
0 (0.0%)
0 (0.0%)
0.00
1,692 (7.2%)
2,355 (12.9%)
-0.19
...2019; n (%)
727 (16.2%)
1,514 (29.8%)
-0.33
631 (10.0%)
1,206 (25.2%)
-0.41
0 (0.0%)
0 (0.0%)
0.00
1,358 (5.7%)
2,720 (14.9%)
-0.31
...2020; n (%)
220 (4.9%)
794 (15.6%)
-0.36
0 (0.0%)
0 (0.0%)
0.00
0 (0.0%)
0 (0.0%)
0.00
220 (0.9%)
794 (4.4%)
-0.22
Race
...White; n (%)
3,257 (72.4%)
3,455 (67.9%)
0.10
0 (0.0%)
0 (0.0%)
0.00
10,471 (81.9%)
6,881 (82.6%)
-0.02
13,728 (58.1%)
10,336 (56.8%)
0.03
...Asian; n (%)
79 (1.8%)
73 (1.4%)
0.03
0 (0.0%)
0 (0.0%)
0.00
100 (0.8%)
76 (0.9%)
-0.01
179 (0.8%)
149 (0.8%)
0.00
...Black; n (%)
635 (14.1%)
822 (16.2%)
-0.06
0 (0.0%)
0 (0.0%)
0.00
1,661 (13.0%)
1,086 (13.0%)
0.00
2,296 (9.7%)
1,908 (10.5%)
-0.03
...Hispanic; n (%)
336 (7.5%)
453 (8.9%)
-0.05
0 (0.0%)
0 (0.0%)
0.00
234 (1.8%)
123 (1.5%)
0.02
570 (2.4%)
576 (3.2%)
-0.05
...North American Native; n (%)
0 (0.0%)
0 (0.0%)
0.00
0 (0.0%)
0 (0.0%)
0.00
68 (0.5%)
22 (0.3%)
0.03
68 (0.3%)
22 (0.1%)
0.04
...Other; n (%)
0 (0.0%)
0 (0.0%)
0.00
0 (0.0%)
0 (0.0%)
0.00
101 (0.8%)
63 (0.8%)
0.00
101 (0.4%)
63 (0.3%)
0.02
...Unknown/Missing; n (%)
192 (4.3%)
284 (5.6%)
-0.06
0 (0.0%)
0 (0.0%)
0.00
151 (1.2%)
78 (0.9%)
0.03
343 (1.5%)
362 (2.0%)
-0.04
Gender
...Males; n (%)
2,247 (49.9%)
2,172 (42.7%)
0.14
3,418 (53.9%)
2,483 (51.9%)
0.04
5,549 (43.4%)
3,206 (38.5%)
0.10
11,214 (47.5%)
7,861 (43.2%)
0.09
...Females; n (%)
2,252 (50.1%)
2,915 (57.3%)
-0.14
2,921 (46.1%)
2,298 (48.1%)
-0.04
7,237 (56.6%)
5,123 (61.5%)
-0.10
12,410 (52.5%)
10,336 (56.8%)
-0.09
Region
...Northeast; n (%)
528 (11.7%)
544 (10.7%)
0.03
1,311 (20.7%)
962 (20.1%)
0.01
2,384 (18.6%)
1,613 (19.4%)
-0.02
4,223 (17.9%)
3,119 (17.1%)
0.02
...South; n (%)
1,870 (41.6%)
2,524 (49.6%)
-0.16
2,549 (40.2%)
2,236 (46.8%)
-0.13
5,001 (39.1%)
3,826 (45.9%)
-0.14
9,420 (39.9%)
8,586 (47.2%)
-0.15
...Midwest; n (%)
1,082 (24.0%)
996 (19.6%)
0.11
1,625 (25.6%)
1,028 (21.5%)
0.10
3,191 (25.0%)
1,720 (20.7%)
0.10
5,898 (25.0%)
3,744 (20.6%)
0.11
...West; n (%)
1,004 (22.3%)
1,016 (20.0%)
0.06
825 (13.0%)
544 (11.4%)
0.05
2,200 (17.2%)
1,162 (14.0%)
0.09
4,029 (17.1%)
2,722 (15.0%)
0.06
...Unknown+missing; n (%)
15 (0.3%)
7 (0.1%)
0.04
29 (0.5%)
11 (0.2%)
0.05
--
--
--
--
Combined comorbidity score, 180 days Copy
...mean (sd)
2.62 (2.34)
3.65 (2.64)
-0.41
1.61 (1.72)
2.19 (1.89)
-0.32
2.17 (2.08)
2.74 (2.27)
-0.26
2.11 (2.04)
2.85 (2.29)
-0.34
...median [IQR]
2.00 [1.00, 4.00]
3.00 [2.00, 5.00]
-0.40
1.00 [0.00, 3.00]
2.00 [1.00, 3.00]
0.00
2.00 [1.00, 3.00]
2.00 [1.00, 4.00]
0.00
1.73 (2.04)
2.28 (2.29)
-0.25
Lifestyle Factors
Lifestyle - Smoking ; n (%)
1,587 (35.3%)
1,929 (37.9%)
-0.05
1,226 (19.3%)
925 (19.3%)
0.00
5,433 (42.5%)
3,322 (39.9%)
0.05
8,246 (34.9%)
6,176 (33.9%)
0.02
Lifestyle - Drug abuse or dependence; n (%)
220 (4.9%)
274 (5.4%)
-0.02
180 (2.8%)
135 (2.8%)
0.00
605 (4.7%)
300 (3.6%)
0.06
1,005 (4.3%)
709 (3.9%)
0.02
Lifestyle - Alcohol abuse or dependence ; n (%)
190 (4.2%)
193 (3.8%)
0.02
166 (2.6%)
127 (2.7%)
-0.01
465 (3.6%)
241 (2.9%)
0.04
821 (3.5%)
561 (3.1%)
0.02
Comorbidities
DM - Diabetic Retinopathy; n (%)
42 (0.9%)
83 (1.6%)
-0.06
33 (0.5%)
32 (0.7%)
-0.03
112 (0.9%)
89 (1.1%)
-0.02
187 (0.8%)
204 (1.1%)
-0.03
DM - Diabetic Neuropathy; n (%)
211 (4.7%)
361 (7.1%)
-0.10
156 (2.5%)
163 (3.4%)
-0.05
589 (4.6%)
440 (5.3%)
-0.03
956 (4.0%)
964 (5.3%)
-0.06
DM - Diabetic Nephropathy; n (%)
144 (3.2%)
381 (7.5%)
-0.19
80 (1.3%)
105 (2.2%)
-0.07
299 (2.3%)
364 (4.4%)
-0.12
523 (2.2%)
850 (4.7%)
-0.14
DM - Diabetes with peripheral circulatory disorders; n (%)
9 (0.2%)
11 (0.2%)
0.00
20 (0.3%)
7 (0.1%)
0.04
64 (0.5%)
27 (0.3%)
0.03
93 (0.4%)
45 (0.2%)
0.04
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)
46 (1.0%)
61 (1.2%)
-0.02
34 (0.5%)
20 (0.4%)
0.01
199 (1.6%)
107 (1.3%)
0.03
279 (1.2%)
188 (1.0%)
0.02
DM - Diabetes with unspecified complications; n (%)
58 (1.3%)
146 (2.9%)
-0.11
879 (13.9%)
768 (16.1%)
-0.06
174 (1.4%)
124 (1.5%)
-0.01
1,111 (4.7%)
1,038 (5.7%)
-0.05
DM - Diabetes mellitus without mention of complications; n (%)
780 (17.3%)
1,249 (24.6%)
-0.18
68 (1.1%)
75 (1.6%)
-0.04
2,920 (22.8%)
1,979 (23.8%)
-0.02
3,768 (15.9%)
3,303 (18.2%)
-0.06
CV - Hypertension; n (%)
2,622 (58.3%)
3,588 (70.5%)
-0.26
2,922 (46.1%)
2,632 (55.1%)
-0.18
9,714 (76.0%)
6,715 (80.6%)
-0.11
15,258 (64.6%)
12,935 (71.1%)
-0.14
CV - Hyperlipidemia; n (%)
1,932 (42.9%)
2,645 (52.0%)
-0.18
2,051 (32.4%)
1,737 (36.3%)
-0.08
6,823 (53.4%)
4,603 (55.3%)
-0.04
10,806 (45.7%)
8,985 (49.4%)
-0.07
CV -Acute MI; n (%)
207 (4.6%)
313 (6.2%)
-0.07
226 (3.6%)
215 (4.5%)
-0.05
507 (4.0%)
466 (5.6%)
-0.07
940 (4.0%)
994 (5.5%)
-0.07
CV - ACS/unstable angina; n (%)
130 (2.9%)
232 (4.6%)
-0.09
147 (2.3%)
151 (3.2%)
-0.06
442 (3.5%)
308 (3.7%)
-0.01
719 (3.0%)
691 (3.8%)
-0.04
CV - Old MI; n (%)
158 (3.5%)
258 (5.1%)
-0.08
104 (1.6%)
92 (1.9%)
-0.02
602 (4.7%)
454 (5.5%)
-0.04
864 (3.7%)
804 (4.4%)
-0.04
CV - Stable angina; n (%)
96 (2.1%)
165 (3.2%)
-0.07
107 (1.7%)
109 (2.3%)
-0.04
277 (2.2%)
240 (2.9%)
-0.04
480 (2.0%)
514 (2.8%)
-0.05
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)
603 (13.4%)
976 (19.2%)
-0.16
539 (8.5%)
482 (10.1%)
-0.06
2,387 (18.7%)
1,832 (22.0%)
-0.08
3,529 (14.9%)
3,290 (18.1%)
-0.09
CV - Other atherosclerosis; n (%)
41 (0.9%)
58 (1.1%)
-0.02
26 (0.4%)
21 (0.4%)
0.00
128 (1.0%)
74 (0.9%)
0.01
195 (0.8%)
153 (0.8%)
0.00
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%)
184 (4.1%)
304 (6.0%)
-0.09
99 (1.6%)
64 (1.3%)
0.03
888 (6.9%)
663 (8.0%)
-0.04
1,171 (5.0%)
1,031 (5.7%)
-0.03
CV - Ischemic stroke; n (%)
239 (5.3%)
446 (8.8%)
-0.14
230 (3.6%)
227 (4.7%)
-0.06
830 (6.5%)
685 (8.2%)
-0.07
1,299 (5.5%)
1,358 (7.5%)
-0.08
CV - Hemorrhagic stroke; n (%)
8 (0.2%)
20 (0.4%)
-0.04
5 (0.1%)
2 (0.0%)
0.04
21 (0.2%)
16 (0.2%)
0.00
34 (0.1%)
38 (0.2%)
-0.03
CV - TIA; n (%)
72 (1.6%)
118 (2.3%)
-0.05
69 (1.1%)
77 (1.6%)
-0.04
216 (1.7%)
176 (2.1%)
-0.03
357 (1.5%)
371 (2.0%)
-0.04
CV - Other cerebrovascular disease; n (%)
122 (2.7%)
246 (4.8%)
-0.11
93 (1.5%)
124 (2.6%)
-0.08
365 (2.9%)
302 (3.6%)
-0.04
580 (2.5%)
672 (3.7%)
-0.07
CV - Late effects of cerebrovascular disease; n (%)
94 (2.1%)
203 (4.0%)
-0.11
67 (1.1%)
59 (1.2%)
-0.01
375 (2.9%)
273 (3.3%)
-0.02
536 (2.3%)
535 (2.9%)
-0.04
CV - Heart failure (CHF); n (%)
538 (12.0%)
974 (19.1%)
0.00
462 (7.3%)
511 (10.7%)
-0.12
1,842 (14.4%)
1,573 (18.9%)
-0.12
2,842 (12.0%)
3,058 (16.8%)
-0.14
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%)
371 (8.2%)
525 (10.3%)
-0.07
301 (4.7%)
247 (5.2%)
-0.02
1,056 (8.3%)
803 (9.6%)
-0.05
1,728 (7.3%)
1,575 (8.7%)
-0.05
CV - Other cardiac dysrhythmia; n (%)
651 (14.5%)
904 (17.8%)
-0.09
773 (12.2%)
653 (13.7%)
-0.04
1,963 (15.4%)
1,347 (16.2%)
-0.02
3,387 (14.3%)
2,904 (16.0%)
-0.05
CV - Cardiac conduction disorders; n (%)
330 (7.3%)
538 (10.6%)
-0.12
311 (4.9%)
266 (5.6%)
-0.03
1,008 (7.9%)
777 (9.3%)
-0.05
1,649 (7.0%)
1,581 (8.7%)
-0.06
CV - Other CVD; n (%)
1,268 (28.2%)
1,764 (34.7%)
-0.14
1,420 (22.4%)
1,311 (27.4%)
-0.12
3,183 (24.9%)
2,346 (28.2%)
-0.07
5,871 (24.9%)
5,421 (29.8%)
-0.11
CV Medications - ACE inhibitors; n (%)
919 (20.4%)
1,236 (24.3%)
-0.09
1,077 (17.0%)
937 (19.6%)
-0.07
3,436 (26.9%)
2,317 (27.8%)
-0.02
5,432 (23.0%)
4,490 (24.7%)
-0.04
CV Medications - ARBs; n (%)
601 (13.4%)
882 (17.3%)
-0.11
720 (11.4%)
659 (13.8%)
-0.07
2,108 (16.5%)
1,547 (18.6%)
-0.06
3,429 (14.5%)
3,088 (17.0%)
-0.07
CV Medications - Alpha blockers; n (%)
319 (7.1%)
480 (9.4%)
-0.08
333 (5.3%)
299 (6.3%)
-0.04
1,308 (10.2%)
845 (10.1%)
0.00
1,960 (8.3%)
1,624 (8.9%)
-0.02
CV Medications - Beta blockers; n (%)
945 (21.0%)
1,496 (29.4%)
-0.19
1,112 (17.5%)
1,052 (22.0%)
-0.11
3,972 (31.1%)
3,007 (36.1%)
-0.11
6,029 (25.5%)
5,555 (30.5%)
-0.11
CV Medications - Loop Diuretics; n (%)
442 (9.8%)
750 (14.7%)
-0.15
373 (5.9%)
435 (9.1%)
-0.12
1,913 (15.0%)
1,613 (19.4%)
-0.12
2,728 (11.5%)
2,798 (15.4%)
-0.11
CV Medications - Other diuretics; n (%)
99 (2.2%)
159 (3.1%)
-0.06
125 (2.0%)
120 (2.5%)
-0.03
346 (2.7%)
277 (3.3%)
-0.04
570 (2.4%)
556 (3.1%)
-0.04
CV Medications - Use of nitrates; n (%)
94 (2.1%)
175 (3.4%)
-0.08
95 (1.5%)
92 (1.9%)
-0.03
554 (4.3%)
480 (5.8%)
-0.07
743 (3.1%)
747 (4.1%)
-0.05
CV Medications - Use of statins; n (%)
1,270 (28.2%)
1,868 (36.7%)
-0.18
1,433 (22.6%)
1,323 (27.7%)
-0.12
5,125 (40.1%)
3,551 (42.6%)
-0.05
7,828 (33.1%)
6,742 (37.1%)
-0.08
CV Medications - Use of other lipid-lowering drugs; n (%)
163 (3.6%)
185 (3.6%)
0.00
234 (3.7%)
195 (4.1%)
-0.02
577 (4.5%)
412 (4.9%)
-0.02
974 (4.1%)
792 (4.4%)
-0.01
Optum 
Medicare
Unmatched
MarketScan
Pooled 
Appendix B

CV Medications - calcium channel blockers; n (%)
765 (17.0%)
1,232 (24.2%)
-0.18
835 (13.2%)
821 (17.2%)
-0.11
2,960 (23.2%)
2,243 (26.9%)
-0.09
4,560 (19.3%)
4,296 (23.6%)
-0.10
CV Medications - Use of Low Weight Molecular Heparins; n (%)
90 (2.0%)
102 (2.0%)
0.00
162 (2.6%)
97 (2.0%)
0.04
217 (1.7%)
158 (1.9%)
-0.02
469 (2.0%)
357 (2.0%)
0.00
Other Comorbidity - Osteoporosis; n (%)
345 (7.7%)
603 (11.9%)
-0.14
184 (2.9%)
156 (3.3%)
-0.02
1,464 (11.5%)
1,109 (13.3%)
-0.05
1,993 (8.4%)
1,868 (10.3%)
-0.07
Other Comorbidity - Dementia; n (%)
494 (11.0%)
958 (18.8%)
-0.22
223 (3.5%)
255 (5.3%)
-0.09
1,816 (14.2%)
1,646 (19.8%)
-0.15
2,533 (10.7%)
2,859 (15.7%)
-0.15
Other Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland ; n (%853 (19.0%)
1,184 (23.3%)
-0.11
863 (13.6%)
770 (16.1%)
-0.07
1,487 (11.6%)
743 (8.9%)
0.09
3,203 (13.6%)
2,697 (14.8%)
-0.03
Other Comorbidity - Edema; n (%)
941 (20.9%)
1,268 (24.9%)
-0.10
986 (15.6%)
810 (16.9%)
-0.04
2,150 (16.8%)
1,563 (18.8%)
-0.05
4,077 (17.3%)
3,641 (20.0%)
-0.07
Other Comorbidity - Depression; n (%)
836 (18.6%)
1,020 (20.1%)
-0.04
816 (12.9%)
635 (13.3%)
-0.01
2,678 (20.9%)
1,758 (21.1%)
0.00
4,330 (18.3%)
3,413 (18.8%)
-0.01
Other Comorbidity - Anxiety; n (%)
908 (20.2%)
1,163 (22.9%)
-0.07
921 (14.5%)
827 (17.3%)
-0.08
2,675 (20.9%)
1,732 (20.8%)
0.00
4,504 (19.1%)
3,722 (20.5%)
-0.04
Other Comorbidity - Pneumonia; n (%)
719 (16.0%)
1,105 (21.7%)
-0.15
833 (13.1%)
729 (15.2%)
-0.06
2,169 (17.0%)
1,518 (18.2%)
-0.03
3,721 (15.8%)
3,352 (18.4%)
-0.07
Other Comorbidity - COPD; n (%)
772 (17.2%)
1,163 (22.9%)
-0.14
585 (9.2%)
496 (10.4%)
-0.04
2,910 (22.8%)
2,061 (24.7%)
-0.04
4,267 (18.1%)
3,720 (20.4%)
-0.06
Other Comorbidity - Asthma; n (%)
479 (10.6%)
557 (10.9%)
-0.01
639 (10.1%)
489 (10.2%)
0.00
1,573 (12.3%)
980 (11.8%)
0.02
2,691 (11.4%)
2,026 (11.1%)
0.01
Other Comorbidity - Acute renal disease; n (%)
493 (11.0%)
960 (18.9%)
-0.22
456 (7.2%)
478 (10.0%)
-0.10
1,430 (11.2%)
1,371 (16.5%)
-0.15
2,379 (10.1%)
2,809 (15.4%)
-0.16
Other Comorbidity CKD Stage 1; n (%)
14 (0.3%)
15 (0.3%)
0.00
11 (0.2%)
4 (0.1%)
0.03
33 (0.3%)
28 (0.3%)
0.00
58 (0.2%)
47 (0.3%)
-0.02
Other Comorbidity - CKD Stage 2; n (%)
88 (2.0%)
142 (2.8%)
-0.05
40 (0.6%)
46 (1.0%)
-0.04
177 (1.4%)
168 (2.0%)
-0.05
305 (1.3%)
356 (2.0%)
-0.05
Other Comorbidity - CKD Stage 3; n (%)
295 (6.6%)
712 (14.0%)
-0.25
147 (2.3%)
203 (4.2%)
-0.11
796 (6.2%)
980 (11.8%)
-0.20
1,238 (5.2%)
1,895 (10.4%)
-0.19
Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%)
245 (5.4%)
473 (9.3%)
-0.15
127 (2.0%)
185 (3.9%)
-0.11
679 (5.3%)
726 (8.7%)
-0.13
1,051 (4.4%)
1,384 (7.6%)
-0.14
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)
385 (8.6%)
553 (10.9%)
-0.08
324 (5.1%)
301 (6.3%)
-0.05
905 (7.1%)
764 (9.2%)
-0.08
1,614 (6.8%)
1,618 (8.9%)
-0.08
Other Comorbidity - Hypertensive nephropathy; n (%)
333 (7.4%)
739 (14.5%)
-0.23
162 (2.6%)
257 (5.4%)
-0.14
1,056 (8.3%)
1,275 (15.3%)
-0.22
1,551 (6.6%)
2,271 (12.5%)
-0.20
Other Comorbidity - Obstructive sleep apnea; n (%)
387 (8.6%)
442 (8.7%)
0.00
626 (9.9%)
533 (11.1%)
-0.04
897 (7.0%)
602 (7.2%)
-0.01
1,910 (8.1%)
1,577 (8.7%)
-0.02
Other Comorbidity - Osteoarthritis; n (%)
1,152 (25.6%)
1,658 (32.6%)
-0.15
1,178 (18.6%)
964 (20.2%)
-0.04
4,067 (31.8%)
2,876 (34.5%)
-0.06
6,397 (27.1%)
5,498 (30.2%)
-0.07
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)
3,025 (67.2%)
3,460 (68.0%)
-0.02
4,026 (63.5%)
2,894 (60.5%)
0.06
8,043 (62.9%)
5,180 (62.2%)
0.01
15,094 (63.9%)
11,534 (63.4%)
0.01
Other Comorbidity - Dorsopathies; n (%)
1,513 (33.6%)
1,835 (36.1%)
-0.05
1,815 (28.6%)
1,452 (30.4%)
-0.04
4,377 (34.2%)
2,780 (33.4%)
0.02
7,705 (32.6%)
6,067 (33.3%)
-0.01
Other Comorbidity - Fractures; n (%)
472 (10.5%)
647 (12.7%)
-0.07
487 (7.7%)
391 (8.2%)
-0.02
1,209 (9.5%)
845 (10.1%)
-0.02
2,168 (9.2%)
1,883 (10.3%)
-0.04
Other Comorbidity - Falls; n (%)
502 (11.2%)
897 (17.6%)
-0.18
263 (4.1%)
243 (5.1%)
-0.05
602 (4.7%)
453 (5.4%)
-0.03
1,367 (5.8%)
1,593 (8.8%)
-0.12
Other Comorbidity - Sleep Disorder; n (%)
217 (4.8%)
171 (3.4%)
0.07
379 (6.0%)
159 (3.3%)
0.13
670 (5.2%)
291 (3.5%)
0.08
1,266 (5.4%)
621 (3.4%)
0.10
Other Comorbidity - Delirium; n (%)
257 (5.7%)
466 (9.2%)
-0.13
142 (2.2%)
144 (3.0%)
-0.05
754 (5.9%)
646 (7.8%)
-0.08
1,153 (4.9%)
1,256 (6.9%)
-0.08
Other Comorbidity - Psychosis; n (%)
149 (3.3%)
191 (3.8%)
-0.03
80 (1.3%)
60 (1.3%)
0.00
775 (6.1%)
401 (4.8%)
0.06
1,004 (4.2%)
652 (3.6%)
0.03
Procedures
Procedure - Hip Surgery; n (%)
38 (0.8%)
74 (1.5%)
-0.07
55 (0.9%)
36 (0.8%)
-0.01
139 (1.1%)
87 (1.0%)
0.01
232 (1.0%)
197 (1.1%)
-0.01
Medications 
DM Medications - Meglitinides; n (%)
5 (0.1%)
6 (0.1%)
0.00
4 (0.1%)
7 (0.1%)
0.00
35 (0.3%)
20 (0.2%)
0.02
44 (0.2%)
33 (0.2%)
0.00
DM Medications - AGIs; n (%)
3 (0.1%)
0 (0.0%)
0.04
1 (0.0%)
2 (0.0%)
0.00
--
--
--
--
DM Medications - Insulin; n (%)
176 (3.9%)
299 (5.9%)
-0.09
32 (0.5%)
26 (0.5%)
0.00
505 (3.9%)
362 (4.3%)
-0.02
713 (3.0%)
687 (3.8%)
-0.04
DM Medications - Glitazones; n (%)
20 (0.4%)
34 (0.7%)
-0.04
210 (3.3%)
221 (4.6%)
-0.07
93 (0.7%)
49 (0.6%)
0.01
323 (1.4%)
304 (1.7%)
-0.02
DM Medications - 1st and 2nd Generation SUs ; n (%)
176 (3.9%)
292 (5.7%)
-0.08
201 (3.2%)
194 (4.1%)
-0.05
640 (5.0%)
466 (5.6%)
-0.03
1,017 (4.3%)
952 (5.2%)
-0.04
DM Medications - DPP-4 Inhibitors; n (%)
63 (1.4%)
116 (2.3%)
-0.07
97 (1.5%)
115 (2.4%)
-0.07
279 (2.2%)
219 (2.6%)
-0.03
439 (1.9%)
450 (2.5%)
-0.04
DM Medications - GLP-1 RA; n (%)
27 (0.6%)
56 (1.1%)
-0.05
53 (0.8%)
54 (1.1%)
-0.03
58 (0.5%)
47 (0.6%)
-0.01
138 (0.6%)
157 (0.9%)
-0.03
DM Medications - SGLT-2 Inhibitors ; n (%)
37 (0.8%)
48 (0.9%)
-0.01
68 (1.1%)
57 (1.2%)
-0.01
59 (0.5%)
40 (0.5%)
0.00
164 (0.7%)
145 (0.8%)
-0.01
DM Medications - Metformin; n (%)
362 (8.0%)
615 (12.1%)
-0.14
509 (8.0%)
438 (9.2%)
-0.04
1,357 (10.6%)
841 (10.1%)
0.02
2,228 (9.4%)
1,894 (10.4%)
-0.03
DM Medciations - All antidiabetic medications except Insulin; n (%)
465 (10.3%)
808 (15.9%)
-0.17
645 (10.2%)
576 (12.0%)
-0.06
1,775 (13.9%)
1,188 (14.3%)
-0.01
2,885 (12.2%)
2,572 (14.1%)
-0.06
Other Medications - Use of NSAIDs; n (%)
887 (19.7%)
936 (18.4%)
0.03
1,479 (23.3%)
1,054 (22.0%)
0.03
2,647 (20.7%)
1,646 (19.8%)
0.02
5,013 (21.2%)
3,636 (20.0%)
0.03
Other Medications - Use of other hypertension drugs; n (%)
174 (3.9%)
296 (5.8%)
-0.09
178 (2.8%)
161 (3.4%)
-0.03
747 (5.8%)
554 (6.7%)
-0.04
1,099 (4.7%)
1,011 (5.6%)
-0.04
Other Medications - Digoxin; n (%)
17 (0.4%)
18 (0.4%)
0.00
12 (0.2%)
19 (0.4%)
-0.04
83 (0.6%)
56 (0.7%)
-0.01
112 (0.5%)
93 (0.5%)
0.00
Other Medications - Use of Anti-arrhythmics; n (%)
17 (0.4%)
27 (0.5%)
-0.01
19 (0.3%)
30 (0.6%)
-0.04
57 (0.4%)
53 (0.6%)
-0.03
93 (0.4%)
110 (0.6%)
-0.03
Other Medications - Use of antipsychotics; n (%)
263 (5.8%)
357 (7.0%)
-0.05
230 (3.6%)
214 (4.5%)
-0.05
1,436 (11.2%)
864 (10.4%)
0.03
1,929 (8.2%)
1,435 (7.9%)
0.01
Other Medications - Use of dementia meds; n (%)
210 (4.7%)
386 (7.6%)
-0.12
94 (1.5%)
105 (2.2%)
-0.05
936 (7.3%)
800 (9.6%)
-0.08
1,240 (5.2%)
1,291 (7.1%)
-0.08
Other Medications - Use of antiparkinsonian meds; n (%)
148 (3.3%)
193 (3.8%)
-0.03
139 (2.2%)
118 (2.5%)
-0.02
722 (5.6%)
493 (5.9%)
-0.01
1,009 (4.3%)
804 (4.4%)
0.00
Other Medications - Use of anxiolytics/hypnotics; n (%)
291 (6.5%)
330 (6.5%)
0.00
443 (7.0%)
362 (7.6%)
-0.02
1,091 (8.5%)
679 (8.2%)
0.01
1,825 (7.7%)
1,371 (7.5%)
0.01
Other Medications - Use of anticonvulsants; n (%)
738 (16.4%)
1,036 (20.4%)
-0.10
844 (13.3%)
718 (15.0%)
-0.05
2,968 (23.2%)
1,871 (22.5%)
0.02
4,550 (19.3%)
3,625 (19.9%)
-0.02
Other Medications - Use of antidepressants; n (%)
1,187 (26.4%)
1,520 (29.9%)
-0.08
1,443 (22.8%)
1,205 (25.2%)
-0.06
4,303 (33.7%)
2,949 (35.4%)
-0.04
6,933 (29.3%)
5,674 (31.2%)
-0.04
Other Medications - Use of lithium; n (%)
13 (0.3%)
14 (0.3%)
0.00
21 (0.3%)
15 (0.3%)
0.00
79 (0.6%)
40 (0.5%)
0.01
113 (0.5%)
69 (0.4%)
0.01
Other Medications - Use of Benzos; n (%)
686 (15.2%)
792 (15.6%)
-0.01
929 (14.7%)
734 (15.4%)
-0.02
2,714 (21.2%)
1,762 (21.2%)
0.00
4,329 (18.3%)
3,288 (18.1%)
0.01
Other Medication - Use of CNS stimulants; n (%)
39 (0.9%)
47 (0.9%)
0.00
100 (1.6%)
75 (1.6%)
0.00
94 (0.7%)
49 (0.6%)
0.01
233 (1.0%)
171 (0.9%)
0.01
Other Medications - Use of opioids; n (%)
1,901 (42.3%)
1,922 (37.8%)
0.09
3,029 (47.8%)
2,095 (43.8%)
0.08
5,620 (44.0%)
3,499 (42.0%)
0.04
10,550 (44.7%)
7,516 (41.3%)
0.07
Other Medications - Use of COPD/asthma meds; n (%)
728 (16.2%)
1,062 (20.9%)
-0.12
1,010 (15.9%)
803 (16.8%)
-0.02
2,991 (23.4%)
1,969 (23.6%)
0.00
4,729 (20.0%)
3,834 (21.1%)
-0.03
Other Medications - Use of oral corticosteroids; n (%)
1,204 (26.8%)
1,433 (28.2%)
-0.03
1,628 (25.7%)
1,307 (27.3%)
-0.04
3,906 (30.5%)
2,715 (32.6%)
-0.05
6,738 (28.5%)
5,455 (30.0%)
-0.03
Other Medications - Use of Sympatomimetic agents; n (%)
68 (1.5%)
58 (1.1%)
0.04
156 (2.5%)
135 (2.8%)
-0.02
143 (1.1%)
73 (0.9%)
0.02
367 (1.6%)
266 (1.5%)
0.01
Other Medications - Use of bisphosphonates; n (%)
121 (2.7%)
188 (3.7%)
-0.06
67 (1.1%)
49 (1.0%)
0.01
502 (3.9%)
337 (4.0%)
-0.01
690 (2.9%)
574 (3.2%)
-0.02
Other Medications - Use of thiazide; n (%)
329 (7.3%)
448 (8.8%)
-0.06
363 (5.7%)
362 (7.6%)
-0.08
1,249 (9.8%)
831 (10.0%)
-0.01
1,941 (8.2%)
1,641 (9.0%)
-0.03
Other Medications - Use of estrogens, progestins, androgens; n (%)
388 (8.6%)
281 (5.5%)
0.12
872 (13.8%)
617 (12.9%)
0.03
578 (4.5%)
371 (4.5%)
0.00
1,838 (7.8%)
1,269 (7.0%)
0.03
Healthcare Utilization
HU - Bone mineral density; n (%)
120 (2.7%)
164 (3.2%)
-0.03
86 (1.4%)
73 (1.5%)
-0.01
490 (3.8%)
331 (4.0%)
-0.01
696 (2.9%)
568 (3.1%)
-0.01
HU - Occurrence of creatinine tests ordered ; n (%)
250 (5.6%)
330 (6.5%)
-0.04
264 (4.2%)
203 (4.2%)
0.00
878 (6.9%)
586 (7.0%)
0.00
1,392 (5.9%)
1,119 (6.1%)
-0.01
HU - Number of D-dimer tests
...mean (sd)
0.11 (0.35)
0.11 (0.35)
0.00
0.13 (0.38)
0.12 (0.38)
0.03
0.11 (0.35)
0.10 (0.33)
0.03
0.12 (0.36)
0.11 (0.35)
0.03
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.36)
0.00 (0.35)
0.00
HU - Number of CRP, high-sensitivity CRP tests
...mean (sd)
0.12 (0.55)
0.12 (0.52)
0.00
0.10 (0.47)
0.11 (0.58)
-0.02
0.15 (0.59)
0.16 (0.64)
-0.02
0.13 (0.55)
0.14 (0.59)
-0.02
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.55)
0.00 (0.59)
0.00
HU - Colonoscopy; n (%)
157 (3.5%)
172 (3.4%)
0.01
223 (3.5%)
200 (4.2%)
-0.04
475 (3.7%)
282 (3.4%)
0.02
855 (3.6%)
654 (3.6%)
0.00
HU - Flu vaccine; n (%)
641 (14.2%)
728 (14.3%)
0.00
615 (9.7%)
472 (9.9%)
-0.01
3,737 (29.2%)
2,445 (29.4%)
0.00
4,993 (21.1%)
3,645 (20.0%)
0.03
HU - Mammogram; n (%)
346 (7.7%)
422 (8.3%)
-0.02
453 (7.1%)
379 (7.9%)
-0.03
1,175 (9.2%)
733 (8.8%)
0.01
1,974 (8.4%)
1,534 (8.4%)
0.00
HU - PSA test or Prostate exam for DRE; n (%)
387 (8.6%)
401 (7.9%)
0.03
562 (8.9%)
412 (8.6%)
0.01
1,144 (8.9%)
729 (8.8%)
0.00
2,093 (8.9%)
1,542 (8.5%)
0.01
HU - Pap smear; n (%)
186 (4.1%)
140 (2.8%)
0.07
417 (6.6%)
267 (5.6%)
0.04
349 (2.7%)
185 (2.2%)
0.03
952 (4.0%)
592 (3.3%)
0.04
HU - Pneumonia vaccine; n (%)
912 (20.3%)
1,104 (21.7%)
-0.03
661 (10.4%)
640 (13.4%)
-0.09
3,585 (28.0%)
2,718 (32.6%)
-0.10
5,158 (21.8%)
4,462 (24.5%)
-0.06
Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2
...mean (sd)
0.19 (0.07)
0.21 (0.08)
-0.27
0.16 (0.05)
0.17 (0.06)
-0.18
0.21 (0.07)
0.22 (0.08)
-0.13
0.19 (0.07)
0.20 (0.08)
-0.13
...median [IQR]
0.17 [0.14, 0.22]
0.20 [0.15, 0.26]
-0.40
0.15 [0.12, 0.18]
0.16 [0.13, 0.19]
-0.18
0.19 [0.15, 0.25]
0.20 [0.16, 0.26]
-0.13
0.18 (0.07)
0.19 (0.08)
-0.13
CHADS2 score, 180 days
...mean (sd)
0.80 (1.04)
1.18 (1.20)
-0.34
0.60 (0.91)
0.66 (0.98)
-0.06
0.90 (1.03)
0.80 (0.90)
0.10
0.80 (1.00)
0.87 (1.01)
-0.07
...median [IQR]
0.00 [0.00, 1.00]
1.00 [0.00, 2.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
0.54 (1.00)
0.74 (1.01)
-0.20
HU - Number of Hospitalizations
Appendix B

...mean (sd)
1.18 (0.55)
1.25 (0.66)
-0.12
1.13 (0.41)
1.15 (0.46)
-0.05
1.30 (0.73)
1.31 (0.67)
-0.01
1.23 (0.63)
1.25 (0.62)
-0.03
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 (0.63)
1.00 (0.62)
0.00
HU - Number of hospital days
...mean (sd)
5.54 (7.53)
7.01 (9.17)
-0.18
4.83 (6.87)
5.47 (8.41)
-0.08
6.63 (8.92)
6.78 (7.60)
-0.02
5.94 (8.16)
6.50 (8.28)
-0.07
...median [IQR]
4.00 [3.00, 6.00]
4.00 [3.00, 7.00]
0.00
3.00 [2.00, 5.00]
4.00 [2.00, 5.00]
-0.13
4.00 [3.00, 7.00]
4.00 [3.00, 7.00]
0.00
3.73 (8.16)
4.00 (8.28)
-0.03
HU - Number of Emergency Department (ED) visits
...mean (sd)
1.66 (2.41)
1.83 (2.28)
-0.07
3.07 (4.52)
3.35 (5.71)
-0.05
2.26 (8.21)
2.12 (3.30)
0.02
2.36 (6.56)
2.36 (3.87)
0.00
...median [IQR]
1.00 [1.00, 2.00]
1.00 [1.00, 2.00]
0.00
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.00
1.00 [1.00, 3.00]
1.00 [1.00, 3.00]
0.00
1.27 (6.56)
1.26 (3.87)
0.00
HU - Number of internal medicine/family medicine visits
...mean (sd)
9.55 (14.11)
12.64 (16.03)
-0.20
5.11 (7.96)
5.61 (9.10)
-0.06
10.96 (11.24)
11.46 (10.71)
-0.05
9.12 (11.10)
10.25 (12.09)
-0.10
...median [IQR]
5.00 [2.00, 12.00]
8.00 [3.00, 16.00]
-0.20
3.00 [1.00, 6.00]
3.00 [1.00, 7.00]
0.00
8.00 [4.00, 14.00]
9.00 [5.00, 15.00]
-0.09
6.09 (11.10)
7.14 (12.09)
-0.09
HU - Number of different/distinct medication prescriptions
...mean (sd)
7.95 (5.27)
9.08 (5.48)
-0.21
7.55 (5.18)
8.25 (5.32)
-0.13
9.54 (5.35)
10.02 (5.31)
-0.09
8.70 (5.29)
9.29 (5.36)
-0.11
...median [IQR]
7.00 [4.00, 11.00]
8.00 [5.00, 12.00]
-0.19
6.00 [4.00, 10.00]
7.00 [4.00, 11.00]
-0.19
9.00 [6.00, 12.00]
9.00 [6.00, 13.00]
0.00
7.81 (5.29)
8.19 (5.36)
-0.07
HU Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level
...mean (sd)
12.59 (13.28)
18.31 (15.13)
-0.40
8.39 (9.96)
11.92 (11.17)
-0.33
14.89 (13.11)
17.85 (13.14)
-0.23
12.71 (12.38)
16.42 (13.26)
-0.29
...median [IQR]
9.00 [1.00, 19.00]
15.00 [7.00, 26.00]
-0.42
5.00 [0.00, 14.00]
11.00 [2.00, 18.00]
-0.57
13.00 [4.00, 22.00]
16.00 [8.00, 25.00] -0.23
10.09 (12.38)
14.41 (13.26)
-0.34
HU - Number of Office visits
...mean (sd)
4.38 (4.11)
4.56 (4.04)
-0.04
4.32 (4.06)
4.47 (4.13)
-0.04
11.38 (13.70)
11.16 (11.88)
0.02
8.15 (10.45)
7.56 (8.58)
0.06
...median [IQR]
3.00 [1.00, 6.00]
4.00 [2.00, 6.00]
-0.25
3.00 [1.00, 6.00]
4.00 [2.00, 6.00]
-0.24
8.00 [3.00, 15.00]
8.00 [3.00, 15.00]
0.00
5.71 (10.45)
5.83 (8.58)
-0.01
HU - Number of Cardiologist visits
...mean (sd)
2.32 (3.74)
2.91 (4.20)
-0.15
0.61 (1.84)
0.74 (2.03)
-0.07
2.52 (3.93)
2.83 (4.43)
-0.07
1.97 (3.45)
2.30 (3.87)
-0.09
...median [IQR]
1.00 [0.00, 3.00]
1.00 [0.00, 4.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 1.00]
0.00
1.00 [0.00, 3.00]
1.00 [0.00, 4.00]
0.00
0.73 (3.45)
0.74 (3.87)
0.00
HU - Number electrocardiograms
...mean (sd)
1.79 (1.98)
2.06 (2.21)
-0.13
0.75 (1.19)
0.80 (1.23)
-0.04
1.93 (2.08)
1.99 (1.96)
-0.03
1.59 (1.86)
1.70 (1.88)
-0.06
...median [IQR]
1.00 [1.00, 2.00]
2.00 [1.00, 3.00]
-0.48
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
1.00 [1.00, 3.00]
2.00 [1.00, 3.00]
-0.49
0.73 (1.86)
1.47 (1.88)
-0.40
HU - Number of echocardiograms
...mean (sd)
1.07 (3.06)
1.16 (3.08)
-0.03
0.61 (0.71)
0.70 (0.77)
-0.12
0.73 (0.93)
0.80 (0.97)
-0.07
0.76 (1.54)
0.87 (1.80)
-0.07
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
1.00 (1.54)
1.00 (1.80)
0.00
HU - Number of neurologist visits
...mean (sd)
0.53 (2.11)
0.71 (2.70)
-0.07
0.30 (1.41)
0.43 (2.85)
-0.06
0.51 (2.05)
0.59 (2.52)
-0.03
0.46 (1.91)
0.58 (2.66)
-0.05
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (1.91)
0.00 (2.66)
0.00
HU - Fecal occult blood (FOB) test; n (%)
122 (2.7%)
114 (2.2%)
0.03
176 (2.8%)
124 (2.6%)
0.01
308 (2.4%)
221 (2.7%)
-0.02
606 (2.6%)
459 (2.5%)
0.00
HU - Number of PT or aPTTt tests
...mean (sd)
0.44 (1.15)
0.51 (1.26)
-0.06
0.43 (1.04)
0.45 (1.18)
-0.02
0.26 (0.65)
0.25 (0.65)
0.02
0.34 (0.88)
0.38 (1.00)
-0.04
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.88)
0.00 (1.00)
0.00
N of days in database anytime prior
...mean (sd)
1,791.06 (1,353.03)
1,916.04 (1,463.00)
-0.09
2,164.61 (1,520.58) 2,298.62 (1,602.77)
-0.09
715.30 (383.18)
742.93 (368.81)
-0.07
1309.06 (1023.95)
1479.61 (1155.63) -0.16
...median [IQR]
1,406.00 [684.00, 2,6341,475.00 [741.00, 2,799 -0.05
1,847.00 [812.00, 3, 2,022.00 [872.50, 3,42 -0.11
644.00 [486.00, 830 675.00 [518.00, 890-0.08
1111.92 (1023.95)
1252.55 (1155.63) -0.13
Socioeconomic Status Proxy Variables
SES - Mean Copay for per prescription cost (charges in U.S. $)
...mean (sd)
18.46 (26.31)
18.38 (27.06)
0.00
12.27 (21.28)
11.83 (19.16)
0.02
18.70 (36.80)
19.70 (48.22)
-0.02
16.93 (31.41)
17.26 (36.95)
-0.01
...median [IQR]
12.11 [4.29, 24.08]
10.72 [4.02, 23.29]
17.55
7.50 [0.96, 15.55]
7.30 [1.00, 15.00]
0.01
9.07 [2.67, 22.95]
9.93 [2.88, 24.06]
-0.02
9.23 (31.41)
9.46 (36.95)
-0.01
...Missing; n (%)
479 (10.6%)
370 (7.3%)
0.12
1,021 (16.1%)
1,094 (22.9%)
-0.17
1,930 (15.1%)
453 (5.4%)
0.32
3,430 (14.5%)
1,917 (10.5%)
0.12
SES - Copay: pharmacy cost
...mean (sd)
161.56 (270.51)
184.68 (336.22)
-0.08
99.03 (224.48)
91.21 (179.55)
0.04
181.04 (376.97)
226.18 (755.70)
-0.08
155.32 (323.07)
179.12 (549.07)
-0.05
...median [IQR]
65.00 [8.28, 207.12]
72.61 [14.35, 228.00]
-0.02
24.78 [0.00, 117.74] 16.90 [0.00, 107.17]
0.04
55.69 [2.93, 202.24] 79.75 [17.63, 254.7 -0.04
49.17 (323.07)
61.24 (549.07)
-0.03
SES - Business type: Commercial vs Medicare
...Commerical; n (%)
2,178 (48.4%)
1,399 (27.5%)
0.44
4,978 (78.5%)
3,523 (73.7%)
0.11
0 (0.0%)
0 (0.0%)
0.00
7,156 (30.3%)
4,922 (27.0%)
0.07
...Medicare; n (%)
2,321 (51.6%)
3,688 (72.5%)
-0.44
1,361 (21.5%)
1,258 (26.3%)
-0.11
0 (0.0%)
0 (0.0%)
0.00
3,682 (15.6%)
4,946 (27.2%)
-0.29
SES - Low income indicator; n (%)
615 (13.7%)
931 (18.3%)
-0.13
0 (0.0%)
0 (0.0%)
0.00
0 (0.0%)
0 (0.0%)
0.00
615 (2.6%)
931 (5.1%)
-0.13
SES - Urban vs Rural (MSA variable)
0.00
...Urban; n (%)
0 (0.0%)
0 (0.0%)
0.00
4,492 (70.9%)
3,008 (62.9%)
0.17
0 (0.0%)
0 (0.0%)
0.00
4,492 (19.0%)
3,008 (16.5%)
0.07
...Rural; n (%)
0 (0.0%)
0 (0.0%)
0.00
407 (6.4%)
557 (11.7%)
-0.19
0 (0.0%)
0 (0.0%)
0.00
4,492 (19.0%)
557 (3.1%)
0.52
...Unknown/Missing; n (%)
0 (0.0%)
0 (0.0%)
0.00
1,440 (22.7%)
1,216 (25.4%)
-0.06
0 (0.0%)
0 (0.0%)
0.00
1,440 (6.1%)
1,216 (6.7%)
-0.02
SES - Dual Status; n (%)
0 (0.0%)
0 (0.0%)
0.00
0 (0.0%)
0 (0.0%)
0.00
4,066 (31.8%)
2,524 (30.3%)
0.03
4,066 (17.2%)
2,524 (13.9%)
0.09
SES - Generic name prescription - unique value
...mean (sd)
7.95 (5.27)
9.08 (5.48)
-0.21
7.55 (5.18)
8.25 (5.32)
-0.13
9.54 (5.35)
10.02 (5.31)
-0.09
8.70 (5.29)
9.29 (5.36)
-0.11
...median [IQR]
7.00 [4.00, 11.00]
8.00 [5.00, 12.00]
-0.19
6.00 [4.00, 10.00]
7.00 [4.00, 11.00]
-0.19
9.00 [6.00, 12.00]
9.00 [6.00, 13.00]
0.00
7.81 (5.29)
8.19 (5.36)
-0.07
SES - Brand name prescription - unique value
...mean (sd)
8.04 (5.38)
9.17 (5.59)
-0.21
7.64 (5.28)
8.34 (5.42)
-0.13
9.65 (5.46)
10.13 (5.41)
-0.09
8.80 (5.40)
9.39 (5.46)
-0.11
...median [IQR]
7.00 [4.00, 11.00]
8.00 [5.00, 12.00]
-0.18
6.00 [4.00, 10.00]
7.00 [4.00, 11.00]
-0.19
9.00 [6.00, 13.00]
9.00 [6.00, 13.00]
0.00
7.81 (5.40)
8.19 (5.46)
-0.07
Appendix B

Variable
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Rivaroxaban
Apixaban
St. Diff
Number of patients
3,032
3,032
3,694
3,694
7,476
7,476
14,202
14,202
Age
...mean (sd)
65.10 (16.13)
65.21 (16.49)
-0.006743918
55.41 (15.52)
55.52 (15.87)
-0.007008166
73.18 (12.05)
73.20 (12.34)
-0.0016399
66.83 (13.95)
66.90 (14.27)
-0.004960702
...median [IQR]
68.00 [56.00, 77.00]
68.00 [55.00, 78.00]
0
56.00 [46.00, 64.00]56.00 [45.00, 64.00]
0
74.00 [68.00, 81.00] 74.00 [68.00, 82.00 0
68.04 (13.95)
68.04 (14.27)
0
Age categories
...18 - 54; n (%)
704 (23.2%)
740 (24.4%)
-0.028181129
1,653 (44.7%)
1,662 (45.0%)
-0.00603211
601 (8.0%)
586 (7.8%)
0.007414632
2,958 (20.8%)
2,988 (21.0%)
-0.004918922
...55 - 64; n (%)
521 (17.2%)
498 (16.4%)
0.021399249
1,191 (32.2%)
1,170 (31.7%)
0.010723258
576 (7.7%)
604 (8.1%)
-0.01482957
2,288 (16.1%)
2,272 (16.0%)
0.002724285
...65 - 74; n (%)
834 (27.5%)
784 (25.9%)
0.036172905
407 (11.0%)
408 (11.0%)
0
2,648 (35.4%)
2,668 (35.7%)
-0.006267468
3,889 (27.4%)
3,860 (27.2%)
0.004489341
...>= 75; n (%)
973 (32.1%)
1,010 (33.3%)
-0.025582051
443 (12.0%)
454 (12.3%)
-0.009182624
3,651 (48.8%)
3,618 (48.4%)
0.008003202
5,067 (35.7%)
5,082 (35.8%)
-0.002086535
Calendar Year (2014-2020)
...2014; n (%)
26 (0.9%)
23 (0.8%)
0.010893078
63 (1.7%)
69 (1.9%)
-0.015043548
183 (2.4%)
175 (2.3%)
0.006601343
272 (1.9%)
267 (1.9%)
0
...2015; n (%)
187 (6.2%)
193 (6.4%)
-0.008231777
450 (12.2%)
464 (12.6%)
-0.012136825
1,518 (20.3%)
1,558 (20.8%)
-0.012374437
2,155 (15.2%)
2,215 (15.6%)
-0.011082076
...2016; n (%)
477 (15.7%)
472 (15.6%)
0.002752331
891 (24.1%)
861 (23.3%)
0.018813637
2,825 (37.8%)
2,838 (38.0%)
-0.004122546
4,193 (29.5%)
4,171 (29.4%)
0.002193861
...2017; n (%)
621 (20.5%)
630 (20.8%)
-0.007411238
897 (24.3%)
881 (23.8%)
0.011699196
2,950 (39.5%)
2,905 (38.9%)
0.012290361
4,468 (31.5%)
4,416 (31.1%)
0.00862608
...2018; n (%)
797 (26.3%)
777 (25.6%)
0.015969108
772 (20.9%)
788 (21.3%)
-0.009803598
0 (0.0%)
0 (0.0%)
0
1,569 (11.0%)
1,565 (11.0%)
0
...2019; n (%)
704 (23.2%)
725 (23.9%)
-0.016497898
621 (16.8%)
631 (17.1%)
-0.00799595
0 (0.0%)
0 (0.0%)
0
1,325 (9.3%)
1,356 (9.5%)
-0.006853375
...2020; n (%)
220 (7.3%)
212 (7.0%)
0.011643529
0 (0.0%)
0 (0.0%)
0
0 (0.0%)
0 (0.0%)
0
220 (1.5%)
212 (1.5%)
0
Race
...White; n (%)
2,141 (70.6%)
2,149 (70.9%)
-0.006594737
0 (0.0%)
0 (0.0%)
0
6,174 (82.6%)
6,188 (82.8%)
-0.005287565
8,315 (58.5%)
8,337 (58.7%)
-0.004060522
...Asian; n (%)
50 (1.6%)
44 (1.5%)
0.008095242
0 (0.0%)
0 (0.0%)
0
72 (1.0%)
66 (0.9%)
0.010309004
122 (0.9%)
110 (0.8%)
0.010893078
...Black; n (%)
445 (14.7%)
457 (15.1%)
-0.011233341
0 (0.0%)
0 (0.0%)
0
938 (12.5%)
951 (12.7%)
-0.006026858
1,383 (9.7%)
1,408 (9.9%)
-0.006726918
...Hispanic; n (%)
245 (8.1%)
235 (7.8%)
0.011090024
0 (0.0%)
0 (0.0%)
0
118 (1.6%)
117 (1.6%)
0
363 (2.6%)
352 (2.5%)
0.006343679
...North American Native; n (%)
0 (0.0%)
0 (0.0%)
0
0 (0.0%)
0 (0.0%)
0
25 (0.3%)
22 (0.3%)
0
25 (0.2%)
22 (0.2%)
0
...Other; n (%)
0 (0.0%)
0 (0.0%)
0
0 (0.0%)
0 (0.0%)
0
66 (0.9%)
57 (0.8%)
0.010893078
66 (0.5%)
57 (0.4%)
0.014941191
...Unknown/Missing; n (%)
151 (5.0%)
147 (4.8%)
0.00926502
0 (0.0%)
0 (0.0%)
0
83 (1.1%)
75 (1.0%)
0.009810761
234 (1.6%)
222 (1.6%)
0
Gender
...Males; n (%)
1,404 (46.3%)
1,427 (47.1%)
-0.016035478
1,969 (53.3%)
1,953 (52.9%)
0.008015485
2,990 (40.0%)
2,968 (39.7%)
0.006127613
6,363 (44.8%)
6,348 (44.7%)
0.002011118
...Females; n (%)
1,628 (53.7%)
1,605 (52.9%)
0.016035478
1,725 (46.7%)
1,741 (47.1%)
-0.008015485
4,486 (60.0%)
4,508 (60.3%)
-0.006127613
7,839 (55.2%)
7,854 (55.3%)
-0.002011118
Region
...Northeast; n (%)
353 (11.6%)
341 (11.2%)
0.012586336
737 (20.0%)
751 (20.3%)
-0.007479099
1,451 (19.4%)
1,445 (19.3%)
0.002531382
2,541 (17.9%)
2,537 (17.9%)
0
...South; n (%)
1,330 (43.9%)
1,347 (44.4%)
-0.010069283
1,643 (44.5%)
1,637 (44.3%)
0.004025335
3,275 (43.8%)
3,282 (43.9%)
-0.002015304
6,248 (44.0%)
6,266 (44.1%)
-0.002014314
...Midwest; n (%)
676 (22.3%)
678 (22.4%)
-0.00240044
848 (23.0%)
849 (23.0%)
0
1,624 (21.7%)
1,629 (21.8%)
-0.002423977
3,148 (22.2%)
3,156 (22.2%)
0
...West; n (%)
667 (22.0%)
662 (21.8%)
0.004835971
459 (12.4%)
447 (12.1%)
0.009150276
1,119 (15.0%)
1,112 (14.9%)
0.002804418
2,245 (15.8%)
2,221 (15.6%)
0.005497535
...Unknown+missing; n (%)
6 (0.2%)
4 (0.1%)
0.025841432
7 (0.2%)
10 (0.3%)
-0.020026051
7 (0.1%)
8 (0.1%)
0
20 (0.1%)
22 (0.2%)
-0.025841432
Combined comorbidity score, 180 days
...mean (sd)
3.08 (2.42)
3.13 (2.42)
-0.020661157
1.97 (1.78)
1.98 (1.76)
-0.005649627
2.51 (2.14)
2.52 (2.16)
-0.004651112
2.49 (2.12)
2.51 (2.12)
-0.009433962
...median [IQR]
3.00 [1.00, 4.00]
3.00 [1.00, 5.00]
0
2.00 [1.00, 3.00]
2.00 [1.00, 3.00]
0
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0
2.21 (2.12)
2.21 (2.12)
0
Lifestyle Factors
Lifestyle - Smoking ; n (%)
1,128 (37.2%)
1,123 (37.0%)
0.004140175
752 (20.4%)
742 (20.1%)
0.007465285
3,003 (40.2%)
3,057 (40.9%)
-0.014257314
4,883 (34.4%)
4,922 (34.7%)
-0.006308768
Lifestyle - Drug abuse or dependence; n (%)
143 (4.7%)
152 (5.0%)
-0.013965503
109 (3.0%)
101 (2.7%)
0.018029973
275 (3.7%)
287 (3.8%)
-0.005263632
527 (3.7%)
540 (3.8%)
-0.005263632
Lifestyle - Alcohol abuse or dependence ; n (%)
128 (4.2%)
117 (3.9%)
0.01521892
97 (2.6%)
96 (2.6%)
0
232 (3.1%)
233 (3.1%)
0
457 (3.2%)
446 (3.1%)
0.005725279
Comorbidities
DM - Diabetic Retinopathy; n (%)
36 (1.2%)
32 (1.1%)
0.009379237
20 (0.5%)
23 (0.6%)
-0.013521541
71 (0.9%)
78 (1.0%)
-0.010309004
127 (0.9%)
133 (0.9%)
0
DM - Diabetic Neuropathy; n (%)
163 (5.4%)
172 (5.7%)
-0.013103373
108 (2.9%)
107 (2.9%)
0
361 (4.8%)
376 (5.0%)
-0.00926502
632 (4.5%)
655 (4.6%)
-0.004798523
DM - Diabetic Nephropathy; n (%)
136 (4.5%)
140 (4.6%)
-0.004798523
61 (1.7%)
68 (1.8%)
-0.00762637
249 (3.3%)
245 (3.3%)
0
446 (3.1%)
453 (3.2%)
-0.005725279
DM - Diabetes with peripheral circulatory disorders; n (%)
6 (0.2%)
6 (0.2%)
0
7 (0.2%)
7 (0.2%)
0
23 (0.3%)
24 (0.3%)
0
036 (0.3%)
37 (0.3%)
0
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)
35 (1.2%)
34 (1.1%)
0.009379237
16 (0.4%)
14 (0.4%)
0
91 (1.2%)
95 (1.3%)
-0.009000794
142 (1.0%)
143 (1.0%)
0
DM - Diabetes with unspecified complications; n (%)
52 (1.7%)
52 (1.7%)
0
555 (15.0%)
573 (15.5%)
-0.013908354
102 (1.4%)
106 (1.4%)
0
709 (5.0%)
731 (5.1%)
-0.004566758
DM - Diabetes mellitus without mention of complications; n (%)
600 (19.8%)
603 (19.9%)
-0.002507081
46 (1.2%)
52 (1.4%)
-0.01765699
1,709 (22.9%)
1,734 (23.2%)
-0.007123349
2,355 (16.6%)
2,389 (16.8%)
-0.005362296
CV - Hypertension; n (%)
1,947 (64.2%)
1,945 (64.1%)
0.002085246
1,885 (51.0%)
1,859 (50.3%)
0.014001526
5,908 (79.0%)
5,907 (79.0%)
0
9,740 (68.6%)
9,711 (68.4%)
0.004305568
CV - Hyperlipidemia; n (%)
1,426 (47.0%)
1,422 (46.9%)
0.002003732
1,264 (34.2%)
1,249 (33.8%)
0.008444082
4,068 (54.4%)
4,081 (54.6%)
-0.004016307
6,758 (47.6%)
6,752 (47.5%)
0.002002406
CV -Acute MI; n (%)
164 (5.4%)
153 (5.0%)
0.018016556
140 (3.8%)
148 (4.0%)
-0.010330986
359 (4.8%)
360 (4.8%)
0
663 (4.7%)
661 (4.7%)
0
CV - ACS/unstable angina; n (%)
103 (3.4%)
103 (3.4%)
0
94 (2.5%)
95 (2.6%)
-0.006343679
273 (3.7%)
268 (3.6%)
0.00533248
470 (3.3%)
466 (3.3%)
0
CV - Old MI; n (%)
129 (4.3%)
137 (4.5%)
-0.00975169
60 (1.6%)
66 (1.8%)
-0.015471833
380 (5.1%)
376 (5.0%)
0.004566758
569 (4.0%)
579 (4.1%)
-0.005072843
CV - Stable angina; n (%)
77 (2.5%)
82 (2.7%)
-0.012568181
72 (1.9%)
69 (1.9%)
0
194 (2.6%)
189 (2.5%)
0.006343679
343 (2.4%)
340 (2.4%)
0
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)
475 (15.7%)
471 (15.5%)
0.005511859
333 (9.0%)
342 (9.3%)
-0.010405288
1,549 (20.7%)
1,561 (20.9%)
-0.004927618
2,357 (16.6%)
2,374 (16.7%)
-0.002684358
CV - Other atherosclerosis; n (%)
30 (1.0%)
34 (1.1%)
-0.009810761
15 (0.4%)
14 (0.4%)
0
57 (0.8%)
66 (0.9%)
-0.010893078
102 (0.7%)
114 (0.8%)
-0.011590746
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%)
150 (4.9%)
140 (4.6%)
0.01410434
48 (1.3%)
50 (1.4%)
-0.008665401
566 (7.6%)
564 (7.5%)
0.003785069
764 (5.4%)
754 (5.3%)
0.004443896
CV - Ischemic stroke; n (%)
192 (6.3%)
179 (5.9%)
0.016713886
162 (4.4%)
149 (4.0%)
0.019942251
540 (7.2%)
565 (7.6%)
-0.015280984
894 (6.3%)
893 (6.3%)
0
CV - Hemorrhagic stroke; n (%)
7 (0.2%)
7 (0.2%)
0
2 (0.1%)
2 (0.1%)
0
11 (0.1%)
14 (0.2%)
-0.025841432
020 (0.1%)
23 (0.2%)
-0.025841432
CV - TIA; n (%)
53 (1.7%)
49 (1.6%)
0.007850082
52 (1.4%)
50 (1.4%)
0
159 (2.1%)
148 (2.0%)
0.007057056
264 (1.9%)
247 (1.7%)
0.015043548
CV - Other cerebrovascular disease; n (%)
99 (3.3%)
97 (3.2%)
0.005639422
74 (2.0%)
73 (2.0%)
0
246 (3.3%)
254 (3.4%)
-0.005557486
419 (3.0%)
424 (3.0%)
0
CV - Late effects of cerebrovascular disease; n (%)
78 (2.6%)
73 (2.4%)
0.012810515
43 (1.2%)
36 (1.0%)
0.019175887
228 (3.0%)
230 (3.1%)
-0.005815379
349 (2.5%)
339 (2.4%)
0.00646853
CV - Heart failure (CHF); n (%)
433 (14.3%)
439 (14.5%)
-0.005696572
308 (8.3%)
326 (8.8%)
-0.01788185
1,253 (16.8%)
1,266 (16.9%)
-0.002671587
1,994 (14.0%)
2,031 (14.3%)
-0.008607498
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%)
269 (8.9%)
270 (8.9%)
0
165 (4.5%)
173 (4.7%)
-0.009547328
664 (8.9%)
681 (9.1%)
-0.006988608
1,098 (7.7%)
1,124 (7.9%)
-0.007457963
CV - Other cardiac dysrhythmia; n (%)
469 (15.5%)
470 (15.5%)
0
482 (13.0%)
471 (12.8%)
0.005966615
1,151 (15.4%)
1,177 (15.7%)
-0.008278658
2,102 (14.8%)
2,118 (14.9%)
-0.002812191
CV - Cardiac conduction disorders; n (%)
271 (8.9%)
280 (9.2%)
-0.010456866
199 (5.4%)
195 (5.3%)
0.004443896
680 (9.1%)
657 (8.8%)
0.010509348
1,150 (8.1%)
1,132 (8.0%)
0.003675589
CV - Other CVD; n (%)
954 (31.5%)
952 (31.4%)
0.002153705
934 (25.3%)
917 (24.8%)
0.011539515
1,999 (26.7%)
2,016 (27.0%)
-0.00676931
3,887 (27.4%)
3,885 (27.4%)
0
CV Medications - ACE inhibitors; n (%)
674 (22.2%)
675 (22.3%)
-0.00240428
678 (18.4%)
689 (18.7%)
-0.007718039
2,019 (27.0%)
2,047 (27.4%)
-0.008989059
3,371 (23.7%)
3,411 (24.0%)
-0.007039548
CV Medications - ARBs; n (%)
449 (14.8%)
451 (14.9%)
-0.002812191
449 (12.2%)
449 (12.2%)
0
1,341 (17.9%)
1,351 (18.1%)
-0.00520581
2,239 (15.8%)
2,251 (15.8%)
0
CV Medications - Alpha blockers; n (%)
251 (8.3%)
265 (8.7%)
-0.014343368
216 (5.8%)
222 (6.0%)
-0.008488151
769 (10.3%)
756 (10.1%)
0.006608366
1,236 (8.7%)
1,243 (8.8%)
-0.003538997
CV Medications - Beta blockers; n (%)
733 (24.2%)
714 (23.5%)
0.016426065
732 (19.8%)
720 (19.5%)
0.007550055
2,528 (33.8%)
2,539 (34.0%)
-0.004225036
3,993 (28.1%)
3,973 (28.0%)
0.002225966
CV Medications - Loop Diuretics; n (%)
355 (11.7%)
350 (11.5%)
0.006245641
259 (7.0%)
267 (7.2%)
-0.007787468
1,315 (17.6%)
1,316 (17.6%)
0
1,929 (13.6%)
1,933 (13.6%)
0
CV Medications - Other diuretics; n (%)
74 (2.4%)
73 (2.4%)
0
84 (2.3%)
83 (2.2%)
0.006742995
227 (3.0%)
225 (3.0%)
0
385 (2.7%)
381 (2.7%)
0
CV Medications - Use of nitrates; n (%)
71 (2.3%)
68 (2.2%)
0.006742995
64 (1.7%)
63 (1.7%)
0
379 (5.1%)
365 (4.9%)
0.009176726
514 (3.6%)
496 (3.5%)
0.005404261
CV Medications - Use of statins; n (%)
967 (31.9%)
950 (31.3%)
0.012905912
936 (25.3%)
898 (24.3%)
0.023157643
3,142 (42.0%)
3,111 (41.6%)
0.008109871
5,045 (35.5%)
4,959 (34.9%)
0.012563221
CV Medications - Use of other lipid-lowering drugs; n (%)
108 (3.6%)
106 (3.5%)
0.005404261
151 (4.1%)
137 (3.7%)
0.0206628
355 (4.7%)
364 (4.9%)
-0.009356117
614 (4.3%)
607 (4.3%)
0
CV Medications - calcium channel blockers; n (%)
608 (20.1%)
617 (20.3%)
-0.004981432
570 (15.4%)
553 (15.0%)
0.011141586
1,887 (25.2%)
1,905 (25.5%)
-0.00689636
3,065 (21.6%)
3,075 (21.7%)
-0.002428018
CV Medications - Use of low weight molecular heparins; n (%)
60 (2.0%)
58 (1.9%)
0.007232055
80 (2.2%)
85 (2.3%)
-0.006742995
137 (1.8%)
129 (1.7%)
0.00762637
277 (2.0%)
272 (1.9%)
0.007232055
Other Comorbidity - Osteoporosis; n (%)
293 (9.7%)
284 (9.4%)
0.010207536
120 (3.2%)
116 (3.1%)
0.005725279
959 (12.8%)
962 (12.9%)
-0.002988238
1,372 (9.7%)
1,362 (9.6%)
0.00338667
Other Comorbidity - Dementia; n (%)
414 (13.7%)
419 (13.8%)
-0.002903819
173 (4.7%)
161 (4.4%)
0.014395901
1,321 (17.7%)
1,317 (17.6%)
0.002622987
1,908 (13.4%)
1,897 (13.4%)
0
Other Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland ; n (%)
653 (21.5%)
626 (20.6%)
0.022078362
553 (15.0%)
574 (15.5%)
-0.013908354
694 (9.3%)
700 (9.4%)
-0.003434875
1,900 (13.4%)
1,900 (13.4%)
0
Other Comorbidity - Edema; n (%)
703 (23.2%)
695 (22.9%)
0.007123349
596 (16.1%)
592 (16.0%)
0.002724285
1,352 (18.1%)
1,345 (18.0%)
0.002600083
2,651 (18.7%)
2,632 (18.5%)
0.005139996
Other Comorbidity - Depression; n (%)
600 (19.8%)
590 (19.5%)
0.007550055
484 (13.1%)
469 (12.7%)
0.011933389
1,562 (20.9%)
1,560 (20.9%)
0
2,646 (18.6%)
2,619 (18.4%)
0.005150706
Other Comorbidity - Anxiety; n (%)
665 (21.9%)
661 (21.8%)
0.002419971
607 (16.4%)
600 (16.2%)
0.005414708
1,565 (20.9%)
1,540 (20.6%)
0.007398021
2,837 (20.0%)
2,801 (19.7%)
0.00752129
Other Comorbidity - Pneumonia; n (%)
551 (18.2%)
551 (18.2%)
0
502 (13.6%)
531 (14.4%)
-0.023057149
1,324 (17.7%)
1,315 (17.6%)
0.002622987
2,377 (16.7%)
2,397 (16.9%)
-0.005349525
Other Comorbidity - COPD; n (%)
597 (19.7%)
626 (20.6%)
-0.022438553
344 (9.3%)
356 (9.6%)
-0.010255736
1,780 (23.8%)
1,804 (24.1%)
-0.007029454
2,721 (19.2%)
2,786 (19.6%)
-0.010115728
Other Comorbidity - Asthma; n (%)
328 (10.8%)
328 (10.8%)
0
369 (10.0%)
368 (10.0%)
0
888 (11.9%)
892 (11.9%)
0
1,585 (11.2%)
1,588 (11.2%)
0
Other Comorbidity - Acute renal disease; n (%)
406 (13.4%)
408 (13.5%)
-0.002930932
307 (8.3%)
313 (8.5%)
-0.007210169
1,049 (14.0%)
1,041 (13.9%)
0.002886276
1,762 (12.4%)
1,762 (12.4%)
0
Other Comorbidity CKD Stage 1; n (%)
10 (0.3%)
7 (0.2%)
0.020026051
5 (0.1%)
4 (0.1%)
0
21 (0.3%)
22 (0.3%)
0
36 (0.3%)
33 (0.2%)
0.020026051
Other Comorbidity - CKD Stage 2; n (%)
64 (2.1%)
72 (2.4%)
-0.020229904
27 (0.7%)
27 (0.7%)
0
131 (1.8%)
125 (1.7%)
0.00762637
222 (1.6%)
224 (1.6%)
0
Other Comorbidity - CKD Stage 3; n (%)
265 (8.7%)
270 (8.9%)
-0.007059825
112 (3.0%)
119 (3.2%)
-0.011539699
638 (8.5%)
658 (8.8%)
-0.010672474
1,015 (7.1%)
1,047 (7.4%)
-0.011569179
Pooled 
Optum 
MarketScan
Matched
Medicare
Appendix B

Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%)
200 (6.6%)
194 (6.4%)
0.008112806
90 (2.4%)
100 (2.7%)
-0.019031802
518 (6.9%)
516 (6.9%)
0
808 (5.7%)
810 (5.7%)
0
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)
297 (9.8%)
293 (9.7%)
0.003371124
210 (5.7%)
220 (6.0%)
-0.012783272
607 (8.1%)
607 (8.1%)
0
1,114 (7.8%)
1,120 (7.9%)
-0.003718076
Other Comorbidity - Hypertensive nephropathy; n (%)
289 (9.5%)
295 (9.7%)
-0.006789107
133 (3.6%)
138 (3.7%)
-0.00533248
852 (11.4%)
851 (11.4%)
0
1,274 (9.0%)
1,284 (9.0%)
0
Other Comorbidity - Obstructive sleep apnea; n (%)
260 (8.6%)
273 (9.0%)
-0.014119914
399 (10.8%)
389 (10.5%)
0.009725329
552 (7.4%)
550 (7.4%)
0
1,211 (8.5%)
1,212 (8.5%)
0
Other Comorbidity - Osteoarthritis; n (%)
870 (28.7%)
898 (29.6%)
-0.019804989
717 (19.4%)
739 (20.0%)
-0.015085952
2,532 (33.9%)
2,528 (33.8%)
0.002113275
4,119 (29.0%)
4,165 (29.3%)
-0.006601375
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)
2,025 (66.8%)
2,049 (67.6%)
-0.017040573
2,284 (61.8%)
2,264 (61.3%)
0.010278117
4,654 (62.3%)
4,631 (61.9%)
0.008245145
8,963 (63.1%)
8,944 (63.0%)
0.002071813
Other Comorbidity - Dorsopathies; n (%)
1,039 (34.3%)
1,052 (34.7%)
-0.008414603
1,079 (29.2%)
1,089 (29.5%)
-0.00658815
2,509 (33.6%)
2,516 (33.7%)
-0.002116349
4,627 (32.6%)
4,657 (32.8%)
-0.004263336
Other Comorbidity - Fractures; n (%)
331 (10.9%)
342 (11.3%)
-0.012733753
298 (8.1%)
296 (8.0%)
0.003675589
750 (10.0%)
746 (10.0%)
0
1,379 (9.7%)
1,384 (9.7%)
0
Other Comorbidity - Falls; n (%)
403 (13.3%)
408 (13.5%)
-0.005871114
174 (4.7%)
184 (5.0%)
-0.013965503
395 (5.3%)
378 (5.1%)
0.009008004
972 (6.8%)
970 (6.8%)
0
Other Comorbidity - Sleep Disorder; n (%)
92 (3.0%)
97 (3.2%)
-0.011539699
137 (3.7%)
137 (3.7%)
0
267 (3.6%)
275 (3.7%)
-0.00533248
496 (3.5%)
509 (3.6%)
-0.005404261
Other Comorbidity - Delirium; n (%)
211 (7.0%)
203 (6.7%)
0.011876602
105 (2.8%)
94 (2.5%)
0.018678813
520 (7.0%)
519 (6.9%)
0.003932333
836 (5.9%)
816 (5.7%)
0.008556468
Other Comorbidity - Psychosis; n (%)
107 (3.5%)
117 (3.9%)
-0.021191923
47 (1.3%)
43 (1.2%)
0.009000794
386 (5.2%)
370 (4.9%)
0.013700558
540 (3.8%)
530 (3.7%)
0.005263632
Procedures
Procedure - Hip Surgery; n (%)
33 (1.1%)
33 (1.1%)
0
27 (0.7%)
28 (0.8%)
-0.011590746
86 (1.2%)
79 (1.1%)
0.009379237
146 (1.0%)
140 (1.0%)
0
Medications 
DM Medications - Meglitinides; n (%)
3 (0.1%)
3 (0.1%)
0
2 (0.1%)
4 (0.1%)
0
18 (0.2%)
17 (0.2%)
0
23 (0.2%)
24 (0.2%)
0
DM Medications - AGIs; n (%)
0 (0.0%)
0 (0.0%)
0
1 (0.0%)
1 (0.0%)
0
--
--
--
--
--
--
DM Medications - Insulin; n (%)
137 (4.5%)
129 (4.3%)
0.00975169
20 (0.5%)
21 (0.6%)
-0.013521541
299 (4.0%)
308 (4.1%)
-0.005072843
581 (4.1%)
458 (3.2%)
0.04800597
DM Medications - Glitazones; n (%)
15 (0.5%)
11 (0.4%)
0.014941191
145 (3.9%)
145 (3.9%)
0
49 (0.7%)
43 (0.6%)
0.012444223
209 (1.5%)
199 (1.4%)
0.008365492
DM Medications - 1st and 2nd Generation SUs ; n (%)
140 (4.6%)
142 (4.7%)
-0.004749134
137 (3.7%)
144 (3.9%)
-0.0104606
398 (5.3%)
399 (5.3%)
0
675 (4.8%)
685 (4.8%)
0
DM Medications - DPP-4 Inhibitors; n (%)
49 (1.6%)
42 (1.4%)
0.016454358
75 (2.0%)
75 (2.0%)
0
175 (2.3%)
188 (2.5%)
-0.013067988
299 (2.1%)
305 (2.1%)
0
DM Medications - GLP-1 RA; n (%)
25 (0.8%)
20 (0.7%)
0.011590746
38 (1.0%)
38 (1.0%)
0
38 (0.5%)
40 (0.5%)
0
101 (0.7%)
98 (0.7%)
0
DM Medications - SGLT-2 Inhibitors ; n (%)
27 (0.9%)
21 (0.7%)
0.022452077
42 (1.1%)
44 (1.2%)
-0.009379237
33 (0.4%)
37 (0.5%)
-0.014941191
102 (0.7%)
102 (0.7%)
0
DM Medications - Metformin; n (%)
285 (9.4%)
284 (9.4%)
0
328 (8.9%)
335 (9.1%)
-0.006988608
757 (10.1%)
770 (10.3%)
-0.006608366
1,370 (9.6%)
1,389 (9.8%)
-0.00675776
Other Medications - Use of NSAIDs; n (%)
555 (18.3%)
597 (19.7%)
-0.035692574
822 (22.3%)
851 (23.0%)
-0.016724339
1,508 (20.2%)
1,517 (20.3%)
-0.002488413
2,885 (20.3%)
2,965 (20.9%)
-0.014836086
Other Medications - Use of other hypertension drugs; n (%)
143 (4.7%)
149 (4.9%)
-0.009356117
103 (2.8%)
120 (3.2%)
-0.023450027
458 (6.1%)
476 (6.4%)
-0.012393785
704 (5.0%)
745 (5.2%)
-0.009091097
Other Medications - Digoxin; n (%)
10 (0.3%)
9 (0.3%)
0
8 (0.2%)
10 (0.3%)
-0.020026051
51 (0.7%)
49 (0.7%)
0
69 (0.5%)
68 (0.5%)
0
Other Medications - Use of Anti-arrhythmics; n (%)
12 (0.4%)
15 (0.5%)
-0.014941191
13 (0.4%)
16 (0.4%)
0
36 (0.5%)
36 (0.5%)
0
61 (0.4%)
67 (0.5%)
-0.014941191
Other Medications - Use of antipsychotics; n (%)
195 (6.4%)
198 (6.5%)
-0.004070982
154 (4.2%)
144 (3.9%)
0.01521892
775 (10.4%)
774 (10.4%)
0
1,124 (7.9%)
1,116 (7.9%)
0
Other Medications - Use of dementia meds; n (%)
174 (5.7%)
161 (5.3%)
0.017546054
66 (1.8%)
66 (1.8%)
0
667 (8.9%)
648 (8.7%)
0.007059825
907 (6.4%)
875 (6.2%)
0.008231777
Other Medications - Use of antiparkinsonian meds; n (%)
106 (3.5%)
100 (3.3%)
0.011035921
78 (2.1%)
88 (2.4%)
-0.020229904
427 (5.7%)
442 (5.9%)
-0.008556468
611 (4.3%)
630 (4.4%)
-0.004902461
Other Medications - Use of anxiolytics/hypnotics; n (%)
196 (6.5%)
182 (6.0%)
0.020657013
269 (7.3%)
260 (7.0%)
0.011643529
613 (8.2%)
618 (8.3%)
-0.003634718
1,078 (7.6%)
1,060 (7.5%)
0.003785069
Other Medications - Use of anticonvulsants; n (%)
553 (18.2%)
590 (19.5%)
-0.033243244
525 (14.2%)
504 (13.6%)
0.017344373
1,679 (22.5%)
1,679 (22.5%)
0
2,757 (19.4%)
2,773 (19.5%)
-0.002526433
Other Medications - Use of antidepressants; n (%)
849 (28.0%)
865 (28.5%)
-0.011105971
901 (24.4%)
881 (23.8%)
0.014029188
2,600 (34.8%)
2,592 (34.7%)
0.002100064
4,350 (30.6%)
4,338 (30.5%)
0.002170994
Other Medications - Use of lithium; n (%)
9 (0.3%)
10 (0.3%)
0
15 (0.4%)
12 (0.3%)
0.01693335
41 (0.5%)
39 (0.5%)
0
065 (0.5%)
61 (0.4%)
0.014941191
Other Medications - Use of Benzos; n (%)
467 (15.4%)
472 (15.6%)
-0.005526338
563 (15.2%)
560 (15.2%)
0
1,562 (20.9%)
1,565 (20.9%)
0
2,592 (18.3%)
2,597 (18.3%)
0
Other Medication - Use of CNS stimulants; n (%)
25 (0.8%)
25 (0.8%)
0
54 (1.5%)
62 (1.7%)
-0.015939924
37 (0.5%)
47 (0.6%)
-0.013521541
116 (0.8%)
134 (0.9%)
-0.010893078
Other Medications - Use of opioids; n (%)
1,208 (39.8%)
1,228 (40.5%)
-0.014280199
1,666 (45.1%)
1,658 (44.9%)
0.004020159
3,150 (42.1%)
3,162 (42.3%)
-0.004049587
6,024 (42.4%)
6,048 (42.6%)
-0.004045782
Other Medications - Use of COPD/asthma meds; n (%)
550 (18.1%)
560 (18.5%)
-0.01034497
582 (15.8%)
598 (16.2%)
-0.010911057
1,735 (23.2%)
1,757 (23.5%)
-0.007091277
2,867 (20.2%)
2,915 (20.5%)
-0.007451594
Other Medications - Use of oral corticosteroids; n (%)
837 (27.6%)
877 (28.9%)
-0.028878088
953 (25.8%)
975 (26.4%)
-0.013662146
2,413 (32.3%)
2,401 (32.1%)
0.004280438
4,203 (29.6%)
4,253 (29.9%)
-0.006562313
Other Medications - Use of Sympatomimetic agents; n (%)
44 (1.5%)
39 (1.3%)
0.01702328
99 (2.7%)
109 (3.0%)
-0.018029973
73 (1.0%)
69 (0.9%)
0.010309004
216 (1.5%)
217 (1.5%)
0
Other Medications - Use of bisphosphonates; n (%)
98 (3.2%)
92 (3.0%)
0.011539699
40 (1.1%)
38 (1.0%)
0.009810761
316 (4.2%)
308 (4.1%)
0.005013965
454 (3.2%)
438 (3.1%)
0.005725279
Other Medications - Use of thiazide; n (%)
246 (8.1%)
253 (8.3%)
-0.007289615
233 (6.3%)
245 (6.6%)
-0.012213147
716 (9.6%)
739 (9.9%)
-0.010113486
1,195 (8.4%)
1,237 (8.7%)
-0.010728836
Other Medications - Use of estrogens, progestins, androgens; n (%)
215 (7.1%)
204 (6.7%)
0.015782439
513 (13.9%)
504 (13.6%)
0.008711531
342 (4.6%)
333 (4.5%)
0.004798523
1,070 (7.5%)
1,041 (7.3%)
0.007640325
Healthcare Utilization
HU - Bone mineral density; n (%)
90 (3.0%)
93 (3.1%)
-0.005815379
50 (1.4%)
53 (1.4%)
0
294 (3.9%)
307 (4.1%)
-0.01020634
434 (3.1%)
453 (3.2%)
-0.005725279
HU - Occurrence of creatinine tests ordered ; n (%)
167 (5.5%)
183 (6.0%)
-0.021479316
160 (4.3%)
168 (4.5%)
-0.00975169
526 (7.0%)
533 (7.1%)
-0.003906444
853 (6.0%)
658 (4.6%)
0.062521186
HU - Number of D-dimer tests
...mean (sd)
0.12 (0.36)
0.12 (0.36)
0
0.13 (0.39)
0.13 (0.39)
0
0.11 (0.34)
0.10 (0.34)
0.029411765
0.12 (0.36)
0.11 (0.36)
0.027777778
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 (0.36)
0.00 (0.36)
0
HU - Number of CRP, high-sensitivity CRP tests
...mean (sd)
0.12 (0.52)
0.12 (0.54)
0
0.11 (0.53)
0.11 (0.63)
0
0.15 (0.61)
0.16 (0.65)
-0.015865023
0.13 (0.83)
0.14 (0.62)
-0.013650685
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 (0.83)
0.00 (0.62)
0
HU - Colonoscopy; n (%)
102 (3.4%)
126 (4.2%)
-0.041850988
142 (3.8%)
130 (3.5%)
0.015997896
263 (3.5%)
264 (3.5%)
0
507 (3.6%)
520 (3.7%)
-0.00533248
HU - Flu vaccine; n (%)
446 (14.7%)
423 (14.0%)
0.019967792
352 (9.5%)
354 (9.6%)
-0.003402473
2,224 (29.7%)
2,204 (29.5%)
0.004381258
3,022 (21.3%)
2,981 (21.0%)
0.007346291
HU - Mammogram; n (%)
249 (8.2%)
241 (7.9%)
0.011026916
291 (7.9%)
281 (7.6%)
0.011220031
665 (8.9%)
684 (9.1%)
-0.006988608
1,205 (8.5%)
1,206 (8.5%)
0
HU - PSA test or Prostate exam for DRE; n (%)
253 (8.3%)
256 (8.4%)
-0.003614858
350 (9.5%)
310 (8.4%)
0.038540897
679 (9.1%)
668 (8.9%)
0.006988608
1,282 (9.0%)
1,234 (8.7%)
0.010562758
HU - Pap smear; n (%)
106 (3.5%)
105 (3.5%)
0
225 (6.1%)
225 (6.1%)
0
187 (2.5%)
173 (2.3%)
0.013067988
518 (3.6%)
503 (3.5%)
0.005404261
HU - Pneumonia vaccine; n (%)
685 (22.6%)
668 (22.0%)
0.0144145
465 (12.6%)
472 (12.8%)
-0.006006521
2,451 (32.8%)
2,413 (32.3%)
0.010671113
3,601 (25.4%)
3,553 (25.0%)
0.009213264
Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2
...mean (sd)
0.20 (0.07)
0.20 (0.07)
0
0.16 (0.05)
0.16 (0.05)
0
0.21 (0.07)
0.21 (0.07)
0
0.19 (0.07)
0.19 (0.07)
0
...median [IQR]
0.18 [0.14, 0.23]
0.18 [0.14, 0.23]
0
0.15 [0.12, 0.18]
0.15 [0.13, 0.19]
0
0.20 [0.16, 0.25]
0.20 [0.16, 0.25]
0
0.18 (0.07)
0.18 (0.07)
0
CHADS2 score, 180 days
...mean (sd)
0.89 (1.07)
0.90 (1.08)
-0.009302225
0.58 (0.92)
0.59 (0.94)
-0.010752067
0.79 (0.92)
0.79 (0.93)
0
0.76 (0.95)
0.76 (0.97)
0
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0
0.74 (0.95)
0.74 (0.97)
0
HU - Number of Hospitalizations
...mean (sd)
1.20 (0.57)
1.21 (0.61)
-0.016939423
1.14 (0.43)
1.14 (0.43)
0
1.30 (0.71)
1.30 (0.65)
0
1.24 (0.62)
1.24 (0.59)
0
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
-0.440747751
1.00 (0.62)
1.00 (0.59)
0
HU - Number of hospital days
...mean (sd)
6.06 (8.57)
6.02 (6.84)
0.005159025
5.06 (6.92)
5.11 (7.46)
-0.006949205
6.66 (8.13)
6.61 (7.49)
0.006396682
6.12 (7.93)
6.09 (7.35)
0.003923876
...median [IQR]
4.00 [3.00, 6.00]
4.00 [3.00, 6.00]
0
3.00 [2.00, 5.00]
3.00 [2.00, 5.00]
0
4.00 [3.00, 7.00]
4.00 [3.00, 7.00]
0
3.74 (7.93)
3.74 (7.35)
0
HU - Number of Emergency Department (ED) visits
...mean (sd)
1.78 (2.70)
1.76 (2.25)
0.008047622
3.23 (4.82)
3.15 (5.30)
0.015792523
2.10 (2.95)
2.10 (3.36)
0
2.33 (5.07)
2.30 (3.79)
0.006702426
...median [IQR]
1.00 [1.00, 2.00]
1.00 [1.00, 2.00]
0
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0
1.00 [1.00, 3.00]
1.00 [1.00, 3.00]
0
1.26 (5.07)
1.26 (3.79)
0
HU - Number of internal medicine/family medicine visits
...mean (sd)
10.86 (15.64)
11.07 (15.13)
-0.013647784
5.25 (7.86)
5.28 (7.79)
-0.003833827
11.23 (11.34)
11.19 (10.62)
0.003641031
9.60 (16.95)
9.63 (11.14)
-0.002091717
...median [IQR]
6.00 [2.00, 14.00]
6.00 [2.00, 14.00]
0
3.00 [1.00, 7.00]
3.00 [1.00, 7.00]
0
8.00 [4.00, 14.00]
8.00 [5.00, 14.00]
0
6.27 (16.95)
6.27 (11.14)
0
HU - Number of different/distinct medication prescriptions
...mean (sd)
8.43 (5.39)
8.51 (5.40)
-0.014828539
7.87 (5.42)
7.90 (5.21)
-0.005643302
9.82 (5.36)
9.80 (5.24)
0.003773343
9.02 (7.82)
9.03 (5.27)
-0.001499693
...median [IQR]
7.00 [4.00, 11.00]
8.00 [4.00, 12.00]
-0.185356732
7.00 [4.00, 11.00]
7.00 [4.00, 11.00]
0
9.00 [6.00, 13.00]
9.00 [6.00, 13.00]
0
8.05 (7.82)
8.27 (5.27)
-0.032993243
HU - Number of Office visits
...mean (sd)
4.46 (4.12)
4.56 (3.94)
-0.02480771
4.37 (4.07)
4.38 (4.09)
-0.002450973
11.13 (11.80)
11.20 (12.00)
-0.005882145
7.95 (13.10)
8.01 (9.14)
-0.005312131
...median [IQR]
3.00 [2.00, 6.00]
4.00 [2.00, 6.00]
-0.248077102
3.00 [1.00, 6.00]
3.00 [1.00, 6.00]
0
8.00 [3.00, 15.00]
8.00 [3.00, 15.00]
0
5.63 (13.10)
5.85 (9.14)
-0.019477815
HU - Number of Cardiologist visits
...mean (sd)
2.59 (4.05)
2.58 (3.72)
0.002571684
0.64 (1.84)
0.65 (1.83)
-0.005449571
2.69 (4.21)
2.69 (4.21)
0
2.14 (5.38)
2.14 (3.63)
0
...median [IQR]
1.00 [0.00, 3.00]
1.00 [0.00, 3.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.25]
0
1.00 [0.00, 3.00]
1.00 [0.00, 3.00]
0
0.74 (5.38)
0.74 (3.63)
0
HU - Number electrocardiograms
...mean (sd)
1.91 (2.10)
1.90 (2.01)
0.004865014
0.78 (1.18)
0.77 (1.16)
0.008546696
1.96 (2.02)
1.95 (1.94)
0.005049475
1.64 (2.70)
1.63 (1.79)
0.004365584
...median [IQR]
1.00 [1.00, 3.00]
1.00 [1.00, 3.00]
0
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0
1.00 [1.00, 3.00]
1.00 [1.00, 3.00]
0
0.74 (2.70)
0.74 (1.79)
0
HU - Number of echocardiograms
...mean (sd)
1.07 (2.92)
1.09 (3.00)
-0.00675614
0.67 (0.74)
0.67 (0.79)
0
0.77 (0.94)
0.78 (0.95)
-0.010581862
0.81 (2.26)
0.82 (1.60)
-0.005107228
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0
1.00 (2.26)
1.00 (1.60)
0
HU - Number of neurologist visits
...mean (sd)
0.59 (2.29)
0.60 (2.42)
-0.004244668
0.35 (1.54)
0.35 (2.36)
0
0.55 (2.06)
0.55 (2.15)
0
0.51 (2.90)
0.51 (2.27)
0
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 (2.90)
0.00 (2.27)
0
HU - Fecal occult blood (FOB) test; n (%)
70 (2.3%)
76 (2.5%)
-0.013067988
101 (2.7%)
96 (2.6%)
0.00622603
199 (2.7%)
198 (2.6%)
0.00622603
370 (2.6%)
370 (2.6%)
0
HU - Number of PT or aPTTt tests
Appendix B

...mean (sd)
0.48 (1.19)
0.48 (1.21)
0
0.46 (1.11)
0.46 (1.19)
0
0.26 (0.63)
0.25 (0.66)
0.015499685
0.36 (1.33)
0.35 (0.95)
0.008652578
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0
0.00 (1.33)
0.00 (0.95)
0
Socioeconomic Status Proxy Variables
SES - Mean Copay for per prescription cost (charges in U.S. $)
...mean (sd)
18.05 (23.07)
18.18 (27.14)
-0.005161322
11.59 (18.47)
11.98 (20.33)
-0.020080033
19.52 (36.04)
19.14 (33.98)
0.010849347
17.14 (43.26)
17.07 (29.54)
0.001889809
...median [IQR]
11.75 [4.01, 23.76]
10.66 [3.95, 22.77]
0.043275704
7.21 [1.00, 14.46]
7.19 [0.77, 15.00]
0.001029745
10.06 [2.95, 24.13]
9.71 [2.88, 23.73]
0.00999282
9.68 (43.26)
9.26 (29.54)
0.011338853
...Missing; n (%)
272 (9.0%)
266 (8.8%)
0.007023903
719 (19.5%)
703 (19.0%)
0.012682127
452 (6.0%)
446 (6.0%)
0
1,443 (10.2%)
1,415 (10.0%)
0
SES - Copay: pharmacy cost
...mean (sd)
170.24 (267.22)
171.77 (323.09)
-0.005160655
92.46 (181.81)
96.72 (189.23)
-0.022957894
9.92 (5.45)
9.90 (5.33)
0.003710345
65.62 (224.46)
67.04 (177.80)
-0.007013088
...median [IQR]
70.00 [10.00, 221.90] 65.46 [10.00, 211.95]
0.015313315
20.79 [0.00, 110.18]20.00 [0.00, 112.32]
0.00425745
9.00 [6.00, 13.00]
9.00 [6.00, 13.00]
0
25.09 (224.46)
23.91 (177.80)
0.005827778
SES - Business type: Commercial vs Medicare
...Commerical; n (%)
1,171 (38.6%)
1,154 (38.1%)
0.010283158
2,840 (76.9%)
2,829 (76.6%)
0.00710188
0 (0.0%)
0 (0.0%)
0
4,011 (28.2%)
3,983 (28.0%)
0.004449523
...Medicare; n (%)
1,861 (61.4%)
1,878 (61.9%)
-0.010283158
854 (23.1%)
865 (23.4%)
-0.00710188
0 (0.0%)
0 (0.0%)
0
2,715 (19.1%)
2,743 (19.3%)
-0.005077794
SES - Low income indicator; n (%)
461 (15.2%)
467 (15.4%)
-0.00555577
0 (0.0%)
0 (0.0%)
0
0 (0.0%)
0 (0.0%)
0
461 (3.2%)
467 (3.3%)
-0.005639422
SES - Urban vs Rural (MSA variable)
...Urban; n (%)
0 (0.0%)
0 (0.0%)
0
2,479 (67.1%)
2,458 (66.5%)
0.012740979
0 (0.0%)
0 (0.0%)
0
2,479 (17.5%)
2,458 (17.3%)
0.005275539
...Rural; n (%)
0 (0.0%)
0 (0.0%)
0
365 (9.9%)
369 (10.0%)
-0.003340775
0 (0.0%)
0 (0.0%)
0
365 (2.6%)
369 (2.6%)
0
...Unknown/Missing; n (%)
0 (0.0%)
0 (0.0%)
0
850 (23.0%)
867 (23.5%)
-0.011836599
0 (0.0%)
0 (0.0%)
0
850 (6.0%)
867 (6.1%)
-0.004194449
SES - Dual Status; n (%)
0 (0.0%)
0 (0.0%)
0
0 (0.0%)
0 (0.0%)
0
2,256 (30.2%)
2,260 (30.2%)
0
2,256 (15.9%)
2,260 (15.9%)
0
SES - Generic name prescription - unique value
...mean (sd)
8.43 (5.39)
8.51 (5.40)
-0.014828539
7.87 (5.42)
7.90 (5.21)
-0.005643302
9.82 (5.36)
9.80 (5.24)
0.003773343
9.02 (7.82)
9.03 (5.27)
-0.001499693
...median [IQR]
7.00 [4.00, 11.00]
8.00 [4.00, 12.00]
-0.185356732
7.00 [4.00, 11.00]
7.00 [4.00, 11.00]
0
9.00 [6.00, 13.00]
9.00 [6.00, 13.00]
0
8.05 (7.82)
8.27 (5.27)
-0.032993243
SES - Brand name prescription - unique value
...mean (sd)
8.52 (5.50)
8.60 (5.51)
-0.014532237
7.96 (5.53)
8.00 (5.32)
-0.007371891
9.92 (5.45)
9.90 (5.33)
0.003710345
9.11 (7.97)
9.13 (5.37)
-0.002943122
...median [IQR]
8.00 [4.00, 12.00]
8.00 [4.00, 12.00]
0
7.00 [4.00, 11.00]
7.00 [4.00, 11.00]
0
9.00 [6.00, 13.00]
9.00 [6.00, 13.00]
0
8.27 (7.97)
8.27 (5.37)
0
Appendix B

The c-statistics for the propensity score model, pre-matching was 0.746. The post-matching c-statistic was 0.541
The c-statistics for the propensity score model, pre-matching was 0.732. The post-matching c-statistic was 0.538
The c-statistics for the propensity score model, pre-matching was 0.674. The post-matching c-statistic was 0.52
Optum 
Medicare 
MarketScan
Appendix B